CA2281838A1 - Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders - Google Patents
Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders Download PDFInfo
- Publication number
- CA2281838A1 CA2281838A1 CA002281838A CA2281838A CA2281838A1 CA 2281838 A1 CA2281838 A1 CA 2281838A1 CA 002281838 A CA002281838 A CA 002281838A CA 2281838 A CA2281838 A CA 2281838A CA 2281838 A1 CA2281838 A1 CA 2281838A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- cpg
- seq
- bases
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 68
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 41
- 108091029430 CpG site Proteins 0.000 title description 5
- 239000002158 endotoxin Substances 0.000 claims abstract description 117
- 229920006008 lipopolysaccharide Polymers 0.000 claims abstract description 82
- 238000000034 method Methods 0.000 claims abstract description 69
- 102000004127 Cytokines Human genes 0.000 claims description 45
- 108090000695 Cytokines Proteins 0.000 claims description 45
- 108010065805 Interleukin-12 Proteins 0.000 claims description 32
- 102000013462 Interleukin-12 Human genes 0.000 claims description 32
- 239000002773 nucleotide Substances 0.000 claims description 26
- 125000003729 nucleotide group Chemical group 0.000 claims description 25
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 23
- 230000028709 inflammatory response Effects 0.000 claims description 23
- 108090000174 Interleukin-10 Proteins 0.000 claims description 20
- 102000003814 Interleukin-10 Human genes 0.000 claims description 19
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 16
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 14
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 14
- 230000001154 acute effect Effects 0.000 claims description 11
- 239000013638 trimer Substances 0.000 claims description 10
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 claims description 8
- 229940104302 cytosine Drugs 0.000 claims description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 7
- 229930024421 Adenine Natural products 0.000 claims description 7
- 229960000643 adenine Drugs 0.000 claims description 7
- 229940113082 thymine Drugs 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 8
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 claims 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 4
- 229940104230 thymidine Drugs 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 230000004044 response Effects 0.000 abstract description 26
- 230000028993 immune response Effects 0.000 abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 10
- 208000019693 Lung disease Diseases 0.000 abstract description 7
- 230000001900 immune effect Effects 0.000 abstract description 5
- CTMZLDSMFCVUNX-VMIOUTBZSA-N cytidylyl-(3'->5')-guanosine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(N=C(N)N3)=O)N=C2)O)[C@@H](CO)O1 CTMZLDSMFCVUNX-VMIOUTBZSA-N 0.000 description 123
- 108091034117 Oligonucleotide Proteins 0.000 description 94
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 84
- 210000004027 cell Anatomy 0.000 description 48
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 45
- 210000004072 lung Anatomy 0.000 description 43
- 230000000694 effects Effects 0.000 description 38
- 108020004414 DNA Proteins 0.000 description 30
- 235000013601 eggs Nutrition 0.000 description 30
- 229940117681 interleukin-12 Drugs 0.000 description 30
- 210000003719 b-lymphocyte Anatomy 0.000 description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 18
- 230000004913 activation Effects 0.000 description 17
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- 239000012530 fluid Substances 0.000 description 16
- 238000004519 manufacturing process Methods 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 12
- 208000006673 asthma Diseases 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 210000003979 eosinophil Anatomy 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 230000028327 secretion Effects 0.000 description 9
- 230000004936 stimulating effect Effects 0.000 description 9
- 210000004969 inflammatory cell Anatomy 0.000 description 8
- 230000002101 lytic effect Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 210000003622 mature neutrocyte Anatomy 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 241001529936 Murinae Species 0.000 description 6
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000009089 cytolysis Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000023504 respiratory system disease Diseases 0.000 description 6
- 238000011740 C57BL/6 mouse Methods 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 206010069351 acute lung injury Diseases 0.000 description 5
- 230000000692 anti-sense effect Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- -1 phosphorothioate modified oligonucleotides Chemical class 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 230000009325 pulmonary function Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 241000242680 Schistosoma mansoni Species 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000020411 cell activation Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000008718 systemic inflammatory response Effects 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 3
- 108010042407 Endonucleases Proteins 0.000 description 3
- 208000037487 Endotoxemia Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 3
- 108010093965 Polymyxin B Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 102000006382 Ribonucleases Human genes 0.000 description 3
- 108010083644 Ribonucleases Proteins 0.000 description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000004700 cellular uptake Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000004199 lung function Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 3
- IMBXEJJVJRTNOW-XYMSELFBSA-N methylprednisolone succinate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC(O)=O)CC[C@H]21 IMBXEJJVJRTNOW-XYMSELFBSA-N 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000001991 pathophysiological effect Effects 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 229920000024 polymyxin B Polymers 0.000 description 3
- 229960005266 polymyxin b Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001541 thymus gland Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical group CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108020000946 Bacterial DNA Proteins 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 108090000176 Interleukin-13 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012480 LAL reagent Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 101000981253 Mus musculus GPI-linked NAD(P)(+)-arginine ADP-ribosyltransferase 1 Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 230000010398 acute inflammatory response Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 230000003434 inspiratory effect Effects 0.000 description 2
- 230000019734 interleukin-12 production Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- KDWFDOFTPHDNJL-TUBOTVQJSA-N odn-2006 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=S)O[C@H]2[C@H]([C@@H](O[C@@H]2COP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(S)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C3=C(C(NC(N)=N3)=O)N=C2)O)N2C(N=C(N)C=C2)=O)O)[C@@H](O)C1 KDWFDOFTPHDNJL-TUBOTVQJSA-N 0.000 description 2
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 150000003904 phospholipids Chemical group 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- HWPZZUQOWRWFDB-UHFFFAOYSA-N 1-methylcytosine Chemical compound CN1C=CC(N)=NC1=O HWPZZUQOWRWFDB-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010060921 Abdominal abscess Diseases 0.000 description 1
- 101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102100036850 C-C motif chemokine 23 Human genes 0.000 description 1
- 101100023365 Caenorhabditis elegans mif-2 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 101710200114 Cysteine proteinase inhibitor 10 Proteins 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010063593 DNA modification methylase SssI Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000698776 Duma Species 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150076458 ILI2 gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000010631 Kininogens Human genes 0.000 description 1
- 108010077861 Kininogens Proteins 0.000 description 1
- 241000239218 Limulus Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 208000006816 Neonatal Sepsis Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000002278 Ribosomal Proteins Human genes 0.000 description 1
- 108010000605 Ribosomal Proteins Proteins 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 206010053879 Sepsis syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000005600 alkyl phosphonate group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- BOKOVLFWCAFYHP-UHFFFAOYSA-N dihydroxy-methoxy-sulfanylidene-$l^{5}-phosphane Chemical compound COP(O)(O)=S BOKOVLFWCAFYHP-UHFFFAOYSA-N 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001378 electrochemiluminescence detection Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 208000018875 hypoxemia Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000610 leukopenic effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000002433 mononuclear leukocyte Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- DHYWDEXXBWTTEH-UHFFFAOYSA-N odn 2007 Chemical compound O=C1NC(=O)C(C)=CN1C1OC(COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=O)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP(O)(=O)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(O)=O)C(O)C1 DHYWDEXXBWTTEH-UHFFFAOYSA-N 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Abstract
The present invention is based on the finding that nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide affect immune responses in a subject. These nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide can be used to treat pulmonary disorders having an immunologic component, such as a response to inhaled lipopolysaccharide. The invention provides methods of treating subjects who have or are at risk of having these pulmonary disorders, and methods of altering the immunological components of the pulmonary disorders. The invention also provides pharmaceutical compositions for treating pulmonary disorders that have an immunologic component.
Description
USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG
DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED
DISORDERS
FIELD OF THE INVENTION
This invention relates to generally to pulmonary disorders, and specifically to the use of oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) in the treatment of such disorders.
BACKGROUND OF THE INVENTION
Endotoxin is one of the primary mediators of inflammation released by Gram negative organisms and is an important cause of environmentally induced airway disease, such as ARDS. Inhaled endotoxin can cause airflow obstruction in previously unexposed subjects. Inhaled endotoxin is strongly associated with the development of acute decrements in airflow among cotton workers, wine confinement workers, and poultry workers. The concentration of endotoxin in the bioaerosol appears to be the most important occupational exposure associated with the development and progression of airway disease in agricultural workers (Schwartz, D.A., et al., Am. J. Respir.
Crit. Care Med. 152:603-8, 1995).
In addition to being related to several occupational pulmonary diseases, exposure to endotoxin and to its purified derivative lipopolysaccharide (LPS) is also associated with severe asthma. The concentration of endotoxin in the domestic environment adversely affects asthmatics, with higher concentrations of ambient endotoxin associated with greater degrees of airflow obstruction. In addition, asthmatic individuals develop airflow obstruction at lower concentrations of inhaled endotoxin than normal controls.
Exposure-response studies have shown that inhaled lipopolysaccharide (LPS) produces recruitment of neutrophils, activation of macrophages with production and release of pro-~WO 98/37919 PCT/US98/03678 inflammatory cytokines, and damage to airway epithelia in a dose-dependent manner.
These studies indicate that endotoxin is an important cause of airway disease among exposed individuals.
The acute respiratory distress syndrome CARDS) is a condition characterized by acute hypoxemia respiratory failure due to pulmonary edema (reviewed in Honing, E.G., and Ingram, R.H., Jr., in: Harrison's Principles of Internal Medicine, 14th Edition, A.S.
Fauci, et al. (eds.), McGraw-Hill, New York, pp. 1483-1486, 1998; and Goodman, R.B., et al., Am J. Respir. Crit. Care Med. 154:602-1 l, 1996). ARDS represents a spectrum of responses to acute lung injury (ALI); these response occur as complications of a more widespread systemic response to acute inflammation or injury. ALI develops rapidly after a predisposing condition triggers a systemic inflammatory response and is most strongly associated with conditions that produced direct alveolar injury or direct injury via the pulmonary capillary bed, such as aspiration, diffuse infection, toxic inhalation, direct injury to the alveolar epithelium, or sepsis syndrome. ALI is the consequence of unregulated over-expression of usual systemic inflammatory responses to infection and/or injure. Injury involves the alveolar epithelium and the pulmonary capillary endothelium, and results in a complex cascade of events. Injury is produced by cellular events associated with neutrophils, macrophages, monocytes, and lymphocytes producing various cytokines, in turn producing cellular activation, chemotaxis, and adhesion.
Gram-negative infections are a major cause of morbidity and mortality, especially in hospitalized and immunocompromised patients. (Duma, Am. J. of Med, 78 (Suppl.
6A):154-164, 1985; and Kreger et al., Am.' J. Mecl , 68:344-355, 1980).
Although available antibiotics are generally effective in inhibiting growth of Gram-negative bacteria, they do not neutralize the pathophysiological effects associated with endotoxins.
Endotoxin is a heat stable bacterial toxin composed of lipopolysaccharides (LPS) released from the outer membrane of Gram-negative bacteria upon lysis (Shenep et al., .
DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED
DISORDERS
FIELD OF THE INVENTION
This invention relates to generally to pulmonary disorders, and specifically to the use of oligonucleotides having at least one unmethylated CpG dinucleotide (CpG ODN) in the treatment of such disorders.
BACKGROUND OF THE INVENTION
Endotoxin is one of the primary mediators of inflammation released by Gram negative organisms and is an important cause of environmentally induced airway disease, such as ARDS. Inhaled endotoxin can cause airflow obstruction in previously unexposed subjects. Inhaled endotoxin is strongly associated with the development of acute decrements in airflow among cotton workers, wine confinement workers, and poultry workers. The concentration of endotoxin in the bioaerosol appears to be the most important occupational exposure associated with the development and progression of airway disease in agricultural workers (Schwartz, D.A., et al., Am. J. Respir.
Crit. Care Med. 152:603-8, 1995).
In addition to being related to several occupational pulmonary diseases, exposure to endotoxin and to its purified derivative lipopolysaccharide (LPS) is also associated with severe asthma. The concentration of endotoxin in the domestic environment adversely affects asthmatics, with higher concentrations of ambient endotoxin associated with greater degrees of airflow obstruction. In addition, asthmatic individuals develop airflow obstruction at lower concentrations of inhaled endotoxin than normal controls.
Exposure-response studies have shown that inhaled lipopolysaccharide (LPS) produces recruitment of neutrophils, activation of macrophages with production and release of pro-~WO 98/37919 PCT/US98/03678 inflammatory cytokines, and damage to airway epithelia in a dose-dependent manner.
These studies indicate that endotoxin is an important cause of airway disease among exposed individuals.
The acute respiratory distress syndrome CARDS) is a condition characterized by acute hypoxemia respiratory failure due to pulmonary edema (reviewed in Honing, E.G., and Ingram, R.H., Jr., in: Harrison's Principles of Internal Medicine, 14th Edition, A.S.
Fauci, et al. (eds.), McGraw-Hill, New York, pp. 1483-1486, 1998; and Goodman, R.B., et al., Am J. Respir. Crit. Care Med. 154:602-1 l, 1996). ARDS represents a spectrum of responses to acute lung injury (ALI); these response occur as complications of a more widespread systemic response to acute inflammation or injury. ALI develops rapidly after a predisposing condition triggers a systemic inflammatory response and is most strongly associated with conditions that produced direct alveolar injury or direct injury via the pulmonary capillary bed, such as aspiration, diffuse infection, toxic inhalation, direct injury to the alveolar epithelium, or sepsis syndrome. ALI is the consequence of unregulated over-expression of usual systemic inflammatory responses to infection and/or injure. Injury involves the alveolar epithelium and the pulmonary capillary endothelium, and results in a complex cascade of events. Injury is produced by cellular events associated with neutrophils, macrophages, monocytes, and lymphocytes producing various cytokines, in turn producing cellular activation, chemotaxis, and adhesion.
Gram-negative infections are a major cause of morbidity and mortality, especially in hospitalized and immunocompromised patients. (Duma, Am. J. of Med, 78 (Suppl.
6A):154-164, 1985; and Kreger et al., Am.' J. Mecl , 68:344-355, 1980).
Although available antibiotics are generally effective in inhibiting growth of Gram-negative bacteria, they do not neutralize the pathophysiological effects associated with endotoxins.
Endotoxin is a heat stable bacterial toxin composed of lipopolysaccharides (LPS) released from the outer membrane of Gram-negative bacteria upon lysis (Shenep et al., .
,l. Infect. Dis., 150(3):380-388, 1984), and is a potent stimulator of the inflammatory - response. Endotoxemia occurs when endotoxin enters the bloodstream resulting in a dramatic systemic inflammatory response.
The uptake of oligonucleotides by B lymphocytes has been shown to be regulated by LPS-induced cell activation (Krieg, A.M., et al., Antisense Res. bevel. 1:161, 1991).
Many detrimental in vivv effects of LPS have been shown to result from soluble mediators released by inflammatory cells. (Morrison et al., Anr. J. Pathol., 93(2):527-617, 1978). Monocytes and neutrophils, which ingest and kill microorganisms. play a key role in this process. Monocytes and neutrophils respond to endotoxin in vivo by releasing soluble proteins with microbicidal, proteolytic, opsonic, pyrogenic, complement-activating and tissue-damaging effects. These factors mediate many of the pathophysiological effects of endotoxin. For example, tumor necrosis factor (TNF), a cytokine released by endotoxin-stimulated monocytes, causes fever, shock, and alterations in glucose metabolism and is a .potent stimulator of neutrophils.
Other cytokines such as IL-1, IL-6, and IL-8 also mediate many of the pathophysiologic effects of LPS, as well as other pathways involving endothelial cell activation by tissue factor, kininogen, nitric oxide and complement.
Endotoxin-associated disorders result from extra-gastrointestinal exposure to LPS, e.g., administration of LPS-contaminated fluids, inhalation of LPS, or Gram-negative infections. Endotoxin-associated disorders can also result when the natural cellular barrier is injured and the normal Gram-negative flora breach this barrier. For example, endotoxin-associated disorders can occur (a) when there is ischemia of the gastrointestinal tract (e.g., following hemorrhagic shock or during certain surgical procedures), or (b) when systemic or local inflammation causes increased permeability of the gut or lung to endotoxin or Gram-negative organisms. The presence of endotoxin and the resulting inflammatory response may result, for example, in adult respiratory distress syndrome CARDS), dust-induced airway disease, and exacerbation of asthma, in addition to endotoxemia, systemic inflammatory response syndrome (SIRS), sepsis _q._ syndrome, septic shock, disseminated intravascular coagulation (DIC), cardiac dysfunction, organ failure, liver failure (hepatobiliary dysfunction), brain failure (CNS
dysfunction), renal failure, multi-organ failure and shock.
Several therapeutic compounds have been developed to inhibit the toxic effects of endotoxin, including antibacterial LPS-binding agents and anti-LPS antibodies, although each has met with limitations. For example, Polymyxin B (PMB) is a basic polypeptide antibiotic which binds to Lipid A, the most toxic and biologically active component of endotoxin. PMB inhibits endotoxin-mediated activation of neutrophil granule release irz vitro and is a potential therapeutic agent for Gram-negative infections.
However, because of its systemic toxicity, this antibiotic has limited therapeutic use, and is generally used topically. Combination therapy using antibiotics and high doses of methylprednisolone sodium succinate (MPSS) showed more promise as this regimen prevented death in an experimental animal model of Gram-negative sepsis.
However, a clinical study using MPSS with antibiotics in treatment of patients having clinical signs of systemic sepsis showed that mortality rates were not significantly different between the treatment and placebo groups (Bone et al.. N. Engl. .I. Mecl. 317:653, 1987).
SUMMARY OF THE INVENTION
The present invention is based on the finding that nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide affect the immune response in a subject by activating natural killer cells (NK) or redirecting a subject's immune response from a Th2 to a Thl response by inducing monoc~~tic and other cells to produce Thl cytokines. These nucleic acids containing at least one unmethylated CpG can be used to treat pulmonary disorders having an immunologic component, such as asthma or environmentally induced airway disease.
In a first embodiment, a method of treating a subject having or at risk of having an acute -decrement in air flow by administering a therapeutically effective amount of nucleic acids containing at least one unmethylated CpG is provided.
WO' 98/37919 PCT/US98/03678 In another embodiment, a method of treating a subject having or at risk of-having an ~ inflammatory response to Iipopolysaccharide by administering a therapeutically effective amount of nucleic acids containing at least one unmethylated CpG is also provided. The invention also provides a method of modifying the level of a cytokine in a subj ect having or at risk of having inhaled lipopolysaccharide by administering a therapeutically effective nucleic acid containing at least one unmethylated CpG.
In another embodiment, the invention provides a pharmaceutical composition for treating a subject having or at risk of having an inflammatory response to inhaled lipopolysaccharide including a nucleic acid sequence containing at Least one I 0 unmethylated CpG in a pharmacologically acceptable carrier.
In a further embodiment. isolated nucleic acid sequences as set forth in SEQ
ID NOS:2, 17, 18, 59-65 are provided.
>BRIEF DESCRIPTION OF TILE DRAWINGS
FIG. I is a flow chart showing the pathways to sepsis and acute lung injury.
FIG. 2 is a graph plotting the concentration of cytokines (TNF-a, MIP-2, IL-10, IL-12, and IFN-y) in the serum four hours after intravenous treatment with either an oligonucleotide containing embedded CpG motifs or an oligonucleotide without CpG
motifs. Serum samples were obtained immediately following an inhalation challenge with E coli LPS. Error bars show Standard Error (SE).
FIG. 3 is a graph plotting the concentration of total cells and PMNs in the whole lung lavage fluid following inhalation challenge with EscheYichia coli LPS. Thirty minutes, four hours and 12 hours prior to the inhalation challenge, mice were either treated with an oligonucleotide containing embedded CpG motifs or were treated with an oligonucleotide without CpG motifs. Error bars show SE.
WO '98/37919 PCTlUS98/03678 FIG. 4 is a graph showing the concentration of cytokines (TNF-a, MIP-2, and' IL-I2) in the whole lung Iavage fluid following inhalation of E. coli LPS. Mice were pretreated with an oligonucleotide containing embedded CpG motifs or were pretreated with an oligonucleotide without CpG motifs four hours prior to inhalation challenge with LPS.
Error bars show SE.
FIG. 5 is an autoradiograph showing an RNase protection assay of the total mRNA
isolated from lungs of mice exposed to E. coli LPS by inhalation. Mice were pretreated with an oligonucleotide containing embedded CpG motifs or were pretreated with an oligonucleotide without CpG motifs four hours prior to inhalation challenge with LPS.
L32 encodes a ribosomal protein and was used to assess the concentration of RNA
loaded onto the gel.
FIG. 6 is a graph plotting the concentration of total cells and PMNs in the whole lung lavage fluid following inhalation of E. coli LPS. Mice were pretreated with an oligonucleotide containing embedded CpG motifs or were pretreated with an oligonucleotide without CpG motifs four hours prior to inhalation challenge wish LPS.
Error bars show SE.
FIG. 7 is a graph showing the concentration of total cells and PMNs in the whole lung lavage fluid following inhalation of E. coli LPS. C~7BL/6 mice and IL-10 knockout mice (C57BL/6-IL10""'cs") were pretreated with either an oligonucleotide containing embedded CpG motifs or with intravenous saline four hours prior to inhalation challenge with LPS. Error bars show SE.
FIG. 8 is a graph plotting lung lavage cell count over time. The graph shows that when the mice are initially injected intraperitoneally (i.p.) with Schistosoma mansoni eggs "egg," which induces a Th2 immune response, and subsequently inhale Schistosornu n2ansofZi egg antigen "SEA" (open circle), many inflammatory cells are present in the lungs. However, when the mice axe initially given CpG ODN along with egg, the _7_ inflammatory cells in the lung are not as increased by subsequent inhalation of SEA
(open triangles).
FIG. 9 is a graph plotting lung lavage eosinophil count over time. Again, the graph shows that when the mice are initially injected with egg and subsequently inhale SEA
(open circle), many eosinophils are present in the lungs. However, when the mice are initially given CpG ODN along with egg, the inflammatory cells in the lung are not as increased by subsequent inhalation of the SEA (open triangles).
FIG. 10 is a bar graph plotting the effect on the percentage of macTOphage, lymphocyte, neutrophil and eosinophil cells induced by exposure to saline alone; egg, then SEA; egg and CpG ODN, then SEA; and egg and control oligo, then SEA. When the mice are treated with the control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA.
Thus, when mice inhale the eggs on days 14 or ? 1. they develop an acute inflammatory response in the lungs. I-Iowever, giving a CpG oligo along with the eggs at the time of initial antigen exposure on days 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.
FIG. 11 is a bar graph plotting eosinophil count in response to injection of various amounts of the protective oligo SEQ ID NO: 10.
FIG. 12 is a graph plotting interleukin 4 (IL-4) production (pg/ml) in mice over time in response to injection of egg, then SEA (open diamond); egg and CpG ODN, thcn SEA
(open circle); or saline, then saline (open square). The graph shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.
FIG. I3 is a bar graph plotting interleukin 12 (IL-12) production (pg/ml) in mice over time in response to injection of saline; egg, then SEA; or CpG ODN and egg, then SEA.
The graph shows that administration of an oligonucleotide containing an unmethylated _g_ CpG motif can actually redirect the cytokine response of the lung to production of IL-12, indicating a Th 1 type of immune response.
FIG. 14 is a bar graph plotting interferon gamma (IFN-y production (pg/ml) in mice over time in response to injection of saline; egg, then saline; or CpG ODN and egg, then SEA.
The graph shows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN-y, indicating a Th 1 type of immune response.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
1t is to be understood that this invention is not limited to the particular methodology, protocols, sequences, models and reagents described as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the oligonucleotides and methodologies which are described in the publications which might be used in connection with the presently described invention.
The binding of DNA to cells has been shown to be similar to a ligand receptor interaction: binding is saturable, competitive, and leads to DNA endocytosis and degradation into oligonucleotides (Bennet, R.M., et al., J. Clin. Invest.
76:2182, 1985).
Like DNA, oligodeoxyribonucleotides are able to enter cells in a process which is sequence, temperature, and energy independent (3aroszewski and Cohen, Ad. Drug Del.
Rev. 6:235, 1991 ). An "oligodeoxyribonycleotide" as used herein is a deoxyribonucleic acid sequence from about 3-50 bases in length. Lymphocyte oligodeoxyribonucleotide uptake has been shown to be regulated by cell activation (Krieg, A.M., et al., Antisense _g_ Research and Development 1:161, 1991). The present invention is based on the Ending that certain oligonucleotides (ODN) containing at least one unmethylated cytosine-guanine (CpG) din~cleotide activate the immune response.
In one embodiment, the invention provides a method for treating a subject having or at risk ofhaving an acute decrement in air flow by administering a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG.
The term "nucleic acid" or "oligonucleotide" refers to a polymeric form of nucleotides at least five bases in length. The nucleotides of the invention can be deoxyribonucleotides, ribonucleotides, or modified forms of either nucleotide. Generally, double-stranded 3 0 molecules are more stable im vivo, while single-stranded molecules have increased activity.
The nucleic acid molecule can include the use of phosphorothioate or phosphorodithioate rather than phosphodiesterase linkages within the backbone of the molecule, or methylphosphorothioate terminal linkages (Krieg, A.1~~1., et ul., Antisense and Nucl Acid Drug Dev 6:133-9, 1996; Boggs, R.T., et al., Antisense and Nucl Acid Drug Dev, 7:461-71, 1997). The phosphate backbone modification can occur at the 5' end of the nucleic acid, for example at the first two nucleotides of the 5' end of the nucleic acid. The phosphate backbone modification may occur at the 3' end of the nucleic acid, for example at the last five nucleotides of the 3' end of the nucleic acid. International Patent Application WO 95/26204, entitled "immune stimulation by phosphorothioate oligonucleotide analogs'' reports the nonsequence-specific immunostimulatory effect of phosphorothioate modified oligonucleotides. Nontraditional bases such as inosine and queosine, as well as acetyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine can also be included, which are not as easily recognized by endogenous endonucleases. Other stabilized nucleic acid molecules include:
nonionic DNA analogs, such as alkyl- and aryl-phosphonates (in which the charged oxygen moiety is alkylated). Nucleic acid molecules which contain a diol, such as tetrahyleneglycol or hexaethyleneglycol, at either or both termini are also included. The term "oligonucleotide" includes both single and double-stranded forms of DNA.
A "CpG" or "CpG motif ' refers to a nucleic acid having a cytosine followed by a guanine linked by a phosphate bond. The term "methylated CpG" refers to the methylation of the cytosine on the pyrimidine ring, usually occurnng the 5-position of the pyrimidine ring. The term "unmethylated CpG" refers to the absence of methylation of the cytosine on the pyrimidinc ring. Methylation, partial removal, or removal of an unmethylated CpG motif in an oligonucleotide of the invention is believed to reduce its effect. Methylation or removal of all unmethylated CpG motifs in an oligonuclcotide substantially reduces its effect. The effect of methylation or removal of a CpG motif is "substantial" if the effect is similar to that of an oligonucleotide that does not contain a CpG motif.
Preferably the CpG oligonucleotide is in the range of about 8 to 30 bases in size. For use in the instant invention, the nucleic acids can be synthesized de noru using any of a number of procedures well known in the art. For example, the b-cyanoethyl phosphoramidite method (Beaucage, S.L., and Caruthers, M.1L, Tet. Lel. ?:1859, 1981 );
nucleoside H-phosphonate method (Garegg et al., Tet. Let. 27:4051-4054, 1986;
Froehler et al., Nucl. Acid. Res. 14:5399-5407, 1986, ; Garegg et ul., Tet. Let.
27:4055-4058, 1986, Gaffney et al., Tc~t. Let. 29:2619-2622, 1988). These chemistries can be perfornned by a variety of automated oligonucleotide synthesizers available in the market.
Alternatively, CpG dinucleotides can be produced on a large scale in plasmids, (see Sambrook, T., et al., Molecular Cloning: A Laboratory Manual, Cold Spring I-harbor laboratory Press, New York, 1989) which after being administered to a subject are de~aded into oligonucleotides. Oligonucleotides can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.
WO 98/37919 PCT/US98/03.678 For use in vivo, nucleic acids are preferably relatively resistant to degradation-(e.g., via endo-and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished ' via phosphate backbone modifications. A preferred stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl-and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No.
092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A., Chem. Rev. 90:544, 1990;
Goodchild, J., Bioconjugate Chem. 1:165, 1990).
For administration in vivo, nucleic acids may be associated with a molecule that results in higher affinity binding to target cell (e.g., B-cell, monoc5nic cell and natural killer (NIL) cell) surfaces and/or increased cellular uptake by target cells to form a "nucleic acid delivery complex." Nucleic acids can be ioniGally or covalently associated with appropriate molecules using techniques which are well known in the art. A
variety of coupling or cross-linking agents can be used, e.g., protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). Nucleic acids can alternatively be encapsulated in Iiposomes or virosomes using well-known techniques.
In one embodiment, the nucleic acid sequences useful in the methods of the invention are represented by the formula:
SN,X,CGXZN,3' (SEQ ID NO:1) wherein at least one nucleotide separates consecutive CpGs; X, is adenine, guanine, or thymidinc; Xz is cytosine or thymine, N is any nucleotide and N, + IVY is from about 0-26 bases. In a preferred embodiment, N, and NZ do not contain a CCGG quadmer or more than one CGG trimer; and the nucleic acid sequence is from about 8-30 bases in WO 98/37919 PCTlUS98/03678 length. However, nucleic acids of any size (even may kb long) can be used in the invention if CpGs are present, as larger nucleic acids are degraded into oligonucleotides inside cells. Preferred synthetic oligonucleotides do not include a CCGG
quadmer or more than one CCG or CGG trimer at or near the S' or 3' terminals and/or the consensus mitogenic CpG motif is not a palindrome. A "palindromic sequence" or "palindrome"
means an inverted repeat (i.e., a sequence such as ABCDEE'D'C'B'A', in which A
and A' arc bases capable of forming the usual Watson-Crick base pairs. An exemplary nucleic acid sequence of the invention is:
5'-ATAATCGACGTTCAAGCAAG-3' (SEQ ID N0:2).
11~ another embodiment, the method of the invention includes the use of an oligonucleotide which contains a CpG motif represented by the formula:
5' N,X,X,CGX3XQN~ 3' (SEQ ID N0:3) wherein at least one nucleotide separates consecutive CpGs; X,X, is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3 X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N, + N, is from about 0-26 bases.
In a preferred embodiment, N, and N~ do not contain a CCGG quadmer or more than one CCG or CGG trimer. CpG ODN are also preferably in the range of 8 to 30 bases in length, but may be of any size (even many kb long) if sufficient motifs are present, since such larger nucleic acids are degraded into oligonucleotides inside of cells.
Preferred synthetic oligonucleotides of this formula do not include a CCGG quadmer or more than one CCG or CGG trimer at or near the 5' and/or 3' terminals and/or the consensus mitogenic CpG motif is not a palindrome. Other CpG oligonucleotides can be assayed for efficacy using methods described herein.
A prolonged effect can be obtained using stabilized oligonucleotides, where the oligonucleotide incorporates a phosphate backbone modification (e.g., a phosphorothioate or phosphorodithioate modification). More particularly, the phosphate backbone modification occurs at the 5' end of the nucleic acid for example, at the first two nucleotides of the 5' end of the nucleic acid. Further, the phosphate backbone modification may occur at the 3' end of the nucleic acid for example, at the last five - nucleotides of the 3' end of the nucleic acid. Preferred nucleic acids containing an unmethylated CpG'have a relatively high stimulation with regard to B cell, monocyte, ' and/or natural killer cell responses (e.g., induction of cytokines, proliferative responses, lytic responses, among others).
The "stimulation index" is a measure of a CpG ODN to effect an immune response which can be tested in various immune cell assays. The stimulation of the immune response can be assayed by measuring various immune parameters, e.~,~., measuring the antibody-forming capacity, number of lymphocyte subpopulations, mixed leukocyte response assay, lymphocye proliferation assay. The stimulation of the immune response can also be measured in an assay to determine resistance to infection or tumor growth.
Methods for measuring a stimulation index are well known to one of skill in the art.
For example, one assay is the incorporation of 31 I uridine in a murine B cell culture.
which has been contacted with a 20p.M of oligonucleotide for 20h at 37°C and has been pulsed with 1 ~Ci of ~H uridine; and harvested and counted 4h later. The induction of secretion of a particular cytokine can also be used to assess the stimulation index. Without meaning to be bound by theory, for use in vivo, for example to treat a subject having or at risk of having an acute decrement in air flow in response to endotoxin, it is important that the CpG ODN be capable of effectively inducing cytokine secretion by monocytic cells and/or Natural Itiller (NK) cell lytic activity. In one method, the stimulation index of the CpG ODN with regard to B-cell proliferation is at least about 5, preferably at least about 10, more preferably at least about 15 and most preferably at least about 20, while recognizing that there are differences in the stimulation index among individuals.
The CpG ODN of the invention stimulate cytokine production (e.g., IL-6, IL-12, IFN-y, TNF-a and GM-CSF). Exemplary sequences include:
_ TCCATGTCGCTCCTGATGCT (SEQ ID N0:4), TCCATGTCGTTCCTGATGCT (SEQ ID NO:S), and TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6).
The CpG ODN of the invention are also useful for stimulating natural killer-cell (NK) iytic activity in a subject such as a human. Specific, but nonlimiting examples of such sequences include: -TCGTCGTTGTCGTTGTCGTT (SEQ ID N0:7), TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6), TCGTCGTTGTCGTTTTGTCGTT (SEQ ID N0:8), GCGTGCGTTGTCGTTGTCGTT (SEQ ID N0:9), TGTCGTTTGTCGTTTGTCGTT~(SEQ ID NO:10), TGTCGTTGTCGTTGTCGTT (SEQ ID NO:1 I ), and TCGTCGTCGTCGTT (SEQ ID N0:12).
The nucleic acid sequences of the invention are also useful for stimulating B
cell proliferation. Specific, but noniimiting examples of such sequences include:
TCCTGTCGTTCCTTGTCGTT (SEQ ID N0:13), TCCTGTCGTTTT"TTGTCGTT (SEQ ID N0:14), TCGTCGCTGTCTGCCCTTCTT (SEQ ID NO:15), TCGTCGCTGTTGTCGTTTCTT (SEQ ID N0:16), TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6), TCGTCGTTGTCGTTTTGTCGTT (SEQ ID N0:8) and TGTCGTTGTCGTTGTCGTT (SEQ ID NO:11).
Preferred CpG ODN can effect at least about'S00 pg/ml of TNF-a, 15 pg/mi IFN-y, 70 pg/ml of GM-CSF ?75 pg/ml of IL-6, 200 pg/ml IL-12, depending on the therapeutic indication. These cytokines can be measured by assays well known in the art.
The ODNs listed above or other preferred CpG ODN can effect at least about 10%, more preferably at least about 15% and most preferably at least about 20% YAC-1 cell specific lysis or at least about 30%, more preferably at least about 35%, and most preferably at least about 40% 2C 11 cell specific lysis, in assays well known in the art (see Example 4).
The term "acute" refers to a condition having a short and relatively severe course. A
"decrement in air flow" is a decrease in a measurable parameter of lung function. The WO 98/37919 PC'r/US98/03678 terms "lung function" and "pulmonary function" are used interchangeably and shall be interpreted to mean physically measurable operations of a lung including but not limited to inspiratory flow rate, expiratory flow rate, and lung volume. Methods of quantitatively determining pulmonary function are used to measure lung function.
Methods of measuring pulmonary function most commonly employed in clinical practice involve timed measurement of inspiratory and expiraton~ maneuvers to measure specific parameters. For example, forced vital capacity (FVC) measures the total volume in liters exhaled by a patient forcefully from a deep initial inspiration. This parameter, when evaluated in conjunction with the forced expired volume in one second (FEV,), allows bronchoconstriction to be quantitatively evaluated. A problem with forced vital capacity determination is that the forced vital capacity maneuver (i.e., forced exhalation from maximum inspiration to maximum expiration) is largely technique dependent. In other words, a given patient may produce different FVC values during a sequence of consecutive FVC maneuvers. The FEF 2S-7S or forced expiratory flow determined over 1 S the midportion of a forced exhalation maneuver tends to be less technique dependent than the FVC. Similarly, the FEV, tends to be less technique dependent than FVC. In addition to measuring volumes of exhaled air as indices of pulmonan~ function, the flow in liters per minute measured over differing portions of the expiratory cycle can be useful in determining the status of a patient's pulmonary function. In particular, the peak expiratory flow, taken as the highest air flow rate in liters per minute during a forced maximal exhalation, is well correlated with overall pulmonary function in a patient with asthma and other respiratory diseases.
The term "asthma" refers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms.
By "therapeutically effective amount" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest symptoms in a WO'98/379I9 PCT/US98/03678 subject. A subject is any mammal, preferably a human. Amounts effective for therapeutic use will, of course, depend on the severity of the disease and the weight and general state of the subject. Typically, dosages used in vitro may provide useful guidance in the amounts useful for if2 situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, e.g., in Gilman et al., eds., Goodman And Gilman's: T'he Pharmacological Bases of Therapeutics 8th ed., Pergamon Press, 1990; and Remin~ton's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pa., 1990, each of which is herein incorporated by reference.
An oligonucleotide containing at least one unmethylated CpG can be used alone to activate the immune response or can be administered in combination with another therapeutic modality, either a drug or a surgical procedure. For example, when the oligonucleotide containing at least one unmethylated CpG is administered in conjunction W th another therapeutic modality, the oligonucleotide can be administered before, after, I S and/or simultaneously with the other therapeutic modality. The oligonucleotide containing at least one unmethylated CpG can have an additional efficacy (e.g., through antisense or other means) in addition to its ability to activate the immune response.
In another embodiment, the invention further provides a method of treating a subject having or at risk of having an inflammatory response to LPS by administering to the subject a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG.
Examples of diseases which can be associated with Gram-negative bacterial infections or endotoxemia include bacterial meningitis, neonatal sepsis, cystic fibrosis, , inflammatory bowel disease and liver cirrhosis, Gram-negative pneumonia, Gram-negative abdominal abscess, hemorrhagic shock and disseminated intravascular coagulation. Subjects who are leukopenic or neutropenic, including subjects treated with chemotherapy or immunocompromised subjects (for example with AIDS), are WO '98/37919 PCT/US98/03678 particularly susceptible to bacterial infection and the subsequent effects of endotoxin.
By "lipopolysaccharide" or "LPS" is meant a compound composed of a ' heteropolysaccharide (which contains somatic O antigen) covalently bound to a phospholipid moiety (lipid a). LPS is a major component of the cell wall of Gram-negative bacteria. By "endotoxin" is meant a heat-stable toxin associated with the outer membranes of certain Gram-negative bacteria, including the enterobacteria, brucellae, neisseriae, and vibrios. Endotoxin, normally released upon disruption of the bacterial cells, is composed of lipopolysaccharide molecules (LPS) and any associated proteins. The phospholipid moiety of LPS, lipid a, is associated with LPS
toxicity.
When injected in large quantities endotoxin produces hemorrhagic shock and severe diarrhea; smaller amounts cause fever, altered resistance to bacterial infection, leukopenia followed by leukocytosis, and numerous other biologic effects.
Endotoxin is a type of "bacterial pyrogen," which is any fever-raising bacterial product. The terms "endotoxin," "LPS," and "Iipopolysaccharide" as used herein are essentially synonymous.
The invention further provides a method of treating a subject having or at risk of having an inflammatory response to LPS. It is known that LPS produces an inflammatory response in normal and asthmatic patients. By "inflammatory response" is meant an accumulation of white blood cells, either systemically or locally at the site of inflammation. The inflammatory response may be measured by many methods well known in the art, such as the number of white blood cells (WBC), the number of polymorphonuclear neutophils (PMN). a measure of the degree of PMN activation, such as luminal enhanced-chemiluminescence, or a measure of the amount of cytokines present. The term "cytokine" is used as a generic name for a diverse group of soluble proteins and peptides which act as humoral regulators at nano- to picomolar concentrations and which, either under normal or pathological conditions, modulate the functional activities of individual cells and tissues. These proteins also mediate interactions between cells directly and regulate processes taking place in the extracellular environment. Examples of cytokines include, but are not limited to, TNF-a, IL-10, IL-12, interferon-'y. Importantly, interferon-y is a key cytokine mediating LPS-induced inflammation (e.g., Ozmen, L., et al., J. Exp. Mecl. 180:907-915, 1994). The release of interferon-y is induced by IL-12 derived from macrophage/monocyte/dendritic cells.
(e.g., Balanchard, D.K., et al., J. Immunol. 136:963-970, 1986), and IL-10 inhibits interferon-y via a macrophage-dependent step in which IL-12 production is inhibited (D'Andrea, a., et al., J. Exp. Mec~' 178:1041-1048, 1993). Without wanting to be bound by theory, it is possible that nucleic acids containing unmethylated CpG could reduce the inflammatory response to LPS by increasing the production and response of IL-10, or by modulating the response of a factor which in tum increase the production and response of IL-10 or IL-6.
The invention further provides a method of modulating the level of a cytokine altered in response to inhaled LPS. The term "modulate" envisions the suppression of expression of a particular cytokine when it is overexpressed, or augmentation of the expression of a particular cytokine when it is underexpressed. Modulation of a particular cyokine can occur locally or systemically. It is believed that the CpG oligonucleotides do not directly activate purified NK cells, but rather render them competent to respond to IL-12 with a marked increase in their IFN-y production. By inducing IL-12 production and the subsequent increased IFN-y secretion by NK cells, the immunostimulatory nucleic acids also promote a Thl type immune response. No direct activation of proliferation or cytokine secretion by highly purified T cells has been found. Cytokine profiles determine T cell regulatory and effector functions in immune responses.
Cytokines also play a role in directing the T cell response. Helper (CD4~) T
cells - orchestrate the immune response of mammals through production of soluble factors that act on other immune system cells, including other T cells. Most mature CD4+ T
helper cells express one of two cytokine profiles: Thl or Th2. Thl cells secrete IL-2, IL-3, IFN-y, TNF-(3, GM-CSF and high levels of TNF-a. Th2 cells express IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF and low levels of TNF-a. The Thl subset promotes delayed-type hypersensitivity, cell-mediated immunity, and immunoglobulin class switching to IgG2a. The Th2 subset induces humoral immunity by activating B
cells, promoting antibody production, and inducing class switching to IgG, and IgE.
Several factors have been shown to influence commitment to Thl or Th2 profiles. The best characterized regulators are cytokines. IL-I2 and IFN-y are positive Th I
and negative Th2 regulators. IL-12 promotes IFN-y production, and IFN-'y provides positive feedback for IL-12. IL.-4 and IL-10 appear to be required for the establishment of the Th2 cytokine prof le and to down-regulate Thl cyokine production; the effects of IL-4 are in some cases dominant over those of IL-12. IL-13 was shown to inhibit expression of inflammatory cytokines, including IL-12 and TNF-a by LPS-induced monocytes, in a way similar to IL-4. The IL-12 p40 homodimer binds to the IL-I2 receptor and antagonizes IL-12 biological activity; thus it blocks the pro-Th 1 effects of IL-12.
The invention may be used to treat individuals who are "at risk" of developing a acute decrement in airflow or who are at risk of LPS exposure. These individuals may be identified by any diagnostic means, or by epidemiological evidence such as exposure data. These individuals may be treated by a method of the invention prior to, at the time of, or after the actual onset of the clinical appearance. The "clinical appearance" can be any sign or symptom of the disorder.
This invention further provides administering to a subject having or at risk of having an inflammatory response to inhaled LPS, a therapeutically effective dose of a pharmaceutical composition containing the compounds of the present invention and a pharmaceutically acceptable carrier. "Administering" the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan.
The pharmaceutical compositions according to the invention are in general administered topically, intravenously, orally, parenterally or as implants, and even rectal use is possible in principle. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipicnts and additives and/or auxiliaries such as disintegnants, binders, IO coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizcrs are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see Langer, Science 249:1527-1533, 1990, which is incorporated herein by reference.
The pharmaceutical compositions are preferably prepared and administered in dose units.
Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the patient, different daily doses are necessary.
Under certain circumstances, however, higher or lower daily doses may be appropriate.
The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.
The pharmaceutical compositions according to the invention may be administered locally or systemically. By "therapeutically effective dose" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest the symptoms of the disorder and its complications. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the patient. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various ' considerations are described, e.~ , in Gilman et al., eds., Goodman And Gilman's: The Pharmacolo;~ical Bases of Therapeutics, 8th ed., Pergamon Press, 1990; and Reminaton's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pa., 1990, each of which is herein incorporated by reference.
The following examples are intended to illustrate but not to limit the invention in any manner, shape, or form, either explicitly or implicitly. While they arc typical of those that might be used, other procedures, methpdologies, or techniques known to those skilled in the an may alternatively be used.
EJiAMPLE 1 METHODS FOR PULMONARY RESPONSE TO INHALED LPS
In the first series of experiments, mice were intravenously treated with 20 base pair (bp) I 5 oligonucleotides containing CpG motifs (CpG oligo) or 20 by oligonucleotides without embedded CpG motifs (non CpG oligo) 30 min, 4 hours, or 12 hours prior to a 4 hour inhalation challenge with E. cnli LPS (1.5 ug/m3). To determine whether unmethylated CpG motifs were responsible for the protective effect, we pretreated mice with oligonucleotides containing either unmethylated CpG motifs or methylated CpG
motifs prior to an inhalation challenge with E. coli LPS. Finally, to determine the role of IL-10, we pretreated IL-lU knockout mice with CpG oIigos and then performed a similar inhalation challenge with E. coli LPS. Immediately post inhalation challenge, all mice were sacrificed, blood samples were obtained, whole lung lavage was performed, and lungs were harvested for mRNA analysis.
AtZimals. C3H/HeBFEJ, C57BL/6, and C57BL/6-II10'"''c~' male mice (Jackson Laboratories, Bar Harbor, ME) were obtained at 6 weeks of age and used within 2 weeks.
All animal care and housing requirements set forth by the National Institutes of Health WO '98/37919 PCT/US98/03678 Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources were followed, and animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee. Mice were maintained in wood-chip bedding (Northeastern Product, Warrensberg, NY), with food {Formulab Chow 5008, PMI, Richmond, IN) and water supplied ad libitum.
171i~onucleotides. Twenty base pair oligonucleotides were synthesized with and without the embedded CpG motifs (Oligos etc., Wilsonville, OR). These oligonucleotides contained a nuclease-resistant phosphorothioate-modified backbone, and were purified by two rounds of ethanol precipitation prior to use. The CpG dinucleotide was flanked by two 5' purines and two 3' pyrimidines to enhance the stimulatory effect of the oligonucleotide. The ''nonstimulatory" oligonucleotide v,~as identical to the stimulatory oligonucleotide except that the two embedded CpG motifs were modified, one appearing as an ApG motif and the other appearing as a GpC motif. The two synthesized oligonucleotides had the following sequences: -I S CpG Oligonucleotide: ATAATCGACGTTCAAGCAAG (SEQ ID
N0:17) Non-CpG oligonucleotidc: ATAATAGAGCTTCAAGCAAG (SEQ ID
N0:18) A~ethvlatio~~ Protocol. DNA was methylated as we have described previously (Krieg, A.M., et ul., Nature 374:546-9. 1995) ~~ith 2 U CpG methylase (New England Biolabs;
Beverly. MA) per pg DNA for 18 hours at 37°C. Methylated DNA was tested to confirm that it was completely protected against digestion with Hpa-II but not Msp-I.
Chemicals. Endotoxin was purchased as lyopholized purified ~. coli OII1:B4 lipopolysaccharide (LPS) (Sigma Chemical Co., St. Louis, MO, PN# L2630) and had a specified activity of 1.3 x 106 ng/mg and protein content less than 3%.
Endo~o~in A~.sav. The endotoxin concentrations of LPS solution, LPS aerosol, and - oligonucleotides were assayed using the chromogenic Limulus amebocyte lysate (LAL) assay (QCL-1000, ~Vhittaker Bioproducts, Inc., Walkersville, MD) with sterile, pyrogen-free labware and a temperature controlled microplate block and microplate reader (405 S nm). The LPS solution was serially diluted in pyrogen-free water and assayed. The airborne concentration of LPS was assessed by sampling 0.30 m3 of air drawn from the exposure chamber through 47 mm binder-free glass microfiber filters (EPM-2000, Whatman Intl. Ltd., Maidstone, England) held within a 47 mm stainless steel in-line air sampling filter holder (Gelman Sciences Inc., Ann Arbor, MI). Air sampling filters were I 0 extracted with 10 ml of pfw at room temperature with gentle shaking for 1 hour. They were then serially diluted with pfw and assayed for endotoxin. Four to 6 air samples were assayed for each exposure. All standard curves (0. I to 1.0 EU/ml) achieved a linear regression coefficient exceeding 1=0.995. Spiked samples and filter blanks and participates were run routinely; interlaboratory validation studies were also performed 15 routinely.
Ex~nszrre Prntncvl and Monit~zring Eguinment. LPS aerosols were generated into a glass 20 L exposure chamber using a PITT#1 nebulizer supplied with extract by a syringe pump. Liquid feed rates ranged from 0.0027 to 0.21 ml/min. HEPA-filtered air was supplied to the nebulizer at flow rates ranging from 10 to 17 L/min. Mixing within the 20 chamber was aided by a magnetically coupled rotor. The chamber atmosphere was exchanged at 1 change/min. LPS concentrations were determined by sampling the total chamber outflow. Particle size distributions were determined with an Aerodynamic Particle Sizer (TSI, Inc., St. Paul, MN) and gravimetrically with a Marble personal cascade impactor and Mylar media (Thorne, P.S., Am. J. hzd. Med. 25:109-1 I2, 1997) 25 by sampling within the exposure chamber.
Lunge. Immediately following the inhalation challenge, mice were euthanized, the chest was opened, and lungs were lavaged in situ via PE-90 tubing inserted into the exposed trachea. A pressure of 25 cm H20 was used to wash the lungs with 6.0 mI of WO 98/37919 PC'r/US98/03678 sterile pyrogen free saline. Following whole lung lavage, the lungs were isolated and frozen in liquid nitrogen and stored at -70°C.
Treat»tent ofBrorcchoalveolar Lavage Fluid. A standard method (Schwartz, D.A., et al., Ant. J. Physiol. 267:L609-617, 1994) of processing the sample was as follows:
immediately following lavage, the volume was noted and 15 ml conical tubes were centrifuged for S min at 200 x g. The supernatant fluid was decanted and frozen at -70°C
for subsequent use. The residual pellet of cells was resuspended and washed twice in HBSS (without Ca" or Mg" ). After the second wash, a small aliquot of the sample was taken for cell count using a hemocytometer. The cells were then washed once more and resuspended in RPMI medium so that the final concentration gave a cell count of 1 x I0'' cells/ml. The cells which were present in 10-12 ~1 of the 1 x 10'' ml cell suspension were spun for 5 minutes onto a glass slide using a special filter card using a cytocentrifuge (Cytospin-2; Shanden Southern. Sewickley, PA). Staining was carried out using a Diff Quick Stain Set (I-iarleco, Gibbstown, NY). The slide was then dried, one drop of optically clear immersion oil was put on the slide over the cells and a coverslip was placed on top.
Cytokine Analysi.s of lavage fluid and serum. Lavage fluid was assayed for TNF-a, MII'-2, IL-6,1L-10, IL-12, and IFN-y. In all cases, a polyclonal antibody specific for the murine recombinant cytokine (TNF-a, MIP-2, IL-6, IL-10, IL-I2, or IFN-y) was used as a capture reagent in a standard commercially available sandwich ELISA (R &
D
Systems; Minneapolis, MN). The limit for detection for TNF-a is 5.1 pg/ml, MIP-2 is 1.5 pg/ml, IL-6 is 10 pg/ml, IL-10 is 10 pg/ml, IL-12 is 5 pg/ml, and IFN-y is 10 pg/ml.
Preparation ofRNA and Multiprohe RNasc ProtectiofZ Assay. Total RNA was extracted from lung specimens using the single-step method (Chomczynski and Pandsacchi, Anal Biochem 162:156-9, 1987; Kedzierski, W., Biotechniques 10:210-214,1991), lysing flash frozen lung in RNA STAT-60 (Tel-Test B; Friendswood, TX). The composition of RNA
STAT-60 includes phenol and guanidinium thiocyanate in a monophase solution.
The lung parenchyma was homogenized in the RNA STAT-60 using a polytron homogenizer.
Chloroform was added, the total RNA was precipitated from the aqueous phase by addition of isopropanol, and the total RNA was washed with ethanol and solubilized in ' wafer. After drying the pellet in a vacuum desiccator, the yield and purity of RNA was quantitated by measuring the ratio of absorbances at 260 and 280 nm. Mini-gel electrophoresis was used to confirm the integrity of the 28s and I 8s rRNA
bands. Gene transcripts were detected using the RNase protection assay as previously described (Hobbs, J.M., et al., J. Immunol. 150:3602, 1993). Equivalent amounts of RNA
were examined, as judged by the amount of L32, which encodes an ubiquitously expressed ribosome subunit protein (Raichel, A., et al., Nucl. Acid Res. 16:2347, 1987) in each sample. Commercially available probes were used to detect TNF-a, MIP-3, IL-6, IL-10, IL-12, and IFN-y.
.stati.rtical Analv:s-i.s. Three comparisons were pursued in this analysis: 1 ) the effect of intravenous CpG containing oligonucleotides versus oligonucleotides without embedded CpG motifs in modulating the inflammatory response to inhaled LPS; 2) the effect of unmethylated CpG motifs versus methylated CpG motifs in controlling the inflammatory response to LPS; and 3) the role of IL-10 in mediating the protective effect of unmethylated CpG containing oligonucleotides. The inflammatory response was assessed using lavage cellularity, lavage fluid cytokine concentration, serum concentration of cytokines, and the relative concentration of mRNA for specific cytokines in the lung parenchyma. After making sure that the data were normally distributed, statistical comparisons were made using parametric statistics including the Student's T-test (Rosner, R., Fundamentals of Biostatistics (3rd edition) Boston, MA, PWS-Kent, 1980).
CnG ODN REDUCES THE PULMONARY RESPONSE TO INHALED
LPS AND STIMULATES THE IMMUNE RESPONSE
Pretreatment with CpG oligonucIeotides (ODN) resulted in a systemic inflammatory response. Although intravenous treatment with CpG ODN did not affect the concentration of peripheral white blood cells; compared to non-CpG ODN, treatment with CpG ODN prior to LPS inhalation resulted in a higher concentration of PMNs 30 min, 4 hours, and 12 hours after injection. As expected, intravenous treatment with CpG
oligonucleotides also affected the concentration of cytokines in the serum.
Compared to non-CpG ODN, CpG ODN resulted in an increase in the concentration of MIf-2, IL-I 0. and IL-12 in the serum of mice following LPS inhalation (FIG. I
). These differences were most pronounced 30 min and 4 hours after intravenous administration but were still present 12 hours after exposure to CpG containing oligonucleotides. No differences were observed for the serum concentration of TNF-a, IL-6, and IFN-y at an}~
of the time points in mice pre-treated with either oligonucleotide and then exposed to LPS (data not shown for IL-6).
Pretreatment with CpG containing oligonucleotides reduced the pulmonary response to inhaled LPS. Animals pretreated with CpG oligonucleotides at 0.5, 4, and 12 hours had a reduced concentration of cells in the lavage fluid following inhalation challenge with LPS (FIG. 2). However, this effect appeared to be time dependent since pretreatment with oligonucleotide at 0.5 and 4 hours resulted in a reduced percentage of savage PMNs while pretreatment with the oligonucleotide 12 hours prior to the inhalation challenge did not affect the percentage of Iavage PMNs (FIG. 2). Although pretreatment with CpG
containing oligonucleotides resulted in significant changes in the concentration of cytokines in the lavage fluid, the changes in cytokine concentration were predominantly evident when mice were pretreated with CpG oligonucleotides 4 hours prior to the inhalation challenge. While significant reductions were observed in the concentration of TNF-a and MIP-2, the lavage fluid concentration of IL-12 was elevated following treatment with CpG oligonucleotides 4 hours prior to the inhalation challenge (FIG. 3).
IL-6, IL-10, and IFN-y were not measurable in the lavage fluid following inhalation of LPS at any of the time points. Interestingly, results from the RNase protection assay indicate that total lung mRNA concentrations for TNF-a, MIP-2, IL-6, IL-I 0, and IFN-y are similar in mice pretreated with the CpG and non-CpG containing oligonucleotide (FIG. 4). These results also demonstrate that mIZNA IL-12 appears to be upregulated in the lung only from mice pretreated with CpG containing oligonucleotides.
To determine the specificity of the CpG oligonucleotides in suppressing the inflammatory response to inhaled LPS, the CpG motifs were methylated. The immunosuppressive effects of two identical oligonucleotides, one with unmethylated CpG motifs and the other with methylated CpG motifs, were compared.
Methylating the CpG motifs abolished the protective effect of CpG oligonucleotides in preventing the cellular inflammatory response to inhaled LPS (FIG. 5).
Further experiments were conducted with the following oligonucleotides:
1908 ATAATAGAGCTTCAAGCAAG (SEQ ID N0:18) 1760 ATAATCGACGTTCAAGCAAG (SEQ ID N0:2) 1631 CGCGCGCGCGCGCGCGCGCG (SEQ ID N0:59) 1835 TCTCCCAGCGAGCGCCAT (SEQ ID N0:60) 1759 ATAATCCAGCTTGAACCAAG (SEQ ID N0:61 ) 1826 TCCATGACGTTCCTGACGTT (SEQ ID N0:62) 1585 GGGGTCAACGTTGAGGGGGG (SEQ ID N0:63) 2010 GCGGCGGGCGGCGCGCGCCC (SEQ ID N0:54) 197? GGGGTCTGTGCTTTTGGGGGG (SEQ ID N0:64) 2001 GGCGGCGGCGGCGGCGGCGG (SEQ ID N0:65) Mice were pretreated with the indicated oligonucleotide and then challenged through the airways with LPS as described above. A saline challenge was used as a control.
The lungs of the mice were lavaged, and the number of cell per mI, number of polymorphonuclear olymorphonuclear cells cells (PMN) per ml, and the percentage of p in the airways -was determined (see Table 1 ).
Table 1 expt 1, C3H/BFeJ
mice ODN Number cells/ml PMNImI x 105 % PMN
x 104 1908 61.4 15.9 59.2115.7 95.810.95 1760 27.813.5 25.8t3.0* 93.32.3 *
1631 47.6 11.1 46.1 t 10.7 96.81 I .1 I
1835 43.87.1 44.47.1 96.80.75 1759 71.0 19.8 67.7120.4 96.812.6 1826 39.87.8 38.37.9 93.51 1.4 None (saline) 71.07.4 ~9.3t6.9 97.8 1.3 expt 2, C57 Bl/6 mice ODN Number cells/ml PMN/ml x 105 % PMN
x 104 1908 I 8.02.6 16.62.7 91.23.7 1760 10.22.3 8.612.1 * 82.bt3.0 *
1585 11.0~2.2* 9.5~2.2* 84.62.9 2010 14.112.1 11.81.9 83.412.1 None (saline) 17.913.4 16.912.1 expt 3 ODN Number cells/ml x 104 PMN/ml x 105 0/
I 908 19.012.5 16.92. I 89.411.4 1760 9.1 ~0.8* 7.7t0.7* 84.610.5 1972 I 5.31.6 13.51.4 84.21.2 2001 13.0 1.6* 11.8 1.6 90.42.2 - -* P < 0.05, Mann-Whitney U test In experiment l, both oligonucleotide 1760 and 1826 appear to be effective. In experiment 2, oligonucleotide 1760 and 1585 were effective. Oligonucleotide 2010 also appears to have had a modest effect. In experiment 3, oligonucleotide 1760 was effective. A modest effect was seen with. oligonucleotide 2001. Thus the best oligonucleotides for inducing a therapeutic effect fit the motifs shown in SEQ
ID NO:1 and SEQ ID N0:3. Oligonucleotides such as 2001 and 2010, which contain CpG
motifs with CCGG, CCG, and CGG, can also have a beneficial effect.
The results indicate that CpG containing oligonucleotides substantially reduce the inflammatory response to inhaled LPS and that the protective effect appears to be specific to unmethylated CpG motifs embedded within the oligonucleotide. Thesc findings suggest that oligonucleotides containing CpG motifs may prove helpful in controlling the inflammatory response to inhaled LPS and other environmental agents.
Sincc endogenous and exogenous IL-10 arc known to suppress the inflammatory response to LPS (Cassatella, M.A., et al., J. Eap. Mecl. 178:2207, 1993; Berg, D.J., et al., J. Clim. Invest. 96:2339-2347, 1995), IL-10 might play a critical role in mediating the immunosuppressive effects of CpG oligonucleotides. To pursue this hypothesis, knockout (C57BL/6-II10'"''cs") mice and C57BL/6 control mice were pretreated with CpG containing oligonucleotides and then an inhalation challenge with E coli LPS was performed. Compared to pretreatment with intravenous saline, CpG containing oligonucleotides significantly reduced the total cellularity and the concentration of PMNs in the lavage fluid in both C57BL/6 and mice with a disrupted IL-10 gene (C57BL/6-ll10'"'"~') (FIG. 6). Importantly, the immunosuppressive effects of CpG
oligonucleotides were equally effective in mice with a disrupted 1L-10 gene compared to wild type mice.
The results indicate that the protective effect of unmethylated CpG motifs is not dependent on IL-10.
INDUCTION OF NK ACTIVITY
Phosphodiester ODN were purchased from Operon Technologies (Alameda, CA).
Phosphorothioate ODN were purchased from the DNA core facility, University of Iowa, or from The Midland Certified Reagent Company (Midland TX). E. coli (strain B) DNA
and calfthymus DNA were purchased from Sigma (St. Louis, MO). All DNA and ODN
were purified by extraction with phenol:chlorofonn:isoamyl alcohol 05:24:1 ) and/or ethanol precipitation. The LPS level in ODN was less than 12.5 ng/mg and E.
cull and calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA by Limulus assay.
Virus-free, 4-6 week oId, DBA/2, C57BL/6 (B6) and congenitally athymic BALB/C
mice were obtained on contract through the Veterans Affairs from the National Cancer Institute (Bethesda, MD). C57BL/6 SCID mice were bred in the SPF barner facility at the University of Iowa Animal Care Unit.
Human peripheral blood mononuclear leukocytes (PBMC) were obtained as previously described (e.g., Ballas, Z.K. et al., J. Aller~~ Clin. hnnTUnol. 85:453, 1990). Human or murine cells were cultured at 5 x 106/well, at 37'C in a 5% CO, humidified atmosphere in 24-well plates with medium alone or with CpG or non-CpG ODN at the indicated concentrations, or with E. coli or calf thymus (50 ~g/ml) at 3TC for 24 hr.
All cultures were harvested at 18 hr. and the cells were used as effectors in a standard 4 hr.
$'Cr-release assay against IL562 (human) or YAC-I (mouse) target cells as previously described. For calculation of lytic units (LU), I LU was defined as the number of cells needed to effect 30% specific lysis. Where indicated, neutralizing antibodies against IFN-y (Lee Biomolecular, San Diego, CA) or IL-12 (Pharmingen) or their isotype controls were added at the initiation of cultures to a concentration of 10 pg/ml. For , anti-IL-12 addition, 10 lxg of each of the 4 MAB (or isotype controls) were added simultaneously. Recombinant human IL-2 was used at a concentration of 100 U/ml.
Experiments were conducted to determine whether CpG containing oligonucleotides stimulated the activity of natural killer (NK) cells in addition to B cells.
As shown in Table 2, a marked induction of NK activity among mouse spleen cells cultured with CpG ODN 1: - GCTAGACGTTAGCGT (SEQ ID N0:19) and 3Dd: GAGAAXGCTGGACCTTCCAT (SEQ )D N0:20), (where X = 5 methyl cytosine) was observed. In contrast, there was relatively no induction in effectors that had been treated with non-CpG control ODN.
Table 2 Induction OfNK Activity By CpG Oligodeoxynucleotides~ODN) YAC-1 Specific Lysis* % 2C1 I Specific Lysis Effector: Target Effector: Target ODN 50:1 100:1 50:1 100:1 None -1.1 -1.4 15.3 16.6 I 16. I 24.5 3 8.7 47.2 3Dd 17.1 27.0 37.0 40.0 non-CpG ODN -1.6 -1.7 14.8 15.4 Induction ofNli actiuit~ y DNA containing CMG motifs. hul not bn non-CpG
DNA.
Bacterial DNA cultured for 18 hrs. at 37°C and then assayed for killing of K562 (human) or Yac-1 (mouse) target cells induced NK lytic activity in both mouse spleen cells depleted of B cells, and human PBMC, but vertebrate DNA did not (Table 3).
To determine whether the stimulatory activity of bacterial DNA may be a consequence of its increased level of unmethylated CpG dinucleotides, the activating properties of more than 50 synthetic ODN containing unmethylated, methylated, or no CpG dinucleotides was tested. The results, summarized in Table 3, demonstrate that synthetic ODN can stimulate significant NK activity, as long as they contain at least one unmethylated CpG dinucleotide (Ballas, Z., et al., Jlmmunol 157:1840-1845, 1996). No difference was observed in the stimulatory effects of ODN in which the CpG was within a palindrome (such as ODN 1585, which contains the palindrome ~WO 98/37919 PC'r/US98/03678 AACGTT) from those ODN without palindromes (such as 1613 or 1619), with the caveat that optimal stimulation was generally seen with ODN in which the CpG
was flanked by two 5' purines or a 5' GpT dinucleotide and two 3' pyrimidines.
Kinetic experiments demonstrated that NK activity peaked around 18 hrs. after addition of the ODN. The data indicates that the murine NK response is dependent on the prior activation of monocytes by CpG DNA, leading to the production of IL-I 2, TNF-a, and IFN.
Table 3 Induction of NK Activity by DNA Containing CpG Motifs but not b~~ Non-CpG DNA
LU/ 10'' DNA or Cytokine Added Mouse Cells Human Cells Expt.l None 0.00 0.00 IL-2 16.68 15.8?
E. Colt DNA 7.23 5.05 Calf thymus DNA , 0.00 0.00 1=;xpt.2 None 0.00 3.28 1585 ggGGTCAACGTTGACgggg (SEQ ID N0:21 ) 7.38 17.98 1629 -----------gtc--------------- (SEQ ID N0:22) 0.00 4.4 Expt.3 None 0.00 1613 GCTAGACGTTAGTGT (SEQ ID N0:23) 5.22 .
1769 --------------X------------- (SEQ ID N0:24) 0.02 ND
1619 TCCATGTCGTTCCTGATGCT (SEQ ID NO:S) 3.35 I765 -______________X___-____________-_____ (SEQ ID N0:25) 0.11 CpG dinucleotides in ODN sequences are indicated by underlining; X indicates methylcytosine. Lower case letters indicate nuclease resistant phosphorothioate modified internucleotide linkages which, in titration experiments, were more than 20 times as potent as non-modified ODN, depending on the flanking bases. Poly G ends (g) were used in some ODN, because they signif candy increase the level of ODN uptake.
Dashes indicate some bases are identical to those in the directly preceding sequence, with the exception of changes noted.
Immune activation by CpG motifs may depend on bases flanking the CpG, and the number and spacing of the CpGs present within an ODN. Although a single CpG in an ideal base context can be a very strong and useful immune activator, superior effects can be seen with ODN containing several CpGs ~~ith the appropriate spacing and flanking bases. For activation of murine B cells, the optimal CpG motif is TGACGTT.
The following studies were conducted to identify optimal ODN sequences for stimulation of human cells by examining the effects of changing the number, spacing, and flanking bases of CpG dinucleotides.
Iclentiftcatiorr of~nlzo.st~horothioate ODN with ontinzcrl CMG mnti s far activation human NIL cells To have clinical utility, ODN must be administered to a subject in a form that protects them against nuclease degradation. Methods to accomplish this with phosphodiester ODN are well known in the art and include encapsulation in lipids or delivery systems such as nanoparticles. This protection can also be achieved using chemical substitutions to the DNA such as modified DNA backbones including those in which the internucleotide linkages are nuclease resistant. Some modifications may confer additional desirable properties such as increasing cellular uptake. For example, the phosphodiester linkage can be modified via replacement of one of the nonbridging oxygen atoms with a sulfur, which constitutes phosphorothioate DNA.
Phosphorothioate ODN have enhanced cellular uptake (Krieg et al., Arztiserzse Res. Dev. 6:133, 1996) and improved B cell stimulation if they also have a CpG motif. Since NK activation correlates strongly with in vivo adjuvant effects, the identification of phosphorothioate ODN that will activate human NK cells is very important.
The effects of different phosphorothioate ODNs, which contain CpG
dinucleotides in various base contexts, on human NK activation (Table 4) were examined. ODN
1840, which contained 2 copies of the TGTCGTT motif, had significant NK lytic activity (Table 4). To further identifj- additional ODNs optimal for NK activation, approximately one hundred ODN containing different numbers and spacing of CpG motifs. were tested with ODN 1982 serving as a control. Sample results are shown in Table 5.
Effective ODNs generally began with a TC or TG at the 5' end. however, this requirement was not mandatory. ODNs with internal CpG motifs (e.g., ODN I 840) are generally less potent stimulators than those in which a GTCGCT motif immediately follows the 5' TC (e.g>., ODN 1967 and 1968). ODN 1968, which has a second GTCGTT
motif in its 3' half, was consistently more stimulatory than ODN 1967, which lacks this second motif. ODN 1967, however, was slightly more potent than ODN 1968 in experiments 1 and 3, but not in experiment 2. ODN 2005, which has a third GTCGTT
motif, induced slightly higher NK activity on average than 1968. However, ODN
2006, in which the spacing between the GTCGTT motifs was increased by the addition of two Ts between each motif, was slightly superior to ODN 2005 and to ODN 2007, in which only one of the motifs had the addition of the spacing two Ts. The minimal acceptable spacing between CpG motifs is one nucleotide as long as the ODN has two pyrimidines (preferably T) at the 3' end (e.g., ODN 2015). Surprisingly, joining two GTCGTT
motifs end to end with a 5' T also created a reasonably strong inducer of NK
activity (e.g>., ODN 2016). The choice of thymine (T) separating consecutive CpG
dinucleotides is not absolute, since ODN 2002 induced appreciable NK activation despite the fact that adenine (a) separated its CpGs (i.e., CGACGTT). It should also be noted that ODNs containing no CpG (e.g., ODN 1982), runs of CpGs, or CpGs in bad sequence contexts (e.g., ODN 2010) had little or no stimulatory effect on NK activation.
Table 4 ODN induction of NK ~L~tic Activity (LU) ODN Sequence (5'-3') LU
None O.OI
1754 ACCATGGACGATCTGTTTCCCCTC (SEQ ID N0:26) 0.02 1758 TCTCCCAGCGTGCGCCAT (SEQ ID N0:27) 0.05 1761 TACCGCGTGCGACCCTCT (SEQ ID N0:28) 0.05 1776 ACCATGGACGAACTGTTTCCCCTC (SEQ ID N0:29) 0.03 1777 ACCATGGACGAGCTGTTTCCCCTC (SEQ ID N0:30) 0.05 101778 ACCATGGACGACCTGTTTCCCCTC (SEQ ID N0:31) 0.01 1779 ACCATGGACGTACTGTTTCCCCTC (SEQ ID N0:32) 0.02 1780 ACCATGGACGGTCTGTTTCCCCTC (SEQ ID N0:33) 0.29 I781 ACCATGGACGTTCTGTTTCCCCTC (SEQ ID N0:34) 0.38 1823 GCATGACGTTGAGCT (SEQ ID N0:35) 0.08 151824 CACGTTGAGGGGCAT (SEQ ID N0:36) 0.01 1825 CTGCTGAGACTGGAG (SEQ ID N0:37) 0.01 1828 TCAGCGTGCGCC (SEQ ID N0:38) 0.01 1829 ATGACGTTCCTGACGTT (SEQ ID N0:39) 0.42 18302 RANDOM SEQUENCE 0.25 201834 TCTCCCAGCGGGCGCAT (SEQ ID N0:40) 0.00 I 836 TCTCCCAGCGCGCGCCAT (SEQ ID N0:41 ) 0.46 1840 TCCATGTCGTTCCTGTCGTT (SEQ ID N0:42) 2.70 I 841 TCCATAGCGTTCCTAGCGTT (SEQ ID N0:43) 1.45 1842 TCGTCGCTGTCTCCGCTTCTT (SEQ ID N0:44) 0.06 251851 TCCTGACGTTCCTGACGTT (SEQ ID N0:45) 2.32 'Lytic units (LU) were measured as described (8). Briefly, PBMC were collected from normal donors and spun over Ficoll, then cultured with or without the indicated ODN
(which were added to cultures at 6 ~g/mi) for 24 hr. Then their ability to lyse 5'Cr-labeled K562 cells was determined. The results shown are typical of those obtained 30 with several different normal human donors.
zThis oligo mixture contained a random selection of all 4 bases at each position.
M
~O O~ 00 ~t o0 N N 00 O~ n oNO ~O v1 ~W D N o~o ~ ~O
X- v G7 v, o ~ C~ Wit; C~ M ,~ Ll os Ll L1 ~ r.i ~i '~ ~ o ....; <'? o o ~
~az~~~zMz~.~zozz~;~~~;~o~~,_~~
''-' ~O 00 M O N ~t ~ .-. N I~ 00 t~ N \D Wit' M d' ø' N C~ V' ('.! ~D L 'ct C~ ~ N C~ L~ C~ L M N ~-~ ~O M O O V~ t~ V1 v1 j '~. z O .--~ .--~ z O z .--~ ~ z z z z ~ ~t v0 N ~-~ O N O v~ ~Y ~p N Y ''-' O M M N ~O N N I~ N v1 O ~ C~1 ~s ~ o M L7 o Ll ~r -yo 00 ~ r~, o .- 00 0 ~ D L~ L D D D L~ L1 G~
~oNz~zMON~Mwo~.io~zzzzzzzzzz p o p ..C -1 .-. .-. ~. ~ ~ .~ o N M
~~~~~~ooo~~~~~~oooo~~~
-° o~::oooozzzoooooo~zzzza~
zzzz way w zozzzzr~~r~z zw~~~~~o ~~r~r~r~~aaa~~ar~r~o~o, ~...z~
z a~ aaaaw w w o-o'aaaaH ~ w w w wwww '.v,v~
wo~wwww w wH aa~~~N~
~~_~~~~~ H ~ ~~~~~~ oI~ "~ ~HI°'z o V~~VV~~~U~~ V~~~~I'u7l~~o~~z UI ~H~ ~~~UIUI HHH UI~~d~
a H UI~IFU-~I(U-INIU U ~ ~ d ~IC7 d NI~ ~ C7 V ~' ~I~ w O' '~ ~ ~' C7 C7 C7 (~ V U C7 ~ U U C7 ~ I-~ E-. UI U UI f-~ E'" ~ ~ UI
~U UC7HUUE-~~ ~UI~~U~~C7~'.
U U U H U U ~ U U UIt7I~ UIC7 UIE-'IC7 C7IH ~ CSI
~~~~~~~~I~~~~~~H~,~H
U C7 U C7 U C7 H E~-~ E--~ N U U ~ U UI ~ ~I ~I UI C7I
~~I~HI~~I~I~I~I~~~I~I~I~~~~I~I~~~~~
d N d H ~ E~-~ H H H d d d d d EU-~) H HI FU-' ~ UI UI UI HI UI
a" U U U U U U UIUIUIU U U U U UIUIUIU UI~ ~ ~ VIA
°i E-~ H H E-~ H E-~ E-~ H E-~ E-~ E-~ H E-~ E-~ E-~ E-~ E-~ C'J t5 H H
E-~ H E-~ O O ~-~ N M ~n ~O I~ 000 N O .--~ N ~n ~ I~ oo O N M ~ W p p~1'~\O~DID~\Ol0\On 0000100000~--, ..r.--a.~.-r o z~,~~~~~~~~~
~ N N N N N N N N N N N
o ~ o N N
WO -98/37919 PCTlUS98/03678 ~ PBMC essentially as described herein. Results are representative of 6 separate experiments; each experiment represents a different donor.
2This is the methylated version of ODN 1840; Z=5-methyl cytosine LU is lytic units;
ND = not done; CpG dinucleotides are underlined for clarity.
IDENTIFICATION OF PHOSPHOROTHIOATI~ ODN WITH OPTIMAL CPG
MOTIFS FOR ACTIVATION OF HUMAN Ii CELL PROLIFERATION
The ability of a CpG ODN to induce B cell proliferation is a good measure of its adjuvant potential. Indeed, ODN with strong adjuvant effects in mouse studies also induce B cell proliferation. To determine whether the optimal CpG ODN for inducing B cell proliferation are the same as those for inducing Nh cell activity, similar panels of ODN
(Table 6) were tested. Many CpG ODN were stimulatory. ODN ?006 produced the most consistant stimulation (Table 6).
W 0 ~ 98/37919 PCT/US98/03678 .n .
M z z M M 'Z ~f M M .-N-n U
.~ Gl Ca Gl ~ Ca O O r~ N
z ~z z zz N z ~ ~ ~ M z n o ca z z M M M z d' '~ ~f cr1 U
_O
._.C C
~
.-S (~ O O~ O~ Q J- O O M tt ~
~-z z N~ ~ z ~
O
': N
O O~ 00 ~ I~ d: O 00 t~
~OC X' z N M M Z M ch V' --~ N
z y.O
_Dc~
cd ~"cdi ~
'~ ~., M z tV z M ~ ~ -n ~t -Z
U
C
cCt ' ' ' a o z o- a a a o a a .~ w ~ ~w w w w o ~ '- o,~ ~ ~ ~ '.
' U U ~
... C7 I I I I I I ~ I
r~ ~-- ~ UI E-. I-, E-~ ~ U Q Q
f-~ C7 C7 C7 V UI U UI
H (-~ .
U U U ~ V U V ~ U
U (-t - ~ ~ I-C~ ~ ~ C7 E ~ C7 C7 ~ C7 I I ~ I
E-r C7 UI ~" UI ~I UI V U ~ Q .
.
~d N~ '~'H~ ~E~-' '-~~H ~E'y') '~(-HI ~~ oU) r~
U ~ ~ U '~ ~' 'r C7I '-" '~" "' "' -H zH HH zH zH zH zH zH zH zH
zz z O ~ O .-d- d W 0~ ~ ~ ~ ~ ~ pNO
00 0o O~ a1 O~ O~ ~ O~ O~ ~ O
.-, .-~ .~ .-, .--i .- m.-~ .--~ .... m" N
WO 98/37919 PCTlUS98/03678 ,o _ ~' o v _o '_ v U ~
>~ ~
. ,_.', ° .~, U
o x" ~
a~ ... 3 o v o z ~ --ML ~~C~L~I~~fM~'~'~Q
z z z z z ~~~ ~ ~ ~ o U
O 00 ~--W O c' l f~! 00 N vW~ ~ r.4~.
MN~'~~MMNM~'f~IO~U'~' 'p .-' C v V O
~r ~~
O c3 N N N d: Os O O ~ t~ ~
-- f~1 Wit- N ~- M d' N ~-~ ~ ~u O
O cC V~ 'C
C G~
c~ c~ w rt ~ L
r N ~n O O v0 00 M ~n o0 .-M 'ct ~t M ~- N N N ~--~ .-~ U
U
r ,~ Ql U '' z o -w o tn ~ M ~ ~ C~l M M V7 cG
y U '-' ~ 4~ v Q' ~ ..c ' a~ c~"'a a ~ °' a a o' " .°z .... ~ ~ ~_ ~
o v .°
.... C7 '-U O' ~ ~, ~ s ~, O
v ~ ~ ~~"~~ ~ L s ~ I>r I UI ~ ~I ~ '~ o ~ a .~ -~ z UI ~I UI ~"I ~ UI C7 ~ UI C7 o a, 3 3 °
U ~" C7 UI E-' UI
C7 C7 ~ U C'7 E- E-. C7I (~ ,~ w ;; ~s 3 U C7I _ '~ ~ C~ ~ ø. o °~' ~I ~ ~i ~ ~I ~ ~ ~ ~ ~ UI ° UI o UI ~I UI ~ ~ ~ ~ v I ~I ~., E-, z H ~ ~ ~, ° .~ o H z°H zH °z~ z~ °zH z~ ~HHIH
tn \O I~ 00 O N M ~ ~W O N
O O O O ~ .-. .-K .--, .-r .~ II
O O O O O O 'O O O O v~ ~
N N N N N N N N N N
U .~ v .~ o ' WO 98/37919 PCT/US98/03678 IDENTIFICATION OF PHOSPI-IOROTHIOATE ODN
The ability of a CpG ODN to induce IL-12 secretion is a good measure of its adjuvant potential, especially in terms of its ability to induce a Thl immune response, which is highly dependent on IL-12. Therefore, the ability of a panel of phosphorothioate ODN
to induce IL-12 secretion from human PBMC in vitro (Table 7) was examined.
These experiments showed that in some human PBMC, most CpG ODN could induce IL-12 secretion (e.g., expt. 1). However, other donors responded to just a few CpG
ODN (e.~=., expt. 2). ODN 2006 was a consistent inducer of ILI2 secretion from most subjects (Table 7).
Table 7 induction of human IL-12 secretion b5~ Phosnhorothioate ~G ODN
ODN~ sequence (5'-3') IL-12 (pg/ml) expt.l expt.2 None 0 0 1962 TCCTGTCGTTCCTTGTCGTT (SEQ ID N0:13) 19 0 1965 TCCTGTCGTTTTTTGTCGTT (SEQ ID N0:14) 36 0 1967 TCGTCGCTGTCTGCCCTTCTT (SEQ ID NO:15) 41 0 1968 TCGTCGCTGTTGTCGTTTCTT (SEQ ID N0:16) 24 0 2005 TCGTCGTTGTCGTTGTCGTT CSEQ ID N0:7) 25 0 2006 TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6) 29 I S
2014 TGTCGTTGTCGTTGTCGTT (S~Q ID NO: I 1 ) 28 0 2015 TCGTCGTCGTCGTT (SEQ ID N0:12) 14 0 2016 TGTCGTTGTCGTT (SEQ ID N0:57) 3 0 ' PBMC were collected from normal donors and spun over Ficoll, then cultured at >~0 cells/well in 96 well microtiter plates with or without the indicated ODN
which were added to cultures at 6 p.g/ml. Supernatants were collected at 24 hr and tested for IL-12 levels by ELISA as described in methods. A standard curve was run in each experiment, which represents a different donor.
IDENTIFICATION OF B CELL AND
MONOCYTE/NK CELL-SPECIFIC OLIGONUCLEOTIDES
CpG DNA can directly activate highly purified B cells and monocytic cells.
There are many similarities in the mechanism through which CpG DNA activates these cell types.
For example, both require NFkB activation as explained further below.
In further studies of different immune effects of CpG DNA, it was found that there is more than one type of CpG motif. Specifically, oligo 1668, with the best mouse B cell motif, is a strong inducer of both B cell and natural killer (Nh) cell activation, while oligo 1758 is a weak B cell activator, but still induces excellent N1 responses (Table 8).
Table 8 Different CpG motifs stimulate optimal murine B cell and NK activation ODN Sequence B cell activation' NI~ activation' 1668 TCCATGACGTTCCTGATGCT (SEQ ID N0:57) 42,849 2.52 1758 TCTCCCAGCGTGCGCCAT (SEQ ID N0:27) 1,747 6.66 NONE 367 0.00 CpG dinucleotides are underlined; oiigonucleotides were synthesized with phosphorothioate modified backbones to improve their nuclease resistance.
'Measured by 3H thymidine incorporation after 48 hr culture with oligodeoxynucleotides at a 200 nM concentration as described in Example 1.
=Measured in lytic units.
PREVENTION OF THE DEVELOPMENT OF AN INFLAMMATORY
- CELLULAR
Six to eight week old C56BL/6 mice (from The Jackson Laboratory, Bar Harbor, ME) were immunized with 5,000 Schistosoma mansoni eggs by intraperitoneal (i.p.) injection on days 0 and 7. Schistosoma mansoni eggs contain an antigen (Schistosoma mansoni egg antigen (SEA)) that induces a Th2 immune response (e.g., production of IgE
antibody). IgE antibody production is knOV~'II to be an important cause of asthma.
The immunized mice were then treated with oligonucleotides (30ug in 200p1 saline by i.p. injection), which either contained an unmethylated CpG motif, i.e., TCCATGACGTTCCTGACGTT (SEQ ID N0:39), or did not, i.c., control, TCCATGAGCTTCCTGAGTCT (SEQ ID N0:58).
Soluble SEA (l0ug in 25u1 of saline) was administered by intranasal instillation on days 14 and ? l . Saline was used as a control.
Mice were sacrificed at various times after airway challenge. Whole lung lavage was performed to harvest airway and alveolar inflammatory cells. Cytokine levels were measured from lavage fluid by ELISA. RNA was isolated from whole lung for Northern analysis and RT-PCR studies using CsCI gradients. Lungs were inflated and perfused with 4% paraformaldehyde for histologic examination.
FIG. 7 shows that when the mice are initially injected with the eggs i.p., and then inhale the egg antigen (open circle), many inflammatory cells are present in the lungs.
However, when the mice are initially given a nucleic acid containing an unmethylated CpG motif along with the eggs, the inflammatory cells in the lung are not increased by subsequent inhalation of the egg antigen (open triangles).
FIG. 8 shows that the same results are obtained when only eosinophils present in the lung lavage are measured. Eosinophils are the type of inflammatory cell most closely associated with asthma.
FIG. 9 shows that when the mice are treated with a control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA. Thus, when mice inhale the eggs on days 14 or 21, they develop an acute inflammatory response in the lungs. However, giving a CpG
oligo S along with the eggs at the time of initial antigen exposure on days 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day I 4.
FIG. 10 shows that very low doses of oligonucleotide (< l0ug) can give this protection.
F1G. 11 shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the Lung.
FIG. 12 shows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect the cytokine response of the lung to production of II-12, indicating a Th I type of immune response.
FIG. 13 shows that administration of an oligonucleotide containing an unmethylated CpG
I S motif can also redirect the cytokine response of the lung to production of IFN-y, indicating a Th 1 type of immune response.
What is claimed is:
The uptake of oligonucleotides by B lymphocytes has been shown to be regulated by LPS-induced cell activation (Krieg, A.M., et al., Antisense Res. bevel. 1:161, 1991).
Many detrimental in vivv effects of LPS have been shown to result from soluble mediators released by inflammatory cells. (Morrison et al., Anr. J. Pathol., 93(2):527-617, 1978). Monocytes and neutrophils, which ingest and kill microorganisms. play a key role in this process. Monocytes and neutrophils respond to endotoxin in vivo by releasing soluble proteins with microbicidal, proteolytic, opsonic, pyrogenic, complement-activating and tissue-damaging effects. These factors mediate many of the pathophysiological effects of endotoxin. For example, tumor necrosis factor (TNF), a cytokine released by endotoxin-stimulated monocytes, causes fever, shock, and alterations in glucose metabolism and is a .potent stimulator of neutrophils.
Other cytokines such as IL-1, IL-6, and IL-8 also mediate many of the pathophysiologic effects of LPS, as well as other pathways involving endothelial cell activation by tissue factor, kininogen, nitric oxide and complement.
Endotoxin-associated disorders result from extra-gastrointestinal exposure to LPS, e.g., administration of LPS-contaminated fluids, inhalation of LPS, or Gram-negative infections. Endotoxin-associated disorders can also result when the natural cellular barrier is injured and the normal Gram-negative flora breach this barrier. For example, endotoxin-associated disorders can occur (a) when there is ischemia of the gastrointestinal tract (e.g., following hemorrhagic shock or during certain surgical procedures), or (b) when systemic or local inflammation causes increased permeability of the gut or lung to endotoxin or Gram-negative organisms. The presence of endotoxin and the resulting inflammatory response may result, for example, in adult respiratory distress syndrome CARDS), dust-induced airway disease, and exacerbation of asthma, in addition to endotoxemia, systemic inflammatory response syndrome (SIRS), sepsis _q._ syndrome, septic shock, disseminated intravascular coagulation (DIC), cardiac dysfunction, organ failure, liver failure (hepatobiliary dysfunction), brain failure (CNS
dysfunction), renal failure, multi-organ failure and shock.
Several therapeutic compounds have been developed to inhibit the toxic effects of endotoxin, including antibacterial LPS-binding agents and anti-LPS antibodies, although each has met with limitations. For example, Polymyxin B (PMB) is a basic polypeptide antibiotic which binds to Lipid A, the most toxic and biologically active component of endotoxin. PMB inhibits endotoxin-mediated activation of neutrophil granule release irz vitro and is a potential therapeutic agent for Gram-negative infections.
However, because of its systemic toxicity, this antibiotic has limited therapeutic use, and is generally used topically. Combination therapy using antibiotics and high doses of methylprednisolone sodium succinate (MPSS) showed more promise as this regimen prevented death in an experimental animal model of Gram-negative sepsis.
However, a clinical study using MPSS with antibiotics in treatment of patients having clinical signs of systemic sepsis showed that mortality rates were not significantly different between the treatment and placebo groups (Bone et al.. N. Engl. .I. Mecl. 317:653, 1987).
SUMMARY OF THE INVENTION
The present invention is based on the finding that nucleic acids containing at least one unmethylated cytosine-guanine (CpG) dinucleotide affect the immune response in a subject by activating natural killer cells (NK) or redirecting a subject's immune response from a Th2 to a Thl response by inducing monoc~~tic and other cells to produce Thl cytokines. These nucleic acids containing at least one unmethylated CpG can be used to treat pulmonary disorders having an immunologic component, such as asthma or environmentally induced airway disease.
In a first embodiment, a method of treating a subject having or at risk of having an acute -decrement in air flow by administering a therapeutically effective amount of nucleic acids containing at least one unmethylated CpG is provided.
WO' 98/37919 PCT/US98/03678 In another embodiment, a method of treating a subject having or at risk of-having an ~ inflammatory response to Iipopolysaccharide by administering a therapeutically effective amount of nucleic acids containing at least one unmethylated CpG is also provided. The invention also provides a method of modifying the level of a cytokine in a subj ect having or at risk of having inhaled lipopolysaccharide by administering a therapeutically effective nucleic acid containing at least one unmethylated CpG.
In another embodiment, the invention provides a pharmaceutical composition for treating a subject having or at risk of having an inflammatory response to inhaled lipopolysaccharide including a nucleic acid sequence containing at Least one I 0 unmethylated CpG in a pharmacologically acceptable carrier.
In a further embodiment. isolated nucleic acid sequences as set forth in SEQ
ID NOS:2, 17, 18, 59-65 are provided.
>BRIEF DESCRIPTION OF TILE DRAWINGS
FIG. I is a flow chart showing the pathways to sepsis and acute lung injury.
FIG. 2 is a graph plotting the concentration of cytokines (TNF-a, MIP-2, IL-10, IL-12, and IFN-y) in the serum four hours after intravenous treatment with either an oligonucleotide containing embedded CpG motifs or an oligonucleotide without CpG
motifs. Serum samples were obtained immediately following an inhalation challenge with E coli LPS. Error bars show Standard Error (SE).
FIG. 3 is a graph plotting the concentration of total cells and PMNs in the whole lung lavage fluid following inhalation challenge with EscheYichia coli LPS. Thirty minutes, four hours and 12 hours prior to the inhalation challenge, mice were either treated with an oligonucleotide containing embedded CpG motifs or were treated with an oligonucleotide without CpG motifs. Error bars show SE.
WO '98/37919 PCTlUS98/03678 FIG. 4 is a graph showing the concentration of cytokines (TNF-a, MIP-2, and' IL-I2) in the whole lung Iavage fluid following inhalation of E. coli LPS. Mice were pretreated with an oligonucleotide containing embedded CpG motifs or were pretreated with an oligonucleotide without CpG motifs four hours prior to inhalation challenge with LPS.
Error bars show SE.
FIG. 5 is an autoradiograph showing an RNase protection assay of the total mRNA
isolated from lungs of mice exposed to E. coli LPS by inhalation. Mice were pretreated with an oligonucleotide containing embedded CpG motifs or were pretreated with an oligonucleotide without CpG motifs four hours prior to inhalation challenge with LPS.
L32 encodes a ribosomal protein and was used to assess the concentration of RNA
loaded onto the gel.
FIG. 6 is a graph plotting the concentration of total cells and PMNs in the whole lung lavage fluid following inhalation of E. coli LPS. Mice were pretreated with an oligonucleotide containing embedded CpG motifs or were pretreated with an oligonucleotide without CpG motifs four hours prior to inhalation challenge wish LPS.
Error bars show SE.
FIG. 7 is a graph showing the concentration of total cells and PMNs in the whole lung lavage fluid following inhalation of E. coli LPS. C~7BL/6 mice and IL-10 knockout mice (C57BL/6-IL10""'cs") were pretreated with either an oligonucleotide containing embedded CpG motifs or with intravenous saline four hours prior to inhalation challenge with LPS. Error bars show SE.
FIG. 8 is a graph plotting lung lavage cell count over time. The graph shows that when the mice are initially injected intraperitoneally (i.p.) with Schistosoma mansoni eggs "egg," which induces a Th2 immune response, and subsequently inhale Schistosornu n2ansofZi egg antigen "SEA" (open circle), many inflammatory cells are present in the lungs. However, when the mice axe initially given CpG ODN along with egg, the _7_ inflammatory cells in the lung are not as increased by subsequent inhalation of SEA
(open triangles).
FIG. 9 is a graph plotting lung lavage eosinophil count over time. Again, the graph shows that when the mice are initially injected with egg and subsequently inhale SEA
(open circle), many eosinophils are present in the lungs. However, when the mice are initially given CpG ODN along with egg, the inflammatory cells in the lung are not as increased by subsequent inhalation of the SEA (open triangles).
FIG. 10 is a bar graph plotting the effect on the percentage of macTOphage, lymphocyte, neutrophil and eosinophil cells induced by exposure to saline alone; egg, then SEA; egg and CpG ODN, then SEA; and egg and control oligo, then SEA. When the mice are treated with the control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA.
Thus, when mice inhale the eggs on days 14 or ? 1. they develop an acute inflammatory response in the lungs. I-Iowever, giving a CpG oligo along with the eggs at the time of initial antigen exposure on days 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day 14.
FIG. 11 is a bar graph plotting eosinophil count in response to injection of various amounts of the protective oligo SEQ ID NO: 10.
FIG. 12 is a graph plotting interleukin 4 (IL-4) production (pg/ml) in mice over time in response to injection of egg, then SEA (open diamond); egg and CpG ODN, thcn SEA
(open circle); or saline, then saline (open square). The graph shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the lung.
FIG. I3 is a bar graph plotting interleukin 12 (IL-12) production (pg/ml) in mice over time in response to injection of saline; egg, then SEA; or CpG ODN and egg, then SEA.
The graph shows that administration of an oligonucleotide containing an unmethylated _g_ CpG motif can actually redirect the cytokine response of the lung to production of IL-12, indicating a Th 1 type of immune response.
FIG. 14 is a bar graph plotting interferon gamma (IFN-y production (pg/ml) in mice over time in response to injection of saline; egg, then saline; or CpG ODN and egg, then SEA.
The graph shows that administration of an oligonucleotide containing an unmethylated CpG motif can also redirect the cytokine response of the lung to production of IFN-y, indicating a Th 1 type of immune response.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
1t is to be understood that this invention is not limited to the particular methodology, protocols, sequences, models and reagents described as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the oligonucleotides and methodologies which are described in the publications which might be used in connection with the presently described invention.
The binding of DNA to cells has been shown to be similar to a ligand receptor interaction: binding is saturable, competitive, and leads to DNA endocytosis and degradation into oligonucleotides (Bennet, R.M., et al., J. Clin. Invest.
76:2182, 1985).
Like DNA, oligodeoxyribonucleotides are able to enter cells in a process which is sequence, temperature, and energy independent (3aroszewski and Cohen, Ad. Drug Del.
Rev. 6:235, 1991 ). An "oligodeoxyribonycleotide" as used herein is a deoxyribonucleic acid sequence from about 3-50 bases in length. Lymphocyte oligodeoxyribonucleotide uptake has been shown to be regulated by cell activation (Krieg, A.M., et al., Antisense _g_ Research and Development 1:161, 1991). The present invention is based on the Ending that certain oligonucleotides (ODN) containing at least one unmethylated cytosine-guanine (CpG) din~cleotide activate the immune response.
In one embodiment, the invention provides a method for treating a subject having or at risk ofhaving an acute decrement in air flow by administering a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG.
The term "nucleic acid" or "oligonucleotide" refers to a polymeric form of nucleotides at least five bases in length. The nucleotides of the invention can be deoxyribonucleotides, ribonucleotides, or modified forms of either nucleotide. Generally, double-stranded 3 0 molecules are more stable im vivo, while single-stranded molecules have increased activity.
The nucleic acid molecule can include the use of phosphorothioate or phosphorodithioate rather than phosphodiesterase linkages within the backbone of the molecule, or methylphosphorothioate terminal linkages (Krieg, A.1~~1., et ul., Antisense and Nucl Acid Drug Dev 6:133-9, 1996; Boggs, R.T., et al., Antisense and Nucl Acid Drug Dev, 7:461-71, 1997). The phosphate backbone modification can occur at the 5' end of the nucleic acid, for example at the first two nucleotides of the 5' end of the nucleic acid. The phosphate backbone modification may occur at the 3' end of the nucleic acid, for example at the last five nucleotides of the 3' end of the nucleic acid. International Patent Application WO 95/26204, entitled "immune stimulation by phosphorothioate oligonucleotide analogs'' reports the nonsequence-specific immunostimulatory effect of phosphorothioate modified oligonucleotides. Nontraditional bases such as inosine and queosine, as well as acetyl-, thio- and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine can also be included, which are not as easily recognized by endogenous endonucleases. Other stabilized nucleic acid molecules include:
nonionic DNA analogs, such as alkyl- and aryl-phosphonates (in which the charged oxygen moiety is alkylated). Nucleic acid molecules which contain a diol, such as tetrahyleneglycol or hexaethyleneglycol, at either or both termini are also included. The term "oligonucleotide" includes both single and double-stranded forms of DNA.
A "CpG" or "CpG motif ' refers to a nucleic acid having a cytosine followed by a guanine linked by a phosphate bond. The term "methylated CpG" refers to the methylation of the cytosine on the pyrimidine ring, usually occurnng the 5-position of the pyrimidine ring. The term "unmethylated CpG" refers to the absence of methylation of the cytosine on the pyrimidinc ring. Methylation, partial removal, or removal of an unmethylated CpG motif in an oligonucleotide of the invention is believed to reduce its effect. Methylation or removal of all unmethylated CpG motifs in an oligonuclcotide substantially reduces its effect. The effect of methylation or removal of a CpG motif is "substantial" if the effect is similar to that of an oligonucleotide that does not contain a CpG motif.
Preferably the CpG oligonucleotide is in the range of about 8 to 30 bases in size. For use in the instant invention, the nucleic acids can be synthesized de noru using any of a number of procedures well known in the art. For example, the b-cyanoethyl phosphoramidite method (Beaucage, S.L., and Caruthers, M.1L, Tet. Lel. ?:1859, 1981 );
nucleoside H-phosphonate method (Garegg et al., Tet. Let. 27:4051-4054, 1986;
Froehler et al., Nucl. Acid. Res. 14:5399-5407, 1986, ; Garegg et ul., Tet. Let.
27:4055-4058, 1986, Gaffney et al., Tc~t. Let. 29:2619-2622, 1988). These chemistries can be perfornned by a variety of automated oligonucleotide synthesizers available in the market.
Alternatively, CpG dinucleotides can be produced on a large scale in plasmids, (see Sambrook, T., et al., Molecular Cloning: A Laboratory Manual, Cold Spring I-harbor laboratory Press, New York, 1989) which after being administered to a subject are de~aded into oligonucleotides. Oligonucleotides can be prepared from existing nucleic acid sequences (e.g., genomic or cDNA) using known techniques, such as those employing restriction enzymes, exonucleases or endonucleases.
WO 98/37919 PCT/US98/03.678 For use in vivo, nucleic acids are preferably relatively resistant to degradation-(e.g., via endo-and exo-nucleases). Secondary structures, such as stem loops, can stabilize nucleic acids against degradation. Alternatively, nucleic acid stabilization can be accomplished ' via phosphate backbone modifications. A preferred stabilized nucleic acid has at least a partial phosphorothioate modified backbone. Phosphorothioates may be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl-and alkyl-phosphonates can be made, e.g., as described in U.S. Patent No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Patent No. 5,023,243 and European Patent No.
092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (Uhlmann, E. and Peyman, A., Chem. Rev. 90:544, 1990;
Goodchild, J., Bioconjugate Chem. 1:165, 1990).
For administration in vivo, nucleic acids may be associated with a molecule that results in higher affinity binding to target cell (e.g., B-cell, monoc5nic cell and natural killer (NIL) cell) surfaces and/or increased cellular uptake by target cells to form a "nucleic acid delivery complex." Nucleic acids can be ioniGally or covalently associated with appropriate molecules using techniques which are well known in the art. A
variety of coupling or cross-linking agents can be used, e.g., protein A, carbodiimide, and N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP). Nucleic acids can alternatively be encapsulated in Iiposomes or virosomes using well-known techniques.
In one embodiment, the nucleic acid sequences useful in the methods of the invention are represented by the formula:
SN,X,CGXZN,3' (SEQ ID NO:1) wherein at least one nucleotide separates consecutive CpGs; X, is adenine, guanine, or thymidinc; Xz is cytosine or thymine, N is any nucleotide and N, + IVY is from about 0-26 bases. In a preferred embodiment, N, and NZ do not contain a CCGG quadmer or more than one CGG trimer; and the nucleic acid sequence is from about 8-30 bases in WO 98/37919 PCTlUS98/03678 length. However, nucleic acids of any size (even may kb long) can be used in the invention if CpGs are present, as larger nucleic acids are degraded into oligonucleotides inside cells. Preferred synthetic oligonucleotides do not include a CCGG
quadmer or more than one CCG or CGG trimer at or near the S' or 3' terminals and/or the consensus mitogenic CpG motif is not a palindrome. A "palindromic sequence" or "palindrome"
means an inverted repeat (i.e., a sequence such as ABCDEE'D'C'B'A', in which A
and A' arc bases capable of forming the usual Watson-Crick base pairs. An exemplary nucleic acid sequence of the invention is:
5'-ATAATCGACGTTCAAGCAAG-3' (SEQ ID N0:2).
11~ another embodiment, the method of the invention includes the use of an oligonucleotide which contains a CpG motif represented by the formula:
5' N,X,X,CGX3XQN~ 3' (SEQ ID N0:3) wherein at least one nucleotide separates consecutive CpGs; X,X, is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3 X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N, + N, is from about 0-26 bases.
In a preferred embodiment, N, and N~ do not contain a CCGG quadmer or more than one CCG or CGG trimer. CpG ODN are also preferably in the range of 8 to 30 bases in length, but may be of any size (even many kb long) if sufficient motifs are present, since such larger nucleic acids are degraded into oligonucleotides inside of cells.
Preferred synthetic oligonucleotides of this formula do not include a CCGG quadmer or more than one CCG or CGG trimer at or near the 5' and/or 3' terminals and/or the consensus mitogenic CpG motif is not a palindrome. Other CpG oligonucleotides can be assayed for efficacy using methods described herein.
A prolonged effect can be obtained using stabilized oligonucleotides, where the oligonucleotide incorporates a phosphate backbone modification (e.g., a phosphorothioate or phosphorodithioate modification). More particularly, the phosphate backbone modification occurs at the 5' end of the nucleic acid for example, at the first two nucleotides of the 5' end of the nucleic acid. Further, the phosphate backbone modification may occur at the 3' end of the nucleic acid for example, at the last five - nucleotides of the 3' end of the nucleic acid. Preferred nucleic acids containing an unmethylated CpG'have a relatively high stimulation with regard to B cell, monocyte, ' and/or natural killer cell responses (e.g., induction of cytokines, proliferative responses, lytic responses, among others).
The "stimulation index" is a measure of a CpG ODN to effect an immune response which can be tested in various immune cell assays. The stimulation of the immune response can be assayed by measuring various immune parameters, e.~,~., measuring the antibody-forming capacity, number of lymphocyte subpopulations, mixed leukocyte response assay, lymphocye proliferation assay. The stimulation of the immune response can also be measured in an assay to determine resistance to infection or tumor growth.
Methods for measuring a stimulation index are well known to one of skill in the art.
For example, one assay is the incorporation of 31 I uridine in a murine B cell culture.
which has been contacted with a 20p.M of oligonucleotide for 20h at 37°C and has been pulsed with 1 ~Ci of ~H uridine; and harvested and counted 4h later. The induction of secretion of a particular cytokine can also be used to assess the stimulation index. Without meaning to be bound by theory, for use in vivo, for example to treat a subject having or at risk of having an acute decrement in air flow in response to endotoxin, it is important that the CpG ODN be capable of effectively inducing cytokine secretion by monocytic cells and/or Natural Itiller (NK) cell lytic activity. In one method, the stimulation index of the CpG ODN with regard to B-cell proliferation is at least about 5, preferably at least about 10, more preferably at least about 15 and most preferably at least about 20, while recognizing that there are differences in the stimulation index among individuals.
The CpG ODN of the invention stimulate cytokine production (e.g., IL-6, IL-12, IFN-y, TNF-a and GM-CSF). Exemplary sequences include:
_ TCCATGTCGCTCCTGATGCT (SEQ ID N0:4), TCCATGTCGTTCCTGATGCT (SEQ ID NO:S), and TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6).
The CpG ODN of the invention are also useful for stimulating natural killer-cell (NK) iytic activity in a subject such as a human. Specific, but nonlimiting examples of such sequences include: -TCGTCGTTGTCGTTGTCGTT (SEQ ID N0:7), TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6), TCGTCGTTGTCGTTTTGTCGTT (SEQ ID N0:8), GCGTGCGTTGTCGTTGTCGTT (SEQ ID N0:9), TGTCGTTTGTCGTTTGTCGTT~(SEQ ID NO:10), TGTCGTTGTCGTTGTCGTT (SEQ ID NO:1 I ), and TCGTCGTCGTCGTT (SEQ ID N0:12).
The nucleic acid sequences of the invention are also useful for stimulating B
cell proliferation. Specific, but noniimiting examples of such sequences include:
TCCTGTCGTTCCTTGTCGTT (SEQ ID N0:13), TCCTGTCGTTTT"TTGTCGTT (SEQ ID N0:14), TCGTCGCTGTCTGCCCTTCTT (SEQ ID NO:15), TCGTCGCTGTTGTCGTTTCTT (SEQ ID N0:16), TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6), TCGTCGTTGTCGTTTTGTCGTT (SEQ ID N0:8) and TGTCGTTGTCGTTGTCGTT (SEQ ID NO:11).
Preferred CpG ODN can effect at least about'S00 pg/ml of TNF-a, 15 pg/mi IFN-y, 70 pg/ml of GM-CSF ?75 pg/ml of IL-6, 200 pg/ml IL-12, depending on the therapeutic indication. These cytokines can be measured by assays well known in the art.
The ODNs listed above or other preferred CpG ODN can effect at least about 10%, more preferably at least about 15% and most preferably at least about 20% YAC-1 cell specific lysis or at least about 30%, more preferably at least about 35%, and most preferably at least about 40% 2C 11 cell specific lysis, in assays well known in the art (see Example 4).
The term "acute" refers to a condition having a short and relatively severe course. A
"decrement in air flow" is a decrease in a measurable parameter of lung function. The WO 98/37919 PC'r/US98/03678 terms "lung function" and "pulmonary function" are used interchangeably and shall be interpreted to mean physically measurable operations of a lung including but not limited to inspiratory flow rate, expiratory flow rate, and lung volume. Methods of quantitatively determining pulmonary function are used to measure lung function.
Methods of measuring pulmonary function most commonly employed in clinical practice involve timed measurement of inspiratory and expiraton~ maneuvers to measure specific parameters. For example, forced vital capacity (FVC) measures the total volume in liters exhaled by a patient forcefully from a deep initial inspiration. This parameter, when evaluated in conjunction with the forced expired volume in one second (FEV,), allows bronchoconstriction to be quantitatively evaluated. A problem with forced vital capacity determination is that the forced vital capacity maneuver (i.e., forced exhalation from maximum inspiration to maximum expiration) is largely technique dependent. In other words, a given patient may produce different FVC values during a sequence of consecutive FVC maneuvers. The FEF 2S-7S or forced expiratory flow determined over 1 S the midportion of a forced exhalation maneuver tends to be less technique dependent than the FVC. Similarly, the FEV, tends to be less technique dependent than FVC. In addition to measuring volumes of exhaled air as indices of pulmonan~ function, the flow in liters per minute measured over differing portions of the expiratory cycle can be useful in determining the status of a patient's pulmonary function. In particular, the peak expiratory flow, taken as the highest air flow rate in liters per minute during a forced maximal exhalation, is well correlated with overall pulmonary function in a patient with asthma and other respiratory diseases.
The term "asthma" refers to a disorder of the respiratory system characterized by inflammation, narrowing of the airways and increased reactivity of the airways to inhaled agents. Asthma is frequently, although not exclusively associated with atopic or allergic symptoms.
By "therapeutically effective amount" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest symptoms in a WO'98/379I9 PCT/US98/03678 subject. A subject is any mammal, preferably a human. Amounts effective for therapeutic use will, of course, depend on the severity of the disease and the weight and general state of the subject. Typically, dosages used in vitro may provide useful guidance in the amounts useful for if2 situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, e.g., in Gilman et al., eds., Goodman And Gilman's: T'he Pharmacological Bases of Therapeutics 8th ed., Pergamon Press, 1990; and Remin~ton's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pa., 1990, each of which is herein incorporated by reference.
An oligonucleotide containing at least one unmethylated CpG can be used alone to activate the immune response or can be administered in combination with another therapeutic modality, either a drug or a surgical procedure. For example, when the oligonucleotide containing at least one unmethylated CpG is administered in conjunction W th another therapeutic modality, the oligonucleotide can be administered before, after, I S and/or simultaneously with the other therapeutic modality. The oligonucleotide containing at least one unmethylated CpG can have an additional efficacy (e.g., through antisense or other means) in addition to its ability to activate the immune response.
In another embodiment, the invention further provides a method of treating a subject having or at risk of having an inflammatory response to LPS by administering to the subject a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG.
Examples of diseases which can be associated with Gram-negative bacterial infections or endotoxemia include bacterial meningitis, neonatal sepsis, cystic fibrosis, , inflammatory bowel disease and liver cirrhosis, Gram-negative pneumonia, Gram-negative abdominal abscess, hemorrhagic shock and disseminated intravascular coagulation. Subjects who are leukopenic or neutropenic, including subjects treated with chemotherapy or immunocompromised subjects (for example with AIDS), are WO '98/37919 PCT/US98/03678 particularly susceptible to bacterial infection and the subsequent effects of endotoxin.
By "lipopolysaccharide" or "LPS" is meant a compound composed of a ' heteropolysaccharide (which contains somatic O antigen) covalently bound to a phospholipid moiety (lipid a). LPS is a major component of the cell wall of Gram-negative bacteria. By "endotoxin" is meant a heat-stable toxin associated with the outer membranes of certain Gram-negative bacteria, including the enterobacteria, brucellae, neisseriae, and vibrios. Endotoxin, normally released upon disruption of the bacterial cells, is composed of lipopolysaccharide molecules (LPS) and any associated proteins. The phospholipid moiety of LPS, lipid a, is associated with LPS
toxicity.
When injected in large quantities endotoxin produces hemorrhagic shock and severe diarrhea; smaller amounts cause fever, altered resistance to bacterial infection, leukopenia followed by leukocytosis, and numerous other biologic effects.
Endotoxin is a type of "bacterial pyrogen," which is any fever-raising bacterial product. The terms "endotoxin," "LPS," and "Iipopolysaccharide" as used herein are essentially synonymous.
The invention further provides a method of treating a subject having or at risk of having an inflammatory response to LPS. It is known that LPS produces an inflammatory response in normal and asthmatic patients. By "inflammatory response" is meant an accumulation of white blood cells, either systemically or locally at the site of inflammation. The inflammatory response may be measured by many methods well known in the art, such as the number of white blood cells (WBC), the number of polymorphonuclear neutophils (PMN). a measure of the degree of PMN activation, such as luminal enhanced-chemiluminescence, or a measure of the amount of cytokines present. The term "cytokine" is used as a generic name for a diverse group of soluble proteins and peptides which act as humoral regulators at nano- to picomolar concentrations and which, either under normal or pathological conditions, modulate the functional activities of individual cells and tissues. These proteins also mediate interactions between cells directly and regulate processes taking place in the extracellular environment. Examples of cytokines include, but are not limited to, TNF-a, IL-10, IL-12, interferon-'y. Importantly, interferon-y is a key cytokine mediating LPS-induced inflammation (e.g., Ozmen, L., et al., J. Exp. Mecl. 180:907-915, 1994). The release of interferon-y is induced by IL-12 derived from macrophage/monocyte/dendritic cells.
(e.g., Balanchard, D.K., et al., J. Immunol. 136:963-970, 1986), and IL-10 inhibits interferon-y via a macrophage-dependent step in which IL-12 production is inhibited (D'Andrea, a., et al., J. Exp. Mec~' 178:1041-1048, 1993). Without wanting to be bound by theory, it is possible that nucleic acids containing unmethylated CpG could reduce the inflammatory response to LPS by increasing the production and response of IL-10, or by modulating the response of a factor which in tum increase the production and response of IL-10 or IL-6.
The invention further provides a method of modulating the level of a cytokine altered in response to inhaled LPS. The term "modulate" envisions the suppression of expression of a particular cytokine when it is overexpressed, or augmentation of the expression of a particular cytokine when it is underexpressed. Modulation of a particular cyokine can occur locally or systemically. It is believed that the CpG oligonucleotides do not directly activate purified NK cells, but rather render them competent to respond to IL-12 with a marked increase in their IFN-y production. By inducing IL-12 production and the subsequent increased IFN-y secretion by NK cells, the immunostimulatory nucleic acids also promote a Thl type immune response. No direct activation of proliferation or cytokine secretion by highly purified T cells has been found. Cytokine profiles determine T cell regulatory and effector functions in immune responses.
Cytokines also play a role in directing the T cell response. Helper (CD4~) T
cells - orchestrate the immune response of mammals through production of soluble factors that act on other immune system cells, including other T cells. Most mature CD4+ T
helper cells express one of two cytokine profiles: Thl or Th2. Thl cells secrete IL-2, IL-3, IFN-y, TNF-(3, GM-CSF and high levels of TNF-a. Th2 cells express IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, GM-CSF and low levels of TNF-a. The Thl subset promotes delayed-type hypersensitivity, cell-mediated immunity, and immunoglobulin class switching to IgG2a. The Th2 subset induces humoral immunity by activating B
cells, promoting antibody production, and inducing class switching to IgG, and IgE.
Several factors have been shown to influence commitment to Thl or Th2 profiles. The best characterized regulators are cytokines. IL-I2 and IFN-y are positive Th I
and negative Th2 regulators. IL-12 promotes IFN-y production, and IFN-'y provides positive feedback for IL-12. IL.-4 and IL-10 appear to be required for the establishment of the Th2 cytokine prof le and to down-regulate Thl cyokine production; the effects of IL-4 are in some cases dominant over those of IL-12. IL-13 was shown to inhibit expression of inflammatory cytokines, including IL-12 and TNF-a by LPS-induced monocytes, in a way similar to IL-4. The IL-12 p40 homodimer binds to the IL-I2 receptor and antagonizes IL-12 biological activity; thus it blocks the pro-Th 1 effects of IL-12.
The invention may be used to treat individuals who are "at risk" of developing a acute decrement in airflow or who are at risk of LPS exposure. These individuals may be identified by any diagnostic means, or by epidemiological evidence such as exposure data. These individuals may be treated by a method of the invention prior to, at the time of, or after the actual onset of the clinical appearance. The "clinical appearance" can be any sign or symptom of the disorder.
This invention further provides administering to a subject having or at risk of having an inflammatory response to inhaled LPS, a therapeutically effective dose of a pharmaceutical composition containing the compounds of the present invention and a pharmaceutically acceptable carrier. "Administering" the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan.
The pharmaceutical compositions according to the invention are in general administered topically, intravenously, orally, parenterally or as implants, and even rectal use is possible in principle. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipicnts and additives and/or auxiliaries such as disintegnants, binders, IO coating agents, swelling agents, lubricants, flavorings, sweeteners or solubilizcrs are customarily used as described above. The pharmaceutical compositions are suitable for use in a variety of drug delivery systems. For a brief review of present methods for drug delivery, see Langer, Science 249:1527-1533, 1990, which is incorporated herein by reference.
The pharmaceutical compositions are preferably prepared and administered in dose units.
Solid dose units are tablets, capsules and suppositories. For treatment of a patient, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the patient, different daily doses are necessary.
Under certain circumstances, however, higher or lower daily doses may be appropriate.
The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.
The pharmaceutical compositions according to the invention may be administered locally or systemically. By "therapeutically effective dose" is meant the quantity of a compound according to the invention necessary to prevent, to cure or at least partially arrest the symptoms of the disorder and its complications. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the patient. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various ' considerations are described, e.~ , in Gilman et al., eds., Goodman And Gilman's: The Pharmacolo;~ical Bases of Therapeutics, 8th ed., Pergamon Press, 1990; and Reminaton's Pharmaceutical Sciences, 17th ed., Mack Publishing Co., Easton, Pa., 1990, each of which is herein incorporated by reference.
The following examples are intended to illustrate but not to limit the invention in any manner, shape, or form, either explicitly or implicitly. While they arc typical of those that might be used, other procedures, methpdologies, or techniques known to those skilled in the an may alternatively be used.
EJiAMPLE 1 METHODS FOR PULMONARY RESPONSE TO INHALED LPS
In the first series of experiments, mice were intravenously treated with 20 base pair (bp) I 5 oligonucleotides containing CpG motifs (CpG oligo) or 20 by oligonucleotides without embedded CpG motifs (non CpG oligo) 30 min, 4 hours, or 12 hours prior to a 4 hour inhalation challenge with E. cnli LPS (1.5 ug/m3). To determine whether unmethylated CpG motifs were responsible for the protective effect, we pretreated mice with oligonucleotides containing either unmethylated CpG motifs or methylated CpG
motifs prior to an inhalation challenge with E. coli LPS. Finally, to determine the role of IL-10, we pretreated IL-lU knockout mice with CpG oIigos and then performed a similar inhalation challenge with E. coli LPS. Immediately post inhalation challenge, all mice were sacrificed, blood samples were obtained, whole lung lavage was performed, and lungs were harvested for mRNA analysis.
AtZimals. C3H/HeBFEJ, C57BL/6, and C57BL/6-II10'"''c~' male mice (Jackson Laboratories, Bar Harbor, ME) were obtained at 6 weeks of age and used within 2 weeks.
All animal care and housing requirements set forth by the National Institutes of Health WO '98/37919 PCT/US98/03678 Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources were followed, and animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee. Mice were maintained in wood-chip bedding (Northeastern Product, Warrensberg, NY), with food {Formulab Chow 5008, PMI, Richmond, IN) and water supplied ad libitum.
171i~onucleotides. Twenty base pair oligonucleotides were synthesized with and without the embedded CpG motifs (Oligos etc., Wilsonville, OR). These oligonucleotides contained a nuclease-resistant phosphorothioate-modified backbone, and were purified by two rounds of ethanol precipitation prior to use. The CpG dinucleotide was flanked by two 5' purines and two 3' pyrimidines to enhance the stimulatory effect of the oligonucleotide. The ''nonstimulatory" oligonucleotide v,~as identical to the stimulatory oligonucleotide except that the two embedded CpG motifs were modified, one appearing as an ApG motif and the other appearing as a GpC motif. The two synthesized oligonucleotides had the following sequences: -I S CpG Oligonucleotide: ATAATCGACGTTCAAGCAAG (SEQ ID
N0:17) Non-CpG oligonucleotidc: ATAATAGAGCTTCAAGCAAG (SEQ ID
N0:18) A~ethvlatio~~ Protocol. DNA was methylated as we have described previously (Krieg, A.M., et ul., Nature 374:546-9. 1995) ~~ith 2 U CpG methylase (New England Biolabs;
Beverly. MA) per pg DNA for 18 hours at 37°C. Methylated DNA was tested to confirm that it was completely protected against digestion with Hpa-II but not Msp-I.
Chemicals. Endotoxin was purchased as lyopholized purified ~. coli OII1:B4 lipopolysaccharide (LPS) (Sigma Chemical Co., St. Louis, MO, PN# L2630) and had a specified activity of 1.3 x 106 ng/mg and protein content less than 3%.
Endo~o~in A~.sav. The endotoxin concentrations of LPS solution, LPS aerosol, and - oligonucleotides were assayed using the chromogenic Limulus amebocyte lysate (LAL) assay (QCL-1000, ~Vhittaker Bioproducts, Inc., Walkersville, MD) with sterile, pyrogen-free labware and a temperature controlled microplate block and microplate reader (405 S nm). The LPS solution was serially diluted in pyrogen-free water and assayed. The airborne concentration of LPS was assessed by sampling 0.30 m3 of air drawn from the exposure chamber through 47 mm binder-free glass microfiber filters (EPM-2000, Whatman Intl. Ltd., Maidstone, England) held within a 47 mm stainless steel in-line air sampling filter holder (Gelman Sciences Inc., Ann Arbor, MI). Air sampling filters were I 0 extracted with 10 ml of pfw at room temperature with gentle shaking for 1 hour. They were then serially diluted with pfw and assayed for endotoxin. Four to 6 air samples were assayed for each exposure. All standard curves (0. I to 1.0 EU/ml) achieved a linear regression coefficient exceeding 1=0.995. Spiked samples and filter blanks and participates were run routinely; interlaboratory validation studies were also performed 15 routinely.
Ex~nszrre Prntncvl and Monit~zring Eguinment. LPS aerosols were generated into a glass 20 L exposure chamber using a PITT#1 nebulizer supplied with extract by a syringe pump. Liquid feed rates ranged from 0.0027 to 0.21 ml/min. HEPA-filtered air was supplied to the nebulizer at flow rates ranging from 10 to 17 L/min. Mixing within the 20 chamber was aided by a magnetically coupled rotor. The chamber atmosphere was exchanged at 1 change/min. LPS concentrations were determined by sampling the total chamber outflow. Particle size distributions were determined with an Aerodynamic Particle Sizer (TSI, Inc., St. Paul, MN) and gravimetrically with a Marble personal cascade impactor and Mylar media (Thorne, P.S., Am. J. hzd. Med. 25:109-1 I2, 1997) 25 by sampling within the exposure chamber.
Lunge. Immediately following the inhalation challenge, mice were euthanized, the chest was opened, and lungs were lavaged in situ via PE-90 tubing inserted into the exposed trachea. A pressure of 25 cm H20 was used to wash the lungs with 6.0 mI of WO 98/37919 PC'r/US98/03678 sterile pyrogen free saline. Following whole lung lavage, the lungs were isolated and frozen in liquid nitrogen and stored at -70°C.
Treat»tent ofBrorcchoalveolar Lavage Fluid. A standard method (Schwartz, D.A., et al., Ant. J. Physiol. 267:L609-617, 1994) of processing the sample was as follows:
immediately following lavage, the volume was noted and 15 ml conical tubes were centrifuged for S min at 200 x g. The supernatant fluid was decanted and frozen at -70°C
for subsequent use. The residual pellet of cells was resuspended and washed twice in HBSS (without Ca" or Mg" ). After the second wash, a small aliquot of the sample was taken for cell count using a hemocytometer. The cells were then washed once more and resuspended in RPMI medium so that the final concentration gave a cell count of 1 x I0'' cells/ml. The cells which were present in 10-12 ~1 of the 1 x 10'' ml cell suspension were spun for 5 minutes onto a glass slide using a special filter card using a cytocentrifuge (Cytospin-2; Shanden Southern. Sewickley, PA). Staining was carried out using a Diff Quick Stain Set (I-iarleco, Gibbstown, NY). The slide was then dried, one drop of optically clear immersion oil was put on the slide over the cells and a coverslip was placed on top.
Cytokine Analysi.s of lavage fluid and serum. Lavage fluid was assayed for TNF-a, MII'-2, IL-6,1L-10, IL-12, and IFN-y. In all cases, a polyclonal antibody specific for the murine recombinant cytokine (TNF-a, MIP-2, IL-6, IL-10, IL-I2, or IFN-y) was used as a capture reagent in a standard commercially available sandwich ELISA (R &
D
Systems; Minneapolis, MN). The limit for detection for TNF-a is 5.1 pg/ml, MIP-2 is 1.5 pg/ml, IL-6 is 10 pg/ml, IL-10 is 10 pg/ml, IL-12 is 5 pg/ml, and IFN-y is 10 pg/ml.
Preparation ofRNA and Multiprohe RNasc ProtectiofZ Assay. Total RNA was extracted from lung specimens using the single-step method (Chomczynski and Pandsacchi, Anal Biochem 162:156-9, 1987; Kedzierski, W., Biotechniques 10:210-214,1991), lysing flash frozen lung in RNA STAT-60 (Tel-Test B; Friendswood, TX). The composition of RNA
STAT-60 includes phenol and guanidinium thiocyanate in a monophase solution.
The lung parenchyma was homogenized in the RNA STAT-60 using a polytron homogenizer.
Chloroform was added, the total RNA was precipitated from the aqueous phase by addition of isopropanol, and the total RNA was washed with ethanol and solubilized in ' wafer. After drying the pellet in a vacuum desiccator, the yield and purity of RNA was quantitated by measuring the ratio of absorbances at 260 and 280 nm. Mini-gel electrophoresis was used to confirm the integrity of the 28s and I 8s rRNA
bands. Gene transcripts were detected using the RNase protection assay as previously described (Hobbs, J.M., et al., J. Immunol. 150:3602, 1993). Equivalent amounts of RNA
were examined, as judged by the amount of L32, which encodes an ubiquitously expressed ribosome subunit protein (Raichel, A., et al., Nucl. Acid Res. 16:2347, 1987) in each sample. Commercially available probes were used to detect TNF-a, MIP-3, IL-6, IL-10, IL-12, and IFN-y.
.stati.rtical Analv:s-i.s. Three comparisons were pursued in this analysis: 1 ) the effect of intravenous CpG containing oligonucleotides versus oligonucleotides without embedded CpG motifs in modulating the inflammatory response to inhaled LPS; 2) the effect of unmethylated CpG motifs versus methylated CpG motifs in controlling the inflammatory response to LPS; and 3) the role of IL-10 in mediating the protective effect of unmethylated CpG containing oligonucleotides. The inflammatory response was assessed using lavage cellularity, lavage fluid cytokine concentration, serum concentration of cytokines, and the relative concentration of mRNA for specific cytokines in the lung parenchyma. After making sure that the data were normally distributed, statistical comparisons were made using parametric statistics including the Student's T-test (Rosner, R., Fundamentals of Biostatistics (3rd edition) Boston, MA, PWS-Kent, 1980).
CnG ODN REDUCES THE PULMONARY RESPONSE TO INHALED
LPS AND STIMULATES THE IMMUNE RESPONSE
Pretreatment with CpG oligonucIeotides (ODN) resulted in a systemic inflammatory response. Although intravenous treatment with CpG ODN did not affect the concentration of peripheral white blood cells; compared to non-CpG ODN, treatment with CpG ODN prior to LPS inhalation resulted in a higher concentration of PMNs 30 min, 4 hours, and 12 hours after injection. As expected, intravenous treatment with CpG
oligonucleotides also affected the concentration of cytokines in the serum.
Compared to non-CpG ODN, CpG ODN resulted in an increase in the concentration of MIf-2, IL-I 0. and IL-12 in the serum of mice following LPS inhalation (FIG. I
). These differences were most pronounced 30 min and 4 hours after intravenous administration but were still present 12 hours after exposure to CpG containing oligonucleotides. No differences were observed for the serum concentration of TNF-a, IL-6, and IFN-y at an}~
of the time points in mice pre-treated with either oligonucleotide and then exposed to LPS (data not shown for IL-6).
Pretreatment with CpG containing oligonucleotides reduced the pulmonary response to inhaled LPS. Animals pretreated with CpG oligonucleotides at 0.5, 4, and 12 hours had a reduced concentration of cells in the lavage fluid following inhalation challenge with LPS (FIG. 2). However, this effect appeared to be time dependent since pretreatment with oligonucleotide at 0.5 and 4 hours resulted in a reduced percentage of savage PMNs while pretreatment with the oligonucleotide 12 hours prior to the inhalation challenge did not affect the percentage of Iavage PMNs (FIG. 2). Although pretreatment with CpG
containing oligonucleotides resulted in significant changes in the concentration of cytokines in the lavage fluid, the changes in cytokine concentration were predominantly evident when mice were pretreated with CpG oligonucleotides 4 hours prior to the inhalation challenge. While significant reductions were observed in the concentration of TNF-a and MIP-2, the lavage fluid concentration of IL-12 was elevated following treatment with CpG oligonucleotides 4 hours prior to the inhalation challenge (FIG. 3).
IL-6, IL-10, and IFN-y were not measurable in the lavage fluid following inhalation of LPS at any of the time points. Interestingly, results from the RNase protection assay indicate that total lung mRNA concentrations for TNF-a, MIP-2, IL-6, IL-I 0, and IFN-y are similar in mice pretreated with the CpG and non-CpG containing oligonucleotide (FIG. 4). These results also demonstrate that mIZNA IL-12 appears to be upregulated in the lung only from mice pretreated with CpG containing oligonucleotides.
To determine the specificity of the CpG oligonucleotides in suppressing the inflammatory response to inhaled LPS, the CpG motifs were methylated. The immunosuppressive effects of two identical oligonucleotides, one with unmethylated CpG motifs and the other with methylated CpG motifs, were compared.
Methylating the CpG motifs abolished the protective effect of CpG oligonucleotides in preventing the cellular inflammatory response to inhaled LPS (FIG. 5).
Further experiments were conducted with the following oligonucleotides:
1908 ATAATAGAGCTTCAAGCAAG (SEQ ID N0:18) 1760 ATAATCGACGTTCAAGCAAG (SEQ ID N0:2) 1631 CGCGCGCGCGCGCGCGCGCG (SEQ ID N0:59) 1835 TCTCCCAGCGAGCGCCAT (SEQ ID N0:60) 1759 ATAATCCAGCTTGAACCAAG (SEQ ID N0:61 ) 1826 TCCATGACGTTCCTGACGTT (SEQ ID N0:62) 1585 GGGGTCAACGTTGAGGGGGG (SEQ ID N0:63) 2010 GCGGCGGGCGGCGCGCGCCC (SEQ ID N0:54) 197? GGGGTCTGTGCTTTTGGGGGG (SEQ ID N0:64) 2001 GGCGGCGGCGGCGGCGGCGG (SEQ ID N0:65) Mice were pretreated with the indicated oligonucleotide and then challenged through the airways with LPS as described above. A saline challenge was used as a control.
The lungs of the mice were lavaged, and the number of cell per mI, number of polymorphonuclear olymorphonuclear cells cells (PMN) per ml, and the percentage of p in the airways -was determined (see Table 1 ).
Table 1 expt 1, C3H/BFeJ
mice ODN Number cells/ml PMNImI x 105 % PMN
x 104 1908 61.4 15.9 59.2115.7 95.810.95 1760 27.813.5 25.8t3.0* 93.32.3 *
1631 47.6 11.1 46.1 t 10.7 96.81 I .1 I
1835 43.87.1 44.47.1 96.80.75 1759 71.0 19.8 67.7120.4 96.812.6 1826 39.87.8 38.37.9 93.51 1.4 None (saline) 71.07.4 ~9.3t6.9 97.8 1.3 expt 2, C57 Bl/6 mice ODN Number cells/ml PMN/ml x 105 % PMN
x 104 1908 I 8.02.6 16.62.7 91.23.7 1760 10.22.3 8.612.1 * 82.bt3.0 *
1585 11.0~2.2* 9.5~2.2* 84.62.9 2010 14.112.1 11.81.9 83.412.1 None (saline) 17.913.4 16.912.1 expt 3 ODN Number cells/ml x 104 PMN/ml x 105 0/
I 908 19.012.5 16.92. I 89.411.4 1760 9.1 ~0.8* 7.7t0.7* 84.610.5 1972 I 5.31.6 13.51.4 84.21.2 2001 13.0 1.6* 11.8 1.6 90.42.2 - -* P < 0.05, Mann-Whitney U test In experiment l, both oligonucleotide 1760 and 1826 appear to be effective. In experiment 2, oligonucleotide 1760 and 1585 were effective. Oligonucleotide 2010 also appears to have had a modest effect. In experiment 3, oligonucleotide 1760 was effective. A modest effect was seen with. oligonucleotide 2001. Thus the best oligonucleotides for inducing a therapeutic effect fit the motifs shown in SEQ
ID NO:1 and SEQ ID N0:3. Oligonucleotides such as 2001 and 2010, which contain CpG
motifs with CCGG, CCG, and CGG, can also have a beneficial effect.
The results indicate that CpG containing oligonucleotides substantially reduce the inflammatory response to inhaled LPS and that the protective effect appears to be specific to unmethylated CpG motifs embedded within the oligonucleotide. Thesc findings suggest that oligonucleotides containing CpG motifs may prove helpful in controlling the inflammatory response to inhaled LPS and other environmental agents.
Sincc endogenous and exogenous IL-10 arc known to suppress the inflammatory response to LPS (Cassatella, M.A., et al., J. Eap. Mecl. 178:2207, 1993; Berg, D.J., et al., J. Clim. Invest. 96:2339-2347, 1995), IL-10 might play a critical role in mediating the immunosuppressive effects of CpG oligonucleotides. To pursue this hypothesis, knockout (C57BL/6-II10'"''cs") mice and C57BL/6 control mice were pretreated with CpG containing oligonucleotides and then an inhalation challenge with E coli LPS was performed. Compared to pretreatment with intravenous saline, CpG containing oligonucleotides significantly reduced the total cellularity and the concentration of PMNs in the lavage fluid in both C57BL/6 and mice with a disrupted IL-10 gene (C57BL/6-ll10'"'"~') (FIG. 6). Importantly, the immunosuppressive effects of CpG
oligonucleotides were equally effective in mice with a disrupted 1L-10 gene compared to wild type mice.
The results indicate that the protective effect of unmethylated CpG motifs is not dependent on IL-10.
INDUCTION OF NK ACTIVITY
Phosphodiester ODN were purchased from Operon Technologies (Alameda, CA).
Phosphorothioate ODN were purchased from the DNA core facility, University of Iowa, or from The Midland Certified Reagent Company (Midland TX). E. coli (strain B) DNA
and calfthymus DNA were purchased from Sigma (St. Louis, MO). All DNA and ODN
were purified by extraction with phenol:chlorofonn:isoamyl alcohol 05:24:1 ) and/or ethanol precipitation. The LPS level in ODN was less than 12.5 ng/mg and E.
cull and calf thymus DNA contained less than 2.5 ng of LPS/mg of DNA by Limulus assay.
Virus-free, 4-6 week oId, DBA/2, C57BL/6 (B6) and congenitally athymic BALB/C
mice were obtained on contract through the Veterans Affairs from the National Cancer Institute (Bethesda, MD). C57BL/6 SCID mice were bred in the SPF barner facility at the University of Iowa Animal Care Unit.
Human peripheral blood mononuclear leukocytes (PBMC) were obtained as previously described (e.g., Ballas, Z.K. et al., J. Aller~~ Clin. hnnTUnol. 85:453, 1990). Human or murine cells were cultured at 5 x 106/well, at 37'C in a 5% CO, humidified atmosphere in 24-well plates with medium alone or with CpG or non-CpG ODN at the indicated concentrations, or with E. coli or calf thymus (50 ~g/ml) at 3TC for 24 hr.
All cultures were harvested at 18 hr. and the cells were used as effectors in a standard 4 hr.
$'Cr-release assay against IL562 (human) or YAC-I (mouse) target cells as previously described. For calculation of lytic units (LU), I LU was defined as the number of cells needed to effect 30% specific lysis. Where indicated, neutralizing antibodies against IFN-y (Lee Biomolecular, San Diego, CA) or IL-12 (Pharmingen) or their isotype controls were added at the initiation of cultures to a concentration of 10 pg/ml. For , anti-IL-12 addition, 10 lxg of each of the 4 MAB (or isotype controls) were added simultaneously. Recombinant human IL-2 was used at a concentration of 100 U/ml.
Experiments were conducted to determine whether CpG containing oligonucleotides stimulated the activity of natural killer (NK) cells in addition to B cells.
As shown in Table 2, a marked induction of NK activity among mouse spleen cells cultured with CpG ODN 1: - GCTAGACGTTAGCGT (SEQ ID N0:19) and 3Dd: GAGAAXGCTGGACCTTCCAT (SEQ )D N0:20), (where X = 5 methyl cytosine) was observed. In contrast, there was relatively no induction in effectors that had been treated with non-CpG control ODN.
Table 2 Induction OfNK Activity By CpG Oligodeoxynucleotides~ODN) YAC-1 Specific Lysis* % 2C1 I Specific Lysis Effector: Target Effector: Target ODN 50:1 100:1 50:1 100:1 None -1.1 -1.4 15.3 16.6 I 16. I 24.5 3 8.7 47.2 3Dd 17.1 27.0 37.0 40.0 non-CpG ODN -1.6 -1.7 14.8 15.4 Induction ofNli actiuit~ y DNA containing CMG motifs. hul not bn non-CpG
DNA.
Bacterial DNA cultured for 18 hrs. at 37°C and then assayed for killing of K562 (human) or Yac-1 (mouse) target cells induced NK lytic activity in both mouse spleen cells depleted of B cells, and human PBMC, but vertebrate DNA did not (Table 3).
To determine whether the stimulatory activity of bacterial DNA may be a consequence of its increased level of unmethylated CpG dinucleotides, the activating properties of more than 50 synthetic ODN containing unmethylated, methylated, or no CpG dinucleotides was tested. The results, summarized in Table 3, demonstrate that synthetic ODN can stimulate significant NK activity, as long as they contain at least one unmethylated CpG dinucleotide (Ballas, Z., et al., Jlmmunol 157:1840-1845, 1996). No difference was observed in the stimulatory effects of ODN in which the CpG was within a palindrome (such as ODN 1585, which contains the palindrome ~WO 98/37919 PC'r/US98/03678 AACGTT) from those ODN without palindromes (such as 1613 or 1619), with the caveat that optimal stimulation was generally seen with ODN in which the CpG
was flanked by two 5' purines or a 5' GpT dinucleotide and two 3' pyrimidines.
Kinetic experiments demonstrated that NK activity peaked around 18 hrs. after addition of the ODN. The data indicates that the murine NK response is dependent on the prior activation of monocytes by CpG DNA, leading to the production of IL-I 2, TNF-a, and IFN.
Table 3 Induction of NK Activity by DNA Containing CpG Motifs but not b~~ Non-CpG DNA
LU/ 10'' DNA or Cytokine Added Mouse Cells Human Cells Expt.l None 0.00 0.00 IL-2 16.68 15.8?
E. Colt DNA 7.23 5.05 Calf thymus DNA , 0.00 0.00 1=;xpt.2 None 0.00 3.28 1585 ggGGTCAACGTTGACgggg (SEQ ID N0:21 ) 7.38 17.98 1629 -----------gtc--------------- (SEQ ID N0:22) 0.00 4.4 Expt.3 None 0.00 1613 GCTAGACGTTAGTGT (SEQ ID N0:23) 5.22 .
1769 --------------X------------- (SEQ ID N0:24) 0.02 ND
1619 TCCATGTCGTTCCTGATGCT (SEQ ID NO:S) 3.35 I765 -______________X___-____________-_____ (SEQ ID N0:25) 0.11 CpG dinucleotides in ODN sequences are indicated by underlining; X indicates methylcytosine. Lower case letters indicate nuclease resistant phosphorothioate modified internucleotide linkages which, in titration experiments, were more than 20 times as potent as non-modified ODN, depending on the flanking bases. Poly G ends (g) were used in some ODN, because they signif candy increase the level of ODN uptake.
Dashes indicate some bases are identical to those in the directly preceding sequence, with the exception of changes noted.
Immune activation by CpG motifs may depend on bases flanking the CpG, and the number and spacing of the CpGs present within an ODN. Although a single CpG in an ideal base context can be a very strong and useful immune activator, superior effects can be seen with ODN containing several CpGs ~~ith the appropriate spacing and flanking bases. For activation of murine B cells, the optimal CpG motif is TGACGTT.
The following studies were conducted to identify optimal ODN sequences for stimulation of human cells by examining the effects of changing the number, spacing, and flanking bases of CpG dinucleotides.
Iclentiftcatiorr of~nlzo.st~horothioate ODN with ontinzcrl CMG mnti s far activation human NIL cells To have clinical utility, ODN must be administered to a subject in a form that protects them against nuclease degradation. Methods to accomplish this with phosphodiester ODN are well known in the art and include encapsulation in lipids or delivery systems such as nanoparticles. This protection can also be achieved using chemical substitutions to the DNA such as modified DNA backbones including those in which the internucleotide linkages are nuclease resistant. Some modifications may confer additional desirable properties such as increasing cellular uptake. For example, the phosphodiester linkage can be modified via replacement of one of the nonbridging oxygen atoms with a sulfur, which constitutes phosphorothioate DNA.
Phosphorothioate ODN have enhanced cellular uptake (Krieg et al., Arztiserzse Res. Dev. 6:133, 1996) and improved B cell stimulation if they also have a CpG motif. Since NK activation correlates strongly with in vivo adjuvant effects, the identification of phosphorothioate ODN that will activate human NK cells is very important.
The effects of different phosphorothioate ODNs, which contain CpG
dinucleotides in various base contexts, on human NK activation (Table 4) were examined. ODN
1840, which contained 2 copies of the TGTCGTT motif, had significant NK lytic activity (Table 4). To further identifj- additional ODNs optimal for NK activation, approximately one hundred ODN containing different numbers and spacing of CpG motifs. were tested with ODN 1982 serving as a control. Sample results are shown in Table 5.
Effective ODNs generally began with a TC or TG at the 5' end. however, this requirement was not mandatory. ODNs with internal CpG motifs (e.g., ODN I 840) are generally less potent stimulators than those in which a GTCGCT motif immediately follows the 5' TC (e.g>., ODN 1967 and 1968). ODN 1968, which has a second GTCGTT
motif in its 3' half, was consistently more stimulatory than ODN 1967, which lacks this second motif. ODN 1967, however, was slightly more potent than ODN 1968 in experiments 1 and 3, but not in experiment 2. ODN 2005, which has a third GTCGTT
motif, induced slightly higher NK activity on average than 1968. However, ODN
2006, in which the spacing between the GTCGTT motifs was increased by the addition of two Ts between each motif, was slightly superior to ODN 2005 and to ODN 2007, in which only one of the motifs had the addition of the spacing two Ts. The minimal acceptable spacing between CpG motifs is one nucleotide as long as the ODN has two pyrimidines (preferably T) at the 3' end (e.g., ODN 2015). Surprisingly, joining two GTCGTT
motifs end to end with a 5' T also created a reasonably strong inducer of NK
activity (e.g>., ODN 2016). The choice of thymine (T) separating consecutive CpG
dinucleotides is not absolute, since ODN 2002 induced appreciable NK activation despite the fact that adenine (a) separated its CpGs (i.e., CGACGTT). It should also be noted that ODNs containing no CpG (e.g., ODN 1982), runs of CpGs, or CpGs in bad sequence contexts (e.g., ODN 2010) had little or no stimulatory effect on NK activation.
Table 4 ODN induction of NK ~L~tic Activity (LU) ODN Sequence (5'-3') LU
None O.OI
1754 ACCATGGACGATCTGTTTCCCCTC (SEQ ID N0:26) 0.02 1758 TCTCCCAGCGTGCGCCAT (SEQ ID N0:27) 0.05 1761 TACCGCGTGCGACCCTCT (SEQ ID N0:28) 0.05 1776 ACCATGGACGAACTGTTTCCCCTC (SEQ ID N0:29) 0.03 1777 ACCATGGACGAGCTGTTTCCCCTC (SEQ ID N0:30) 0.05 101778 ACCATGGACGACCTGTTTCCCCTC (SEQ ID N0:31) 0.01 1779 ACCATGGACGTACTGTTTCCCCTC (SEQ ID N0:32) 0.02 1780 ACCATGGACGGTCTGTTTCCCCTC (SEQ ID N0:33) 0.29 I781 ACCATGGACGTTCTGTTTCCCCTC (SEQ ID N0:34) 0.38 1823 GCATGACGTTGAGCT (SEQ ID N0:35) 0.08 151824 CACGTTGAGGGGCAT (SEQ ID N0:36) 0.01 1825 CTGCTGAGACTGGAG (SEQ ID N0:37) 0.01 1828 TCAGCGTGCGCC (SEQ ID N0:38) 0.01 1829 ATGACGTTCCTGACGTT (SEQ ID N0:39) 0.42 18302 RANDOM SEQUENCE 0.25 201834 TCTCCCAGCGGGCGCAT (SEQ ID N0:40) 0.00 I 836 TCTCCCAGCGCGCGCCAT (SEQ ID N0:41 ) 0.46 1840 TCCATGTCGTTCCTGTCGTT (SEQ ID N0:42) 2.70 I 841 TCCATAGCGTTCCTAGCGTT (SEQ ID N0:43) 1.45 1842 TCGTCGCTGTCTCCGCTTCTT (SEQ ID N0:44) 0.06 251851 TCCTGACGTTCCTGACGTT (SEQ ID N0:45) 2.32 'Lytic units (LU) were measured as described (8). Briefly, PBMC were collected from normal donors and spun over Ficoll, then cultured with or without the indicated ODN
(which were added to cultures at 6 ~g/mi) for 24 hr. Then their ability to lyse 5'Cr-labeled K562 cells was determined. The results shown are typical of those obtained 30 with several different normal human donors.
zThis oligo mixture contained a random selection of all 4 bases at each position.
M
~O O~ 00 ~t o0 N N 00 O~ n oNO ~O v1 ~W D N o~o ~ ~O
X- v G7 v, o ~ C~ Wit; C~ M ,~ Ll os Ll L1 ~ r.i ~i '~ ~ o ....; <'? o o ~
~az~~~zMz~.~zozz~;~~~;~o~~,_~~
''-' ~O 00 M O N ~t ~ .-. N I~ 00 t~ N \D Wit' M d' ø' N C~ V' ('.! ~D L 'ct C~ ~ N C~ L~ C~ L M N ~-~ ~O M O O V~ t~ V1 v1 j '~. z O .--~ .--~ z O z .--~ ~ z z z z ~ ~t v0 N ~-~ O N O v~ ~Y ~p N Y ''-' O M M N ~O N N I~ N v1 O ~ C~1 ~s ~ o M L7 o Ll ~r -yo 00 ~ r~, o .- 00 0 ~ D L~ L D D D L~ L1 G~
~oNz~zMON~Mwo~.io~zzzzzzzzzz p o p ..C -1 .-. .-. ~. ~ ~ .~ o N M
~~~~~~ooo~~~~~~oooo~~~
-° o~::oooozzzoooooo~zzzza~
zzzz way w zozzzzr~~r~z zw~~~~~o ~~r~r~r~~aaa~~ar~r~o~o, ~...z~
z a~ aaaaw w w o-o'aaaaH ~ w w w wwww '.v,v~
wo~wwww w wH aa~~~N~
~~_~~~~~ H ~ ~~~~~~ oI~ "~ ~HI°'z o V~~VV~~~U~~ V~~~~I'u7l~~o~~z UI ~H~ ~~~UIUI HHH UI~~d~
a H UI~IFU-~I(U-INIU U ~ ~ d ~IC7 d NI~ ~ C7 V ~' ~I~ w O' '~ ~ ~' C7 C7 C7 (~ V U C7 ~ U U C7 ~ I-~ E-. UI U UI f-~ E'" ~ ~ UI
~U UC7HUUE-~~ ~UI~~U~~C7~'.
U U U H U U ~ U U UIt7I~ UIC7 UIE-'IC7 C7IH ~ CSI
~~~~~~~~I~~~~~~H~,~H
U C7 U C7 U C7 H E~-~ E--~ N U U ~ U UI ~ ~I ~I UI C7I
~~I~HI~~I~I~I~I~~~I~I~I~~~~I~I~~~~~
d N d H ~ E~-~ H H H d d d d d EU-~) H HI FU-' ~ UI UI UI HI UI
a" U U U U U U UIUIUIU U U U U UIUIUIU UI~ ~ ~ VIA
°i E-~ H H E-~ H E-~ E-~ H E-~ E-~ E-~ H E-~ E-~ E-~ E-~ E-~ C'J t5 H H
E-~ H E-~ O O ~-~ N M ~n ~O I~ 000 N O .--~ N ~n ~ I~ oo O N M ~ W p p~1'~\O~DID~\Ol0\On 0000100000~--, ..r.--a.~.-r o z~,~~~~~~~~~
~ N N N N N N N N N N N
o ~ o N N
WO -98/37919 PCTlUS98/03678 ~ PBMC essentially as described herein. Results are representative of 6 separate experiments; each experiment represents a different donor.
2This is the methylated version of ODN 1840; Z=5-methyl cytosine LU is lytic units;
ND = not done; CpG dinucleotides are underlined for clarity.
IDENTIFICATION OF PHOSPHOROTHIOATI~ ODN WITH OPTIMAL CPG
MOTIFS FOR ACTIVATION OF HUMAN Ii CELL PROLIFERATION
The ability of a CpG ODN to induce B cell proliferation is a good measure of its adjuvant potential. Indeed, ODN with strong adjuvant effects in mouse studies also induce B cell proliferation. To determine whether the optimal CpG ODN for inducing B cell proliferation are the same as those for inducing Nh cell activity, similar panels of ODN
(Table 6) were tested. Many CpG ODN were stimulatory. ODN ?006 produced the most consistant stimulation (Table 6).
W 0 ~ 98/37919 PCT/US98/03678 .n .
M z z M M 'Z ~f M M .-N-n U
.~ Gl Ca Gl ~ Ca O O r~ N
z ~z z zz N z ~ ~ ~ M z n o ca z z M M M z d' '~ ~f cr1 U
_O
._.C C
~
.-S (~ O O~ O~ Q J- O O M tt ~
~-z z N~ ~ z ~
O
': N
O O~ 00 ~ I~ d: O 00 t~
~OC X' z N M M Z M ch V' --~ N
z y.O
_Dc~
cd ~"cdi ~
'~ ~., M z tV z M ~ ~ -n ~t -Z
U
C
cCt ' ' ' a o z o- a a a o a a .~ w ~ ~w w w w o ~ '- o,~ ~ ~ ~ '.
' U U ~
... C7 I I I I I I ~ I
r~ ~-- ~ UI E-. I-, E-~ ~ U Q Q
f-~ C7 C7 C7 V UI U UI
H (-~ .
U U U ~ V U V ~ U
U (-t - ~ ~ I-C~ ~ ~ C7 E ~ C7 C7 ~ C7 I I ~ I
E-r C7 UI ~" UI ~I UI V U ~ Q .
.
~d N~ '~'H~ ~E~-' '-~~H ~E'y') '~(-HI ~~ oU) r~
U ~ ~ U '~ ~' 'r C7I '-" '~" "' "' -H zH HH zH zH zH zH zH zH zH
zz z O ~ O .-d- d W 0~ ~ ~ ~ ~ ~ pNO
00 0o O~ a1 O~ O~ ~ O~ O~ ~ O
.-, .-~ .~ .-, .--i .- m.-~ .--~ .... m" N
WO 98/37919 PCTlUS98/03678 ,o _ ~' o v _o '_ v U ~
>~ ~
. ,_.', ° .~, U
o x" ~
a~ ... 3 o v o z ~ --ML ~~C~L~I~~fM~'~'~Q
z z z z z ~~~ ~ ~ ~ o U
O 00 ~--W O c' l f~! 00 N vW~ ~ r.4~.
MN~'~~MMNM~'f~IO~U'~' 'p .-' C v V O
~r ~~
O c3 N N N d: Os O O ~ t~ ~
-- f~1 Wit- N ~- M d' N ~-~ ~ ~u O
O cC V~ 'C
C G~
c~ c~ w rt ~ L
r N ~n O O v0 00 M ~n o0 .-M 'ct ~t M ~- N N N ~--~ .-~ U
U
r ,~ Ql U '' z o -w o tn ~ M ~ ~ C~l M M V7 cG
y U '-' ~ 4~ v Q' ~ ..c ' a~ c~"'a a ~ °' a a o' " .°z .... ~ ~ ~_ ~
o v .°
.... C7 '-U O' ~ ~, ~ s ~, O
v ~ ~ ~~"~~ ~ L s ~ I>r I UI ~ ~I ~ '~ o ~ a .~ -~ z UI ~I UI ~"I ~ UI C7 ~ UI C7 o a, 3 3 °
U ~" C7 UI E-' UI
C7 C7 ~ U C'7 E- E-. C7I (~ ,~ w ;; ~s 3 U C7I _ '~ ~ C~ ~ ø. o °~' ~I ~ ~i ~ ~I ~ ~ ~ ~ ~ UI ° UI o UI ~I UI ~ ~ ~ ~ v I ~I ~., E-, z H ~ ~ ~, ° .~ o H z°H zH °z~ z~ °zH z~ ~HHIH
tn \O I~ 00 O N M ~ ~W O N
O O O O ~ .-. .-K .--, .-r .~ II
O O O O O O 'O O O O v~ ~
N N N N N N N N N N
U .~ v .~ o ' WO 98/37919 PCT/US98/03678 IDENTIFICATION OF PHOSPI-IOROTHIOATE ODN
The ability of a CpG ODN to induce IL-12 secretion is a good measure of its adjuvant potential, especially in terms of its ability to induce a Thl immune response, which is highly dependent on IL-12. Therefore, the ability of a panel of phosphorothioate ODN
to induce IL-12 secretion from human PBMC in vitro (Table 7) was examined.
These experiments showed that in some human PBMC, most CpG ODN could induce IL-12 secretion (e.g., expt. 1). However, other donors responded to just a few CpG
ODN (e.~=., expt. 2). ODN 2006 was a consistent inducer of ILI2 secretion from most subjects (Table 7).
Table 7 induction of human IL-12 secretion b5~ Phosnhorothioate ~G ODN
ODN~ sequence (5'-3') IL-12 (pg/ml) expt.l expt.2 None 0 0 1962 TCCTGTCGTTCCTTGTCGTT (SEQ ID N0:13) 19 0 1965 TCCTGTCGTTTTTTGTCGTT (SEQ ID N0:14) 36 0 1967 TCGTCGCTGTCTGCCCTTCTT (SEQ ID NO:15) 41 0 1968 TCGTCGCTGTTGTCGTTTCTT (SEQ ID N0:16) 24 0 2005 TCGTCGTTGTCGTTGTCGTT CSEQ ID N0:7) 25 0 2006 TCGTCGTTTTGTCGTTTTGTCGTT (SEQ ID N0:6) 29 I S
2014 TGTCGTTGTCGTTGTCGTT (S~Q ID NO: I 1 ) 28 0 2015 TCGTCGTCGTCGTT (SEQ ID N0:12) 14 0 2016 TGTCGTTGTCGTT (SEQ ID N0:57) 3 0 ' PBMC were collected from normal donors and spun over Ficoll, then cultured at >~0 cells/well in 96 well microtiter plates with or without the indicated ODN
which were added to cultures at 6 p.g/ml. Supernatants were collected at 24 hr and tested for IL-12 levels by ELISA as described in methods. A standard curve was run in each experiment, which represents a different donor.
IDENTIFICATION OF B CELL AND
MONOCYTE/NK CELL-SPECIFIC OLIGONUCLEOTIDES
CpG DNA can directly activate highly purified B cells and monocytic cells.
There are many similarities in the mechanism through which CpG DNA activates these cell types.
For example, both require NFkB activation as explained further below.
In further studies of different immune effects of CpG DNA, it was found that there is more than one type of CpG motif. Specifically, oligo 1668, with the best mouse B cell motif, is a strong inducer of both B cell and natural killer (Nh) cell activation, while oligo 1758 is a weak B cell activator, but still induces excellent N1 responses (Table 8).
Table 8 Different CpG motifs stimulate optimal murine B cell and NK activation ODN Sequence B cell activation' NI~ activation' 1668 TCCATGACGTTCCTGATGCT (SEQ ID N0:57) 42,849 2.52 1758 TCTCCCAGCGTGCGCCAT (SEQ ID N0:27) 1,747 6.66 NONE 367 0.00 CpG dinucleotides are underlined; oiigonucleotides were synthesized with phosphorothioate modified backbones to improve their nuclease resistance.
'Measured by 3H thymidine incorporation after 48 hr culture with oligodeoxynucleotides at a 200 nM concentration as described in Example 1.
=Measured in lytic units.
PREVENTION OF THE DEVELOPMENT OF AN INFLAMMATORY
- CELLULAR
Six to eight week old C56BL/6 mice (from The Jackson Laboratory, Bar Harbor, ME) were immunized with 5,000 Schistosoma mansoni eggs by intraperitoneal (i.p.) injection on days 0 and 7. Schistosoma mansoni eggs contain an antigen (Schistosoma mansoni egg antigen (SEA)) that induces a Th2 immune response (e.g., production of IgE
antibody). IgE antibody production is knOV~'II to be an important cause of asthma.
The immunized mice were then treated with oligonucleotides (30ug in 200p1 saline by i.p. injection), which either contained an unmethylated CpG motif, i.e., TCCATGACGTTCCTGACGTT (SEQ ID N0:39), or did not, i.c., control, TCCATGAGCTTCCTGAGTCT (SEQ ID N0:58).
Soluble SEA (l0ug in 25u1 of saline) was administered by intranasal instillation on days 14 and ? l . Saline was used as a control.
Mice were sacrificed at various times after airway challenge. Whole lung lavage was performed to harvest airway and alveolar inflammatory cells. Cytokine levels were measured from lavage fluid by ELISA. RNA was isolated from whole lung for Northern analysis and RT-PCR studies using CsCI gradients. Lungs were inflated and perfused with 4% paraformaldehyde for histologic examination.
FIG. 7 shows that when the mice are initially injected with the eggs i.p., and then inhale the egg antigen (open circle), many inflammatory cells are present in the lungs.
However, when the mice are initially given a nucleic acid containing an unmethylated CpG motif along with the eggs, the inflammatory cells in the lung are not increased by subsequent inhalation of the egg antigen (open triangles).
FIG. 8 shows that the same results are obtained when only eosinophils present in the lung lavage are measured. Eosinophils are the type of inflammatory cell most closely associated with asthma.
FIG. 9 shows that when the mice are treated with a control oligo at the time of the initial exposure to the egg, there is little effect on the subsequent influx of eosinophils into the lungs after inhalation of SEA. Thus, when mice inhale the eggs on days 14 or 21, they develop an acute inflammatory response in the lungs. However, giving a CpG
oligo S along with the eggs at the time of initial antigen exposure on days 0 and 7 almost completely abolishes the increase in eosinophils when the mice inhale the egg antigen on day I 4.
FIG. 10 shows that very low doses of oligonucleotide (< l0ug) can give this protection.
F1G. 11 shows that the resultant inflammatory response correlates with the levels of the Th2 cytokine IL-4 in the Lung.
FIG. 12 shows that administration of an oligonucleotide containing an unmethylated CpG motif can actually redirect the cytokine response of the lung to production of II-12, indicating a Th I type of immune response.
FIG. 13 shows that administration of an oligonucleotide containing an unmethylated CpG
I S motif can also redirect the cytokine response of the lung to production of IFN-y, indicating a Th 1 type of immune response.
What is claimed is:
Claims (28)
1. A method of treating a subject having or at risk of having an acute decrement in air flow, comprising:
administering to a subject having or at risk of having an acute decrement in air flow a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG, wherein the nucleic acid includes at least the following formula 5' N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X, is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N, + N2 is from about 2-26 bases.
administering to a subject having or at risk of having an acute decrement in air flow a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG, wherein the nucleic acid includes at least the following formula 5' N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X, is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N, + N2 is from about 2-26 bases.
2. The method of claim 1, wherein the nucleic acid sequence is from 8-30 bases in length.
3. The method of claim 1, wherein the subject is human.
4. The method of claim 1, wherein the acute decrement in airflow results from lipopolysaccharide (LPS) exposure.
5. The method of claim 1, wherein the acute decrement in airflow results from endotoxin exposure.
6. The method of claim 5, wherein N, and N2 do contain a CCGG quadmer or more than one CGG trimer; and the nucleic acid sequence is from about 8-30 bases in length.
7. The method of claim 5, wherein said nucleic acid sequence is SEQ ID NO: 2.
8. The method of claim 1, wherein the nucleic acid sequence has a formula:
5' N1X1X2CGX3X4N2 3' (SEQ ID NO: 3) wherein at least one nucleotide separates consecutive CpGs; X1X2 is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N1 + N2 is from about 0-26 bases.
5' N1X1X2CGX3X4N2 3' (SEQ ID NO: 3) wherein at least one nucleotide separates consecutive CpGs; X1X2 is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N1 + N2 is from about 0-26 bases.
9. The method of claim 8, wherein N, and N2 do contain a CCGG quadmer or more than one CCG or CGG trimer; and the nucleic acid sequence is from about 8-30 bases in length.
10. A method of inhibiting an inflammatory response in a subject having inhaled or at risk of having inhaling lipopolysaccharide (LPS), comprising:
administering to a subject having inhaled or at risk of having inhaling lipopolysaccharide (LPS) an effective amount for inhibiting an inflammatory response of a nucleic acid sequence containing at least one unmethylated CpG, wherein the nucleic acid includes at least the following formula 5' N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X1 is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N1 + N2 is from about 2-26 bases.
administering to a subject having inhaled or at risk of having inhaling lipopolysaccharide (LPS) an effective amount for inhibiting an inflammatory response of a nucleic acid sequence containing at least one unmethylated CpG, wherein the nucleic acid includes at least the following formula 5' N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X1 is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N1 + N2 is from about 2-26 bases.
11. The method of claim 10, wherein the nucleic acid sequence is from 8-30 bases in length.
12. The method of claim 10, wherein the subject is human.
13. The method of claim 10, wherein the subject has inhaled LPS.
14. The method of claim 13, wherein N, and N2 do contain a CCGG quadmer or more than one CGG trimer; and the nucleic acid sequence is from about 8-30 bases in length.
15. The method of claim 13, wherein said nucleic acid sequence is SEQ ID NO:
2.
2.
16. The method of claim 10, wherein the nucleic acid sequence has a formula:
5' N1X1X2CGX3X4N2 3' (SEQ ID NO: 3) wherein at least one nucleotide separates consecutive CpGs; X1X2 is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N1 + N2 is from about 0-26 bases.
5' N1X1X2CGX3X4N2 3' (SEQ ID NO: 3) wherein at least one nucleotide separates consecutive CpGs; X1X2 is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N1 + N2 is from about 0-26 bases.
17. The method of claim 16, wherein N, and N2 do contain a CCGG quadmer or more than one CCG or CGG trimer; and the nucleic acid sequence is from about 8-30 bases in length.
18. A method of modifying the level of a cytokine in a subject having inhaled or at risk of inhaling lipopolysaccharide (LPS), comprising:
administering to a subject a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG, wherein the nucleic acid includes at least the following formula 5' N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X1 is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N, + N2 is from about 2-26 bases.
administering to a subject a therapeutically effective amount of a nucleic acid sequence containing at least one unmethylated CpG, wherein the nucleic acid includes at least the following formula 5' N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X1 is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N, + N2 is from about 2-26 bases.
19. The method of claim 18, wherein the nucleic acid sequence is from about 8-30 bases in length.
20. The method of claim 18, wherein the subject is human.
21. The method of claim 18, wherein the subject has inhaled LPS.
22. The method of claim 18, wherein the nucleic acid sequence has a formula:
5'N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X1 is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N1 + N2 is from about 0-26 bases.
5'N1X1CGX2N2 3' (SEQ ID NO: 1) wherein at least one nucleotide separates consecutive CpGs; X1 is adenine, guanine, or thymidine; X2 is cytosine or thymine, N is any nucleotide and N1 + N2 is from about 0-26 bases.
23. The method of claim 22, wherein N1 and N2 do not contain a CCGG quadmer or more than one CGG trimer; and the nucleic acid sequence is from about 8-30 bases in length.
24. The method of claim 18, wherein the nucleic acid sequence has a formula:
5' N1X1X2CGX3X4N2 3' (SEQ ID NO: 3) wherein at least one nucleotide separates consecutive CpGs; X1X2 is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N1 + N2 is from about 0-26 bases in length.
5' N1X1X2CGX3X4N2 3' (SEQ ID NO: 3) wherein at least one nucleotide separates consecutive CpGs; X1X2 is selected from the group consisting of GpT, GpG, GpA, ApT and ApA; X3X4 is selected from the group consisting of TpT or CpT; N is any nucleotide and N1 + N2 is from about 0-26 bases in length.
25. The method of claim 24, wherein N1 and N2 do contain a CCGG quadmer or more than one CCG or CGG trimer; and the nucleic acid sequence is from about 8-30 bases in length.
26. The method of claim 18, wherein said modulation is a reduction in the level of said cytokine.
27. The method of claim 18, wherein said modulation is an increase in the level of said cytokine, and wherein said cytokine is selected from the group consisting of MIP-2, IL-10 and IL-12.
28. The method of claim 18, wherein said cytokine is selected from the group consisting of TNF-.alpha., MIP-2, IL-10, IL-12, and interferon-.gamma..
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3940597P | 1997-02-28 | 1997-02-28 | |
US60/039,405 | 1997-02-28 | ||
PCT/US1998/003678 WO1998037919A1 (en) | 1997-02-28 | 1998-02-25 | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2281838A1 true CA2281838A1 (en) | 1998-09-03 |
Family
ID=21905269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002281838A Abandoned CA2281838A1 (en) | 1997-02-28 | 1998-02-25 | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
Country Status (6)
Country | Link |
---|---|
US (1) | US6214806B1 (en) |
EP (1) | EP1039935A4 (en) |
JP (1) | JP2001513776A (en) |
AU (1) | AU738513B2 (en) |
CA (1) | CA2281838A1 (en) |
WO (1) | WO1998037919A1 (en) |
Families Citing this family (324)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7189834B2 (en) * | 1993-05-11 | 2007-03-13 | Marshall William E | Oligoribonucleotides alert the immune system of animals to the imminence of microbial infection |
US5849719A (en) * | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
US6727230B1 (en) | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US7935675B1 (en) * | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0909323B1 (en) | 1996-01-04 | 2007-02-28 | Novartis Vaccines and Diagnostics, Inc. | Helicobacter pylori bacterioferritin |
US20030078223A1 (en) * | 1996-01-30 | 2003-04-24 | Eyal Raz | Compositions and methods for modulating an immune response |
CA2268825C (en) | 1996-10-11 | 2006-04-18 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
EP0855184A1 (en) | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination |
JP2001513776A (en) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6426334B1 (en) * | 1997-04-30 | 2002-07-30 | Hybridon, Inc. | Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
JP4101888B2 (en) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US20040006034A1 (en) * | 1998-06-05 | 2004-01-08 | Eyal Raz | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US6589940B1 (en) | 1997-06-06 | 2003-07-08 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
US7138384B1 (en) | 1997-08-29 | 2006-11-21 | The Regents Of The University Of California | Modulators of DNA cytosine-5 methyltransferase and methods for use thereof |
JP4663113B2 (en) * | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation |
GB9727262D0 (en) * | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
ATE356630T1 (en) * | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM USING IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINE |
JP2002514397A (en) * | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | Methods for hematopoietic regulation using CpG oligonucleotides |
WO1999059578A1 (en) | 1998-05-19 | 1999-11-25 | Research Development Foundation | Triterpene compositions and methods for use thereof |
DK1077722T3 (en) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Methods and products for the induction of mucosa immunity |
US6562798B1 (en) * | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
US20030022854A1 (en) | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
JP4620251B2 (en) | 1998-08-10 | 2011-01-26 | アンチジェニックス・インコーポレイテッド | Composition of CPG and saponin adjuvant and method thereof |
EP1113818B1 (en) * | 1998-09-18 | 2006-05-17 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
ATE464907T1 (en) * | 1999-02-17 | 2010-05-15 | Csl Ltd | IMMUNOGENIC COMPLEXES AND METHODS RELATING THEM |
DE60020677T2 (en) | 1999-02-26 | 2006-05-04 | Chiron Corp., Emeryville | MICROEMULSIONS WITH ADSORBED MACROMOLECULES AND MICROPARTICLES |
CA2371994C (en) | 1999-02-26 | 2010-09-28 | Guido Grandi | Enhancement of bactericidal activity of neisseria antigens with oligonucleotides containing cg motifs |
WO2000061151A2 (en) * | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
ES2228497T3 (en) * | 1999-04-19 | 2005-04-16 | Glaxosmithkline Biologicals S.A. | ADJUTIVE COMPOSITION INCLUDING SAPONINA AND AN IMMUNO STIMULANT OLIGONUCLEOTIDE. |
GB9908885D0 (en) * | 1999-04-19 | 1999-06-16 | Smithkline Beecham Biolog | Vccine |
US6558670B1 (en) | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
FR2797263B1 (en) * | 1999-08-06 | 2003-09-19 | Pasteur Merieux Serums Vacc | IMMUNOSTIMULANT OLIGONUCLEOTIDE |
WO2000075304A1 (en) * | 1999-06-08 | 2000-12-14 | Aventis Pasteur | Immunostimulant oligonucleotide |
GB9915204D0 (en) * | 1999-06-29 | 1999-09-01 | Smithkline Beecham Biolog | Vaccine |
EP1198249B1 (en) * | 1999-06-29 | 2005-10-19 | GlaxoSmithKline Biologicals S.A. | Use of cpg as an adjuvant for hiv vaccine |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
JP2003507341A (en) * | 1999-08-19 | 2003-02-25 | ダイナバックス テクノロジーズ コーポレイション | Immunostimulatory sequences and methods for modulating an immune response with compositions for using the same and compositions for using the same |
KR100863630B1 (en) * | 1999-09-25 | 2008-10-15 | 유니버시티 오브 아이오와 리써치 파운데이션 | Immunostimulatory Nucleic Acids |
US6949520B1 (en) | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
US7223398B1 (en) | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
WO2001051083A2 (en) * | 2000-01-13 | 2001-07-19 | Antigenics Inc. | Innate immunity-stimulating compositions of cpg and saponin and methods thereof |
ATE378348T1 (en) * | 2000-01-14 | 2007-11-15 | Us Health | OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE |
CA2398756A1 (en) * | 2000-01-31 | 2001-08-02 | Eyal Raz | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
US7585847B2 (en) * | 2000-02-03 | 2009-09-08 | Coley Pharmaceutical Group, Inc. | Immunostimulatory nucleic acids for the treatment of asthma and allergy |
CA2399550A1 (en) | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US20030130217A1 (en) * | 2000-02-23 | 2003-07-10 | Eyal Raz | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US7157437B2 (en) | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20020098199A1 (en) | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
AU7013401A (en) | 2000-06-22 | 2002-01-02 | Univ Iowa Res Found | Methods for enhancing antibody-induced cell lysis and treating cancer |
WO2002002172A1 (en) * | 2000-06-30 | 2002-01-10 | Univ Jefferson | Dna palindrome - oligoguanylic acid compositions and uses thereof |
KR100917101B1 (en) * | 2000-08-04 | 2009-09-15 | 도요 보세키 가부시키가이샤 | Flexible metal laminate and production method thereof |
JP2005500806A (en) * | 2000-09-15 | 2005-01-13 | コーリー ファーマシューティカル ゲーエムベーハー | Process for high-throughput screening of immune agonist / immunoantagonists based on CpG |
AU2002214127B2 (en) | 2000-10-27 | 2007-06-07 | J. Craig Venter Institute, Inc. | Nucleic acids and proteins from streptococcus groups A and B |
EP1350262B8 (en) * | 2000-12-08 | 2008-08-13 | Coley Pharmaceuticals GmbH | Cpg-like nucleic acids and methods of use thereof |
ATE471374T1 (en) | 2000-12-27 | 2010-07-15 | Dynavax Tech Corp | IMMUNOMODULATORY POLYNUCLEOTIDES AND METHOD FOR USE THEREOF |
US20030050268A1 (en) * | 2001-03-29 | 2003-03-13 | Krieg Arthur M. | Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases |
EP1390494A2 (en) | 2001-05-21 | 2004-02-25 | Intercell AG | Method for stabilising of nucleic acids |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
US20030199466A1 (en) * | 2001-06-21 | 2003-10-23 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same - ll |
US7785610B2 (en) * | 2001-06-21 | 2010-08-31 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—III |
WO2003002065A2 (en) * | 2001-06-29 | 2003-01-09 | Chiron Corporation | Hcv e1e2 vaccine compositions |
GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
GB0121591D0 (en) | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
WO2003012061A2 (en) * | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
US20030133988A1 (en) * | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
WO2003020884A2 (en) * | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
KR100991644B1 (en) * | 2001-08-17 | 2010-11-02 | 콜리 파마슈티칼 게엠베하 | Combination Motif Immune Stimulatory Oligonucleotides with Improved Activity |
CA2457903C (en) | 2001-08-24 | 2018-04-17 | University Of Victoria Innovation And Development Corporation | Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer |
JP2005501917A (en) * | 2001-09-07 | 2005-01-20 | ザ トラスティーズ オブ ボストン ユニバーシティ | Methods and compositions for treating immune complex related diseases |
ES2335979T3 (en) | 2001-09-14 | 2010-04-07 | Cytos Biotechnology Ag | IMMUNOSTIMULATOR CPG PACKAGING IN VIRUS SIMILAR PARTICLES: PREPARATION METHOD AND ITS USE. |
AU2002353783A1 (en) | 2001-09-24 | 2003-04-07 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE |
US20030119774A1 (en) * | 2001-09-25 | 2003-06-26 | Marianna Foldvari | Compositions and methods for stimulating an immune response |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
IL160837A0 (en) * | 2001-10-05 | 2004-08-31 | Coley Pharm Gmbh | Toll-like receptor 3 signaling agonists and antagonists |
CA2462203A1 (en) * | 2001-10-12 | 2003-11-20 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
AU2002366710A1 (en) * | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
EP2572707A3 (en) | 2002-02-20 | 2013-11-06 | Novartis Vaccines and Diagnostics, Inc. | Microparticles with adsorbed polypeptide-containing molecules |
US8153141B2 (en) * | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
KR100456681B1 (en) * | 2002-05-22 | 2004-11-10 | 주식회사 대웅 | Immnune-stimulating and controlling Composition comprising bacterial chromosomal DNA fragments and detoxified lipopolysaccharides |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040009949A1 (en) * | 2002-06-05 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids |
US20040053880A1 (en) * | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7605138B2 (en) * | 2002-07-03 | 2009-10-20 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7569553B2 (en) * | 2002-07-03 | 2009-08-04 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) * | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7576066B2 (en) * | 2002-07-03 | 2009-08-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
AU2003255969A1 (en) * | 2002-07-17 | 2004-02-02 | Coley Pharmaceutical Gmbh | Use of cpg nucleic acids in prion-disease |
JP2005533855A (en) | 2002-07-24 | 2005-11-10 | インターツェル・アクチェンゲゼルシャフト | An antigen encoded by another reading frame from a pathogenic virus. |
EP1575504A4 (en) | 2002-08-01 | 2009-11-04 | Us Gov Health & Human Serv | Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
AR040996A1 (en) | 2002-08-19 | 2005-04-27 | Coley Pharm Group Inc | IMMUNE STIMULATING NUCLEIC ACIDS |
GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
JP2006504687A (en) | 2002-09-13 | 2006-02-09 | インターツェル・アクチェンゲゼルシャフト | Method for isolating hepatitis C virus peptide |
US8263091B2 (en) * | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
US8043622B2 (en) | 2002-10-08 | 2011-10-25 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides |
EP2241325B1 (en) | 2002-10-29 | 2012-02-08 | Coley Pharmaceutical Group, Inc. | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
WO2004041183A2 (en) * | 2002-11-01 | 2004-05-21 | The Regents Of The University Of California | Methods of treating pulmonary fibrotic disorders |
EP1572122A4 (en) * | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
AU2003288660A1 (en) | 2002-11-15 | 2004-06-15 | Chiron Srl | Unexpected surface proteins in neisseria meningitidis |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US20050124565A1 (en) * | 2002-11-21 | 2005-06-09 | Diener John L. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8039443B2 (en) * | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) * | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
GB0227346D0 (en) | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
AU2003300831A1 (en) * | 2002-12-11 | 2004-06-30 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
JP2006512927A (en) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5 'CPG nucleic acids and methods of use thereof |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
DE60329223D1 (en) * | 2002-12-23 | 2009-10-22 | Dynavax Tech Corp | OLIGONUCLEOTIDES WITH AN IMMUNE SYSTEM STIMULATING SEQUENCE AND METHOD FOR THEIR APPLICATION |
US8034378B2 (en) | 2002-12-27 | 2011-10-11 | Novartis Vaccines And Diagnostics, Inc | Immunogenic compositions containing phospholipid |
CA2517673C (en) | 2003-03-24 | 2013-08-13 | Intercell Ag | Improved vaccines for preventing viral infection |
AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
AU2004232848A1 (en) | 2003-04-21 | 2004-11-04 | Archemix Corp. | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
CN1798563A (en) * | 2003-05-15 | 2006-07-05 | 独立行政法人科学技术振兴机构 | Immunostimulant |
AU2004252091B2 (en) | 2003-06-05 | 2010-06-10 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli |
BRPI0411514A (en) * | 2003-06-20 | 2006-08-01 | Coley Pharm Gmbh | small molecule toll-like receptor antagonists |
US20060035242A1 (en) | 2004-08-13 | 2006-02-16 | Michelitsch Melissa D | Prion-specific peptide reagents |
JP4989225B2 (en) * | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Nucleic acid lipophilic conjugate |
SG123799A1 (en) * | 2003-10-30 | 2006-07-26 | Coley Pharm Gmbh | C-class oligonucleotide analogs with enchanced immunostimulatory potency |
US20050239733A1 (en) * | 2003-10-31 | 2005-10-27 | Coley Pharmaceutical Gmbh | Sequence requirements for inhibitory oligonucleotides |
US20050100983A1 (en) * | 2003-11-06 | 2005-05-12 | Coley Pharmaceutical Gmbh | Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling |
US7973016B2 (en) * | 2004-01-23 | 2011-07-05 | Joslin Diebetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
US20050256073A1 (en) * | 2004-02-19 | 2005-11-17 | Coley Pharmaceutical Group, Inc. | Immunostimulatory viral RNA oligonucleotides |
US20060193821A1 (en) * | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
US20070066550A1 (en) * | 2004-03-05 | 2007-03-22 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
TWI235440B (en) * | 2004-03-31 | 2005-07-01 | Advanced Semiconductor Eng | Method for making leadless semiconductor package |
US7579450B2 (en) * | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
JP5014122B2 (en) * | 2004-05-06 | 2012-08-29 | アメリカ合衆国 | Methods and compositions for the treatment of uveitis |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
EP2149583B1 (en) | 2004-09-24 | 2015-10-28 | Novartis AG | Modified VP1-capsid protein of parvovirus B19 |
WO2006042156A2 (en) | 2004-10-08 | 2006-04-20 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS represneted by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION | Modulation of replicative fitness by using less frequently used synonymous codons |
MY159370A (en) * | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
EP2436391A3 (en) | 2004-11-02 | 2012-07-04 | Archemix LLC | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
WO2006065751A2 (en) | 2004-12-13 | 2006-06-22 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods |
CA2590974C (en) | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
US20080009455A9 (en) * | 2005-02-24 | 2008-01-10 | Coley Pharmaceutical Group, Inc. | Immunostimulatory oligonucleotides |
SG161260A1 (en) * | 2005-04-08 | 2010-05-27 | Coley Pharm Group Inc | Methods for treating infectious disease exacerbated asthma |
AU2006241149A1 (en) * | 2005-04-26 | 2006-11-02 | Coley Pharmaceutical Gmbh | Modified oligoribonucleotide analogs with enhanced immunostimulatory activity |
US8916161B2 (en) | 2005-06-14 | 2014-12-23 | Sophiris Bio Inc. | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
CA2613442C (en) | 2005-06-30 | 2016-08-23 | Archemix Corp. | Materials and methods for the generation of fully 2'-modified nucleic acid transcripts |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
PT2179737E (en) | 2005-07-01 | 2013-12-05 | Index Pharmaceuticals Ab | Modulating responsiveness to steroids |
PL2269622T3 (en) | 2005-07-01 | 2014-05-30 | Index Pharmaceuticals Ab | CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient |
JP2009500412A (en) * | 2005-07-07 | 2009-01-08 | コーリー ファーマシューティカル グループ,インコーポレイテッド | Combination therapy of anti-CTLA-4 antibody and CPG motif-containing synthetic oligodeoxynucleotide for the treatment of cancer |
WO2007008904A2 (en) | 2005-07-08 | 2007-01-18 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections |
CA2622679A1 (en) * | 2005-09-16 | 2007-08-09 | Coley Pharmaceutical Gmbh | Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone |
EA013375B1 (en) * | 2005-09-16 | 2010-04-30 | Коли Фармасьютикал Гмбх | MODULATION OF IMMUNOSTIMULATORY PROPERTIES OF SHORT INTERFERING RIBONUCLEIC ACID (siRNA) BY NUCLEOTIDE MODIFICATION |
WO2007041190A2 (en) * | 2005-09-30 | 2007-04-12 | The University Of Iowa Research Foundation | Polymer-based delivery system for immunotherapy of cancer |
CA2625969A1 (en) | 2005-10-28 | 2007-05-03 | Index Pharmaceuticals Ab | Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease |
PL1957647T3 (en) | 2005-11-25 | 2015-07-31 | Zoetis Belgium S A | Immunostimulatory oligoribonucleotides |
EP1973608A1 (en) | 2005-12-14 | 2008-10-01 | Cytos Biotechnology AG | Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity |
US20080045473A1 (en) | 2006-02-15 | 2008-02-21 | Coley Pharmaceutical Gmbh | Compositions and methods for oligonucleotide formulations |
EP2397852B1 (en) | 2006-03-14 | 2013-12-04 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
US20100016250A1 (en) | 2006-04-14 | 2010-01-21 | Kyowa Hakko Kirin Co., Ltd. | Toll-like receptor 9 agonists |
US20070243290A1 (en) * | 2006-04-18 | 2007-10-18 | Melody Thompson | Method of tailoring infant formulas to individual nutritional needs prior to use |
SG172696A1 (en) | 2006-06-12 | 2011-07-28 | Cytos Biotechnology Ag | Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages |
KR101251707B1 (en) * | 2006-09-27 | 2013-04-11 | 콜리 파마슈티칼 게엠베하 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity |
US20100144846A1 (en) * | 2006-10-26 | 2010-06-10 | Coley Pharmaceutical Gmbh | Oligoribonucleotides and uses thereof |
ES2761949T3 (en) | 2006-11-01 | 2020-05-21 | Ventana Med Syst Inc | Haptens, hapten conjugates, compositions thereof and method for their preparation and use |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
DK2918598T3 (en) | 2007-02-28 | 2019-04-29 | The Govt Of U S A As Represented By The Secretary Of The Dept Of Health And Human Services | Brachyury polypeptides and methods of use |
WO2008131074A1 (en) * | 2007-04-19 | 2008-10-30 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders |
US8518903B2 (en) | 2007-04-19 | 2013-08-27 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of toll-like receptor-9 agonists |
US8320302B2 (en) | 2007-04-20 | 2012-11-27 | Elster Electricity, Llc | Over the air microcontroller flash memory updates |
CA2687441A1 (en) * | 2007-05-17 | 2008-11-27 | Coley Pharmaceutical Group, Inc. | Class a oligonucleotides with immunostimulatory potency |
HUE025645T2 (en) * | 2007-05-18 | 2016-04-28 | Adiutide Pharmaceuticals Gmbh | Phosphate-modified oligonucleotide analogs with immunostimulatory activity |
CA2687178C (en) | 2007-05-23 | 2014-02-04 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
JP2010527633A (en) * | 2007-05-25 | 2010-08-19 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Toll-like receptor 3 modulator and use thereof |
CN101820908A (en) * | 2007-10-09 | 2010-09-01 | 科利制药公司 | The immune stimulatory oligonucleotide analogs that comprises modified sugar moieties |
EP2217716A4 (en) | 2007-11-09 | 2011-02-09 | Salk Inst For Biological Studi | Use of tam receptor inhibitors as antimicrobials |
AU2008335457B2 (en) | 2007-12-07 | 2015-04-16 | Glaxosmithkline Biologicals S.A. | Compositions for inducing immune responses |
WO2009114485A2 (en) | 2008-03-10 | 2009-09-17 | Children's Hospital & Research Center At Oakland | Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use |
EP2278979A4 (en) | 2008-05-21 | 2012-09-26 | Us Gov Health & Human Serv | Method of treating pneumoconiosis with oligodeoxynucleotides |
DK2300799T3 (en) | 2008-06-05 | 2015-12-14 | Ventana Med Syst Inc | Process for the histo chemical processing and use of a composition for histo chemical processing |
CN104001170B (en) | 2008-06-27 | 2016-08-24 | 硕腾有限责任公司 | Novel adjunvant composition |
AU2009294850B2 (en) | 2008-09-22 | 2015-07-02 | Oregon Health & Science University | Methods for detecting a Mycobacterium tuberculosis infection |
AU2009304552B2 (en) | 2008-10-16 | 2015-02-19 | Dalhousie University | Combination adjuvant formulation |
EP2376108B1 (en) | 2008-12-09 | 2017-02-22 | Pfizer Vaccines LLC | IgE CH3 PEPTIDE VACCINE |
WO2010099472A2 (en) | 2009-02-27 | 2010-09-02 | The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services | Spanx-b polypeptides and their use |
MX2011010050A (en) | 2009-03-25 | 2011-12-14 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens. |
EP2424562B1 (en) | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
EA022699B1 (en) | 2009-05-27 | 2016-02-29 | Селекта Байосайенсиз, Инк. | Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents |
NZ618391A (en) | 2009-07-30 | 2015-07-31 | Pfizer Vaccines Llc | Antigenic tau peptides and uses thereof |
US8598327B2 (en) | 2009-08-18 | 2013-12-03 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
US8252913B2 (en) * | 2009-08-18 | 2012-08-28 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
WO2011026111A1 (en) | 2009-08-31 | 2011-03-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Oral delivery of a vaccine to the large intestine to induce mucosal immunity |
CN102612558B (en) | 2009-09-03 | 2015-02-11 | 辉瑞疫苗有限责任公司 | Pcsk9 vaccine |
WO2011041886A1 (en) | 2009-10-07 | 2011-04-14 | University Of Victoria Innovation And Development Corporation | Vaccines comprising heat-sensitive transgenes |
WO2011047340A1 (en) | 2009-10-16 | 2011-04-21 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine |
EP2501397B1 (en) | 2009-11-20 | 2017-10-04 | Oregon Health and Science University | Methods for producing an immune response to tuberculosis |
JP6007105B2 (en) | 2009-12-22 | 2016-10-12 | セルデックス・セラピューティクス・インコーポレイテッド | Vaccine composition |
WO2011112599A2 (en) | 2010-03-12 | 2011-09-15 | The United States Of America, As Represented By The Secretary. Department Of Health & Human Services | Immunogenic pote peptides and methods of use |
CN110845585A (en) | 2010-03-30 | 2020-02-28 | 奥克兰儿童医院及研究中心 | Modified Factor H Binding Proteins (FHBP) and methods of use thereof |
CA2798136C (en) | 2010-05-14 | 2019-06-04 | Oregon Health & Science University | Recombinant hcmv and rhcmv vectors and uses thereof |
CN107029223A (en) | 2010-05-26 | 2017-08-11 | 西莱克塔生物科技公司 | Synthesize nano-carrier combined vaccine |
CA2800774A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Vaccines Llc | Ige ch3 peptide vaccine |
CA2798837A1 (en) | 2010-06-07 | 2011-12-15 | Pfizer Inc. | Her-2 peptides and vaccines |
EP2616545B1 (en) | 2010-09-14 | 2018-08-29 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Computationally optimized broadly reactive antigens for influenza |
US10668092B2 (en) | 2010-09-24 | 2020-06-02 | The John Hopkins University | Compositions and methods for treatment of inflammatory disorders |
US9072760B2 (en) | 2010-09-24 | 2015-07-07 | University of Pittsburgh—of the Commonwealth System of Higher Education | TLR4 inhibitors for the treatment of human infectious and inflammatory disorders |
US9994443B2 (en) | 2010-11-05 | 2018-06-12 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
WO2012088425A2 (en) | 2010-12-22 | 2012-06-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease |
WO2012109675A1 (en) | 2011-02-11 | 2012-08-16 | Baxter International Inc. | Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics |
US20140004142A1 (en) | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
US10941399B2 (en) * | 2011-04-14 | 2021-03-09 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction |
FR2975600B1 (en) | 2011-05-24 | 2013-07-05 | Assist Publ Hopitaux De Paris | AGENTS FOR THE TREATMENT OF TUMORS |
US9359361B2 (en) | 2011-06-01 | 2016-06-07 | Janus Biotherapeutics, Inc. | Immune system modulators |
US9353115B2 (en) | 2011-06-01 | 2016-05-31 | Janus Biotherapeutics, Inc. | Immune system modulators |
WO2012177760A1 (en) | 2011-06-20 | 2012-12-27 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Computationally optimized broadly reactive antigens for h1n1 influenza |
KR20140050698A (en) | 2011-07-29 | 2014-04-29 | 셀렉타 바이오사이언시즈, 인크. | Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses |
WO2013039792A1 (en) | 2011-09-12 | 2013-03-21 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunogens based on an hiv-1 gp120 v1v2 epitope |
US20140234360A1 (en) | 2011-09-30 | 2014-08-21 | The United States of America, as represented by the Secretary, Dept.of Health and Human Services | Influenza vaccine |
EP2763677B1 (en) | 2011-10-04 | 2020-02-26 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
EP3269728B1 (en) | 2011-10-20 | 2020-12-16 | The Government of The United States of America as represented by The Secretary, Department of Health and Human Services | Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes |
SG11201402650RA (en) | 2012-01-16 | 2014-06-27 | Elizabeth Mckenna | Compositions and methods for the treatment of hepatic diseases and disorders |
JP6336915B2 (en) | 2012-02-07 | 2018-06-06 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | H3N2, H2N2, and influenza B virus antigens with broad reactivity optimized by calculation |
IN2014DN05695A (en) | 2012-02-13 | 2015-05-15 | Univ Pittsburgh | |
US9421250B2 (en) | 2012-03-23 | 2016-08-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pathogenic phlebovirus isolates and compositions and methods of use |
PL2844282T3 (en) | 2012-05-04 | 2019-11-29 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
IN2014DN09618A (en) | 2012-05-23 | 2015-07-31 | Us Sec Dep Of Health And Human Services | |
WO2013177397A1 (en) | 2012-05-24 | 2013-11-28 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Multivalent meningococcal conjugates and methods for preparing cojugates |
WO2013192144A2 (en) | 2012-06-19 | 2013-12-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Rift valley fever virus replicon particles and use thereof |
US20150224181A1 (en) | 2012-09-14 | 2015-08-13 | The United States Of America As Represented By The Secretary Department Of Health And Human Se | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
JP2015535829A (en) | 2012-09-21 | 2015-12-17 | マッケーナ、エリザベス | Naturally occurring CpG oligonucleotide compositions and therapeutic applications thereof |
US9562066B2 (en) * | 2012-09-25 | 2017-02-07 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oral therapy of necrotizing enterocolitis |
EP2986717A1 (en) | 2013-04-19 | 2016-02-24 | The Regents of The University of California | Lone star virus |
CN112999344A (en) | 2013-05-15 | 2021-06-22 | 阿尔伯达大学董事会 | E1E2HCV vaccine and methods of use |
NZ757210A (en) | 2013-09-19 | 2022-12-23 | Zoetis Services Llc | Oil-based adjuvants |
WO2015048785A2 (en) | 2013-09-30 | 2015-04-02 | Los Alamos National Security, Llc | Mosaic conserved region hiv immunogenic polypeptides |
KR102006527B1 (en) | 2013-11-01 | 2019-08-02 | 화이자 인코포레이티드 | Vectors for expression of prostate-associated antigens |
AU2014361788B2 (en) | 2013-12-13 | 2019-10-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multi-epitope TARP peptide vaccine and uses thereof |
NZ755769A (en) | 2014-01-21 | 2023-06-30 | Pfizer | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
EP3583947B1 (en) | 2014-01-21 | 2023-10-11 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
CA2937184A1 (en) | 2014-01-21 | 2015-07-30 | Pfizer Inc. | Streptococcus pneumoniae capsular polysaccharides and conjugates thereof |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US10279019B2 (en) | 2014-02-11 | 2019-05-07 | Stc.Unm | PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same |
WO2015184272A2 (en) | 2014-05-30 | 2015-12-03 | Sanofi Pasteur Biologics Llc | Expression and conformational analysis of engineered influenza hemagglutinin |
CN106535876B (en) | 2014-06-04 | 2020-09-11 | 埃克西奎雷股份有限公司 | Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications |
US20170275287A1 (en) | 2014-08-22 | 2017-09-28 | Janus Biotherapeutics, Inc. | Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
HRP20230416T1 (en) | 2015-01-15 | 2023-07-07 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
LT3244920T (en) | 2015-01-16 | 2023-08-25 | Zoetis Services Llc | Foot-and-mouth disease vaccine |
EP3256608A4 (en) | 2015-02-13 | 2019-02-20 | Icahn School of Medicine at Mount Sinai | Rna containing compositions and methods of their use |
US10584148B2 (en) | 2015-06-02 | 2020-03-10 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
CN108291210B (en) | 2015-06-10 | 2022-03-11 | 美国政府(由卫生和人类服务部的部长所代表) | Methods for producing and purifying nucleic acid-containing compositions |
EP3325008A1 (en) | 2015-07-21 | 2018-05-30 | Pfizer Inc | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
WO2017062246A1 (en) | 2015-10-05 | 2017-04-13 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human rota virus g9p[6] strain and use as a vaccine |
JP7171433B2 (en) | 2015-10-30 | 2022-11-15 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | Compositions and methods for treatment of HER-2 expressing solid tumors |
WO2017085586A1 (en) | 2015-11-20 | 2017-05-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
HUE051722T2 (en) | 2016-01-19 | 2021-03-29 | Pfizer | Cancer vaccines |
WO2017189448A1 (en) | 2016-04-25 | 2017-11-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bivalent immunogenic conjugate for malaria and typhoid |
EP3452598A4 (en) | 2016-05-06 | 2020-04-29 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
US11173207B2 (en) | 2016-05-19 | 2021-11-16 | The Regents Of The University Of Michigan | Adjuvant compositions |
US10844097B2 (en) | 2016-06-02 | 2020-11-24 | Sanofi Pasteur Inc. | Engineered influenza antigenic polypeptides and immunogenic compositions thereof |
CN115746107A (en) | 2016-06-03 | 2023-03-07 | 圣诺菲·帕斯图尔公司 | Modification of engineered influenza hemagglutinin polypeptides |
WO2017218339A1 (en) | 2016-06-13 | 2017-12-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays |
WO2018009603A1 (en) | 2016-07-08 | 2018-01-11 | The United State of America, as represented by the Secretary, Department of Health and Human Service | Chimeric west nile/zika viruses and methods of use |
WO2018009604A1 (en) | 2016-07-08 | 2018-01-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric dengue/zika viruses live-attenuated zika virus vaccines |
CN109862908B (en) | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | Multivalent pneumococcal polysaccharide-protein conjugate composition |
MX2019001341A (en) | 2016-08-05 | 2019-07-04 | Sanofi Pasteur Inc | Multivalent pneumococcal polysaccharide-protein conjugate composition. |
US10172933B2 (en) | 2016-10-31 | 2019-01-08 | The United States Of America, As Represented By The Secretary Of Agriculture | Mosaic vaccines for serotype a foot-and-mouth disease virus |
CA3050622A1 (en) | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
WO2019018744A1 (en) | 2017-07-21 | 2019-01-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neisseria meningitidis immunogenic compositions |
US11235046B2 (en) | 2017-11-04 | 2022-02-01 | Nevada Research & Innovation Corporation | Immunogenic conjugates and methods of use thereof |
US11116830B2 (en) | 2017-12-18 | 2021-09-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bacterial polysaccharide-conjugated carrier proteins and use thereof |
JP2021506851A (en) | 2017-12-19 | 2021-02-22 | マサチューセッツ インスティテュート オブ テクノロジー | Antigen-adjuvant coupling reagent and method of use |
CN111629751A (en) | 2018-01-22 | 2020-09-04 | 美国政府(由卫生和人类服务部的部长所代表) | Broad spectrum protective inactivated influenza virus vaccines |
US11633471B2 (en) | 2018-03-06 | 2023-04-25 | Unm Rainforest Innovations | Compositions and methods for reducing serum triglycerides |
WO2019191257A1 (en) | 2018-03-28 | 2019-10-03 | Sanofi Pasteur Inc. | Methods of generating broadly protective vaccine compositions comprising hemagglutinin |
EP3773708A2 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Antigenic epstein barr virus polypeptides |
EP3773698A1 (en) | 2018-04-03 | 2021-02-17 | Sanofi | Ferritin proteins |
WO2019195276A1 (en) | 2018-04-03 | 2019-10-10 | Sanofi | Antigenic ospa polypeptides |
CN112512565A (en) | 2018-04-03 | 2021-03-16 | 赛诺菲 | Antigenic influenza-ferritin polypeptides |
JP2021519597A (en) | 2018-04-03 | 2021-08-12 | サノフイSanofi | Antigenic respiratory syncytial virus polypeptide |
US11260119B2 (en) | 2018-08-24 | 2022-03-01 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
AU2019393745A1 (en) | 2018-12-04 | 2021-06-10 | California Institute Of Technology | HIV vaccine immunogens |
EP3894547A1 (en) | 2018-12-12 | 2021-10-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins |
EP3893926A1 (en) | 2018-12-12 | 2021-10-20 | Pfizer Inc. | Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof |
WO2020123989A1 (en) | 2018-12-14 | 2020-06-18 | University Of Georgia Research Foundation, Inc. | Crimean-congo hemorrhagic fever virus replicon particles and use thereof |
CN114957407A (en) | 2019-04-02 | 2022-08-30 | 赛诺菲 | Antigenic multimeric respiratory syncytial virus polypeptides |
US20220184199A1 (en) | 2019-04-10 | 2022-06-16 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
JP2021087420A (en) | 2019-11-01 | 2021-06-10 | ファイザー・インク | Escherichia coli compositions and methods thereof |
BR112022010228A2 (en) | 2019-12-17 | 2022-09-06 | Us Health | ATTENUATED LIVE LEISHMANIA PARASITE VACCINES WITH INCREASED SAFETY CHARACTERISTICS |
WO2021165928A2 (en) | 2020-02-23 | 2021-08-26 | Pfizer Inc. | Escherichia coli compositions and methods thereof |
EP4110382A1 (en) | 2020-02-28 | 2023-01-04 | Sanofi Pasteur Inc. | High dose influenza vaccine for pediatric subjects |
US11213482B1 (en) | 2020-03-05 | 2022-01-04 | University of Pittsburgh—Of the Commonwealth System of Higher Educat | SARS-CoV-2 subunit vaccine and microneedle array delivery system |
IL302362A (en) | 2020-10-27 | 2023-06-01 | Pfizer | Escherichia coli compositions and methods thereof |
CA3200602A1 (en) | 2020-11-04 | 2022-05-12 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
JP2023549736A (en) | 2020-11-10 | 2023-11-29 | ファイザー・インク | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
US20220202923A1 (en) | 2020-12-23 | 2022-06-30 | Pfizer Inc. | E. coli fimh mutants and uses thereof |
WO2022147373A1 (en) | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2022196699A1 (en) | 2021-03-16 | 2022-09-22 | 国立大学法人大阪大学 | Follicular helper t (tfh) cells specific to sars-cov-2 virus |
CN117441103A (en) | 2021-03-16 | 2024-01-23 | 国立大学法人大阪大学 | Novel medical technology using follicular T cells |
AU2022281543A1 (en) | 2021-05-28 | 2023-11-23 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
TW202306969A (en) | 2021-05-28 | 2023-02-16 | 美商輝瑞大藥廠 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
AU2022311955A1 (en) | 2021-07-16 | 2024-01-18 | The Board Of Trustees Of The University Of Illinois | Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs |
WO2023018817A1 (en) | 2021-08-11 | 2023-02-16 | Sanofi Pasteur Inc. | Truncated influenza neuraminidase and methods of using the same |
WO2023059857A1 (en) | 2021-10-08 | 2023-04-13 | Sanofi Pasteur Inc. | Multivalent influenza vaccines |
AR127585A1 (en) | 2021-11-05 | 2024-02-07 | Sanofi Sa | RESPIRATORY SYNCYCIAL VIRUS RNA VACCINE |
WO2023079113A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi | Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same |
WO2023081798A1 (en) | 2021-11-05 | 2023-05-11 | Sanofi Pasteur Inc. | Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same |
US20230310571A1 (en) | 2021-11-30 | 2023-10-05 | Sanofi Pasteur Inc. | Human metapneumovirus vaccines |
WO2023102388A1 (en) | 2021-11-30 | 2023-06-08 | Sanofi Pasteur Inc. | Human metapneumovirus viral vector-based vaccines |
WO2023111262A1 (en) | 2021-12-17 | 2023-06-22 | Sanofi | Lyme disease rna vaccine |
WO2023135515A1 (en) | 2022-01-13 | 2023-07-20 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
WO2023144206A1 (en) | 2022-01-27 | 2023-08-03 | Sanofi Pasteur | Modified vero cells and methods of using the same for virus production |
WO2023161817A1 (en) | 2022-02-25 | 2023-08-31 | Pfizer Inc. | Methods for incorporating azido groups in bacterial capsular polysaccharides |
WO2023177577A1 (en) | 2022-03-14 | 2023-09-21 | Sanofi Pasteur Inc. | Machine-learning techniques in protein design for vaccine generation |
WO2023214082A2 (en) | 2022-05-06 | 2023-11-09 | Sanofi | Signal sequences for nucleic acid vaccines |
WO2023218322A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Process for producing of vaccine formulations with preservatives |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
DE3280400D1 (en) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | OLIGONUCLEOTIDES MEDICINE AND THEIR PRODUCTION METHOD. |
CA1339596C (en) | 1987-08-07 | 1997-12-23 | New England Medical Center Hospitals, Inc. | Viral expression inhibitors |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5786189A (en) | 1989-11-29 | 1998-07-28 | Smithkline Beecham Biologicals (S.A.) | Vaccine |
US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5591720A (en) | 1990-08-16 | 1997-01-07 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
US5683985A (en) | 1991-04-18 | 1997-11-04 | The Salk Institute For Biological Studies | Oligonucleotide decoys and methods relating thereto |
EP0587749A4 (en) | 1991-05-31 | 1995-08-30 | Genta Inc | Compositions and delivery systems for transdermal administration of neutral oligomers |
JPH07509136A (en) * | 1992-07-17 | 1995-10-12 | バイシス,インク. | Enrichment and identification of fetal cells in maternal blood for in situ (IN SITU) hybridization |
US5585479A (en) | 1992-07-24 | 1996-12-17 | The United States Of America As Represented By The Secretary Of The Navy | Antisense oligonucleotides directed against human ELAM-I RNA |
US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
CA2169635C (en) | 1993-08-26 | 2002-11-12 | Dennis A. Carson | Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides |
US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
US5830877A (en) | 1993-08-26 | 1998-11-03 | The Regents Of The University Of California | Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory |
US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
WO1995026204A1 (en) | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
PT772619E (en) * | 1994-07-15 | 2006-10-31 | Univ Iowa Res Found | OLIGONUCLEOTIDOS IMUNOMODULADORES |
AU3133695A (en) * | 1994-07-18 | 1996-02-16 | University Of North Carolina At Chapel Hill, The | Oligonucleoside compounds and methods for inhibiting tumor growth, invasion and metastasis |
MX9708663A (en) | 1995-05-11 | 1998-02-28 | Applied Research Systems | Il-6 activity inhibitor. |
US5994315A (en) * | 1995-06-07 | 1999-11-30 | East Carolina University | Low adenosine agent, composition, kit and method for treatment of airway disease |
EP0879284B1 (en) | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
JP2001513776A (en) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders |
WO1998055450A1 (en) | 1997-06-05 | 1998-12-10 | Huntsman Ici Chemicals Llc | Method for the preparation of carbamates |
JP4101888B2 (en) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
-
1998
- 1998-02-25 JP JP53781098A patent/JP2001513776A/en not_active Ceased
- 1998-02-25 AU AU66674/98A patent/AU738513B2/en not_active Ceased
- 1998-02-25 WO PCT/US1998/003678 patent/WO1998037919A1/en active IP Right Grant
- 1998-02-25 CA CA002281838A patent/CA2281838A1/en not_active Abandoned
- 1998-02-25 US US09/030,701 patent/US6214806B1/en not_active Expired - Fee Related
- 1998-02-25 EP EP98908714A patent/EP1039935A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US6214806B1 (en) | 2001-04-10 |
EP1039935A4 (en) | 2005-04-27 |
JP2001513776A (en) | 2001-09-04 |
WO1998037919A1 (en) | 1998-09-03 |
EP1039935A1 (en) | 2000-10-04 |
AU6667498A (en) | 1998-09-18 |
AU738513B2 (en) | 2001-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU738513B2 (en) | Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders | |
Pastore et al. | Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. | |
EP1511845B1 (en) | Immunostimulatory oligonucleotides and uses thereof | |
EP2901856B1 (en) | Immunostimulatory oligonucleotide multimers | |
DE60029460T3 (en) | METHOD USING NUCLEIC ACID-INDUCED IMMUNOSTIMULATORY INTERFERON | |
EP2269622B1 (en) | CpG oligonucleotides used for enhancing steroid activity in a steroid dependent patient | |
DE69736331T2 (en) | IMMUNOSTIMULATING NUCLEIC ACID MOLECULES | |
EP1009413B1 (en) | Use of immunostimulatory oligonucleotides for preventing or treating asthma | |
Deng et al. | CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection | |
EP1904077B1 (en) | Modulating responsiveness to steroids | |
US20050250716A1 (en) | Immunostimulatory oligodeoxynucleotides | |
US20090062224A1 (en) | Therapeutic use of cpg oligodeoxynucleotide for skin disease | |
JP2002514397A (en) | Methods for hematopoietic regulation using CpG oligonucleotides | |
JP2003527352A (en) | Innate immune stimulating compounds of CPG and saponin and methods thereof | |
EP2034015A1 (en) | Immunostimulatory oligonucleotide and pharmaceutical application thereof | |
Murad et al. | CPG-7909 (PF-3512676, ProMune®): Toll-like receptor-9 agonist in cancer therapy | |
Zhang et al. | Acute alcohol intoxication suppresses the CXC chemokine response during endotoxemia | |
Sjölinder et al. | Important role for Toll-like receptor 9 in host defense against meningococcal sepsis | |
Yamamoto et al. | Oligodeoxyribonucleotides with 5′-ACGT-3′ or 5′-TCGA-3′ sequence induce production of interferons | |
Edelman et al. | Lipopolysaccharide stimulates alveolar macrophage adherence in vivo and in vitro | |
CN101426370A (en) | Immunostimulatory oligonucleotide multimers | |
Alam et al. | In Vivo Role of p38 Mitogen-Activated Protein Kinase in Mediating the Anti-inflammatory Effects of CpG... |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |